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Abstract
Accessory mutations are thought to arise alongside major or primary drug resistance
mutations in order to augment resistance, restore viral fitness, or both. The H208Y
mutation in the HIV-1 reverse transcriptase (RT) gene was hypothesised to be an
accessory mutation. This thesis characterises the H208Y mutation in terms of
linkage of H208Y to other major and accessory resistance mutations, and examines
two phenotypic aspects, drug susceptibility and viral fitness. The HIV Resistance
Database held at the Royal Free Hospital was searched for genotypes containing the
H208Y mutation. The prevalence of H208Y in antiretroviral treatment naïve and
treatment experienced patients was 5/3783 (0.1%) and 12/1304 (0.9%), respectively,
indicating a high degree of conservation of position 208 in wild type virus and an
increase in prevalence under selective drug pressure. Four patients were chosen to
conduct further analysis of virus with H208Y, comprising a treatment naïve patient
with subtype B virus, and three treatment experienced patients harbouring subtype A,
subtype B and subtype C virus respectively. The RT gene from these patients was
cloned and sequenced. H208Y was found to be associated with the thymidine
analogue mutations (TAMs), particularly mutations at positions D67, T215 and
K219. H208Y was always associated with accessory mutations at positions V35,
K122 and T200. Recombinant viruses containing patient derived RT genes with and
without H208Y were constructed to examine the impact of H208Y on drug
susceptibility and viral fitness. A multiple cycle drug susceptibility assay showed
that H208Y conferred a reduced susceptibility to the nucleotide RT inhibitor
tenofovir in the context of subtype B wild type RT and subtype B RT containing
iv
TAMs. Growth competition assays were used to examine the fitness effects of
H208Y using allele-specific PCR to differentiate between competing strains with and
without H208Y. In the context of subtype B wild type RT, H208Y conferred a
reduced viral fitness both in the presence and absence of drug. The effect may be
proposed to contribute to the overall high degree of conservation of position 208. In
contrast, H208Y did not appear to impact on viral fitness in the context of subtype B
and subtype A RT containing TAMs.
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Chapter one
1 Introduction
11.1 HIV discovery
In 1981 the CDC received reports of a disease affecting young homosexual men in
San Francisco, New York and Los Angeles (CDC Weekly, 1982c;CDC Weekly,
1982a;CDC Weekly, 1982b). These patients presented with Pneumocystis carnii
pneumonia infection (PCP) and Kaposi’s sarcoma with or without other opportunistic
infections. These patients showed evidence of cellular immune dysfunction with the
hallmark of the disease being the depletion of CD4+ T cells. Therefore the disease
was named Acquired Immune Deficiency Syndrome (AIDS).
The virus was isolated in the Pasteur Institute by Luc Montagnier’s group in 1983
and named lymphadenopathy-associated virus (LAV) (Barre-Sinoussi et al., 1983).
Later at the NIH, Robert Gallo’s group also isolated the virus and named it human T-
lymphotropic viruses type III (HTLV-III) (Popovic et al., 1984). At the time, the
virus was also known by other names such as immunodeficiency-associated virus
(IDAV) and AIDS-associated retrovirus (ARV). In May 1986, the International
Committee on the Taxonomy of Viruses published an article suggesting a common
name for the etiological agent of AIDS be named and Human Immunodeficiency
Virus (HIV) was designated (Coffin et al., 1986).
1.2 Strains and subtypes
HIV can be divided into two types, HIV-1 and HIV-2. The majority of HIV
infections are caused by HIV-1 which can be divided into four main phylogenetic
groups thought to represent three distinct transmission events from chimpanzees and
one distinct transmission event from gorillas (Hahn et al., 2000). Group M (main) is
2responsible for the majority of HIV-1 infections worldwide. Group O (outlier) and
group N (non-M/non-O) are limited to West-Central Africa, particularly Cameroon
(Buonaguro et al., 2007) Recently, a French group isolated a virus from a
Cameroonian woman that was related to SIV in gorillas. Since this virus was distinct
from HIV-1 groups M, N and O, a new group P was designated (Plantier et al., 2009).
Within group M there are 9 clades or subtypes, A-D, F-H, J and K which have a 15%
and 25% amino acid variability for the gag and env genes respectively (Kandathil et
al., 2005;Geretti, 2006). Subtypes can be further divided into additional
phylogenetic clusters called sub subtypes. For example, subtype F is divided into F1
and F2 and subtype A is divided into A and A2 (TakebE et al., 2004b). A major
source of HIV-1 diversity is the ability of two HIV-1 virions from different subtypes
infecting the same cell, leading to the generation of hybrid viruses from each of the
subtypes. Recombinant forms are classified epidemiologically as circulating
recombinant forms (CRF) and unique recombinant forms (URF) (Kandathil et al.,
2005).
CRFs must be identified by full genome sequencing in at least three unlinked
individuals. The first CRF was characterised by sequencing viruses from Thailand
and central Africa and was originally designated subtype E until it was shown to
contain regions of subtype A and as yet an unidentified pure subtype E (TakebE et
al., 2004a;Thomson et al., 2002b). At least 20 CRFs have been reported since, with
the majority of originating from Africa. The relevance of CRFs is becoming
3increasingly significant as they account for 18% of HIV-1 infections (Buonaguro et
al., 2007).
Unique recombinant forms contain unique mosaic structures that are observed in a
few epidemiologically linked individuals without any evidence of spread. The
majority of URFs are located in areas where multiple subtypes are circulating
particularly in central Africa (Thomson et al., 2002a;Thomson and Najera, 2005).
Recombinant strains are generated within individuals that either acquire dual HIV-1
infection or experience superinfection (McCutchan, 2006).
HIV-2 is most closely related to SIV from sooty mangabeys and is thought to have
entered the human population on at least eight occasions, generating 8 distinct
groups. Despite there being eight distinct groups only two, group A and group B are
endemic with the remaining groups consisting of single person infections which are
mainly confined to Western Africa (de Silva et al., 2008;Hirsch et al., 1989).
41.3 Epidemiology of HIV-1
Estimations of the first introduction into humans of the common ancestor of group M
strains have been elucidated to be around 1931 (1915-1941) (Hahn et al.,
2000;Korber et al., 2000). Since then, the radiation of different subtypes has
occurred throughout the world. As shown in figure 1-1, five strains dominate the
current global epidemic, subtype A, B and C and the CRFs CRF01_AE and
CRF02_AG. Subtype A is observed in central and eastern Africa and eastern Europe.
Subtype B is the dominating strain circulating in western and eastern Europe, the
Americas and Australia. Subtype C accounts for nearly 50% of HIV-1 infections and
resides in southern Africa and India. In terms of the CRFs, CRF02_AG dominates
west and west central Africa whilst CRF01_AE is detected in Southeast Asia
(Buonaguro et al., 2007;McCutchan, 2006). Subtype D is seen in eastern Africa and
subtypes F, G, H, J and K dominate in central Africa (Geretti, 2006).
Figure 1.1 Geographical distribution of HIV-1 subtypes around the world.
Letters represent the dominant subtype in the selected countries.
B
5The prevalence of HIV-1 is now widespread with an estimated 33.4 million people
infected with the virus. The majority (22.4 million) of which are living in sub-
Saharan Africa. There were an estimated 2.7 million newly infected in 2009
(UNIAIDS, 2009).
The current pandemic can be depicted in two patterns. The first pattern involves
sexual transmission, which includes both homosexual and heterosexual transmission.
The second pattern involves parenteral transmission, which includes transmission via
infected blood and injecting drug users (IDUs). In the majority of countries in sub-
Saharan Africa, the epidemic is attributed to heterosexual transmission. Similarly,
the main mode of transmission in the Caribbean is via heterosexual means. In Asia
and Eastern Europe, the most common transmission route is via heterosexual
transmission and IDUs. In Latin America, heterosexual and homosexual
transmission account for the majority of infections. In North America, homosexual,
followed by heterosexual transmission is still the predominant mode of transmission
(UNIAIDS, 2009).
In the UK there are two types of epidemics occurring within the population, that
occurring in the homosexual population and that occurring in the heterosexual
population. Within the heterosexual population, the majority of infections are of
non-B subtypes, suggesting that these viruses originate through immigration,
predominantly from sub-Saharan Africa (Hughes et al., 2009). Within the
homosexual population, the majority of infections are of B subtype. However, a
recent study showed that there was an increase of non-B subtype infections within
6the homosexual population, with the most commonly detected subtypes being
subtype C (102/437) and subtype A (53/437). This suggests that there maybe an
increase in non-B subtypes within the homosexual community as a result of mixing
between individuals who harbour non-B subtypes from abroad with those individuals
who are born in the UK (Fox et al., 2010).
71.4 Human Immunodeficiency Virus
HIV is a lentivirus and is part of the bigger family called the retroviridae family.
Mature HIV-1 virions have a spherical shape and are 100-120nm in diameter (Barre-
Sinoussi et al., 1983). As with other lentiviruses, HIV is enveloped by a lipid bilayer
and is studded with around 72 spikes of the Env glycoproteins. The envelope
surrounds the nucleocapsid core which contains two strands of the viral RNA
genome, three essential enzymes; integrase, reverse transcriptase (RT) and protease;
accessory proteins and some cellular factors (figure 1.2a). The RNA genome is
9.2kb in length and encodes the structural proteins common to other retroviruses.
The ends of the HIV-1 genome are flanked by long terminal repeats (LTR). From the
5’ end there are the gag-pol genes, which encode two polyprotein precursors gag and
pol. The Env gene encodes gp120 and gp41. Accessory genes include Nef, Vif, Vpr,
Tat, Vpu and Rev (figure 1.2b).
Gag encodes a polyprotein that is cleaved into matrix (MA or p17), capsid (CA or
p24), and nucleocapsid (NC or p7). In addition, p6 and the two spacer domains p2
and p1 are also present in the gag polyprotein. Gag is responsible for the assembly,
budding and release of HIV-1 virions. Matrix associates with the plasma membrane
and targets gag and pol proteins to the site of assembly. The main role of capsid is to
homo oligomerise with around 1500 capsid molecules and assemble to form a
conical capsid that encapsidates the viral RNA, nucleocapsid, RT and integrase.
Nucleocapsid plays essential roles in assembly, reverse transcription and maturation.
During the assembly process, nucleocapsid is responsible for binding to RNA and
ensuring its packaging into the virion. Another important step during particle
8assembly involves the incorporation of tRNA molecules into virions. Nucleocapsid
promotes the annealing of tRNA to the RNA so that reverse transcription can by
initiated. A critical step in viral maturation involves the formation of a stable dimer
complex between the two molecules of RNA. The nucleocapsid aids this process by
assisting the RNA to find the most stable structure. The p6 protein is situated at the
end of the gag polyprotein and has a role in viral budding. The p6 protein interacts
with the host cellular factors Tsg101 and ALIX. Tsg101 is a component of the
ESCRT-I complex which is involved in the budding of proteins. ALIX is known to
interact with Tsg101 and also binds to p6 however binding of p6 and ALIX alone is
not sufficient for viral budding (Turner and Summers, 1999).
The pol gene also encodes a polyprotein which is cleaved into the three essential
enzymes, protease, RT and integrase. Protease is a homodimeric aspartyl enzyme
consisting of 99 amino acids. The main function of protease is to recognise specific
sites in the gag and pol polyproteins and cleave them into their constitutive proteins.
The RT is a heterodimer composed of two subunits, p51 which has mainly a
structural role and p66, which carries out the catalytic activities of the enzyme. The
two functions of RT include the synthesis of a double stranded DNA copy from a
single stranded RNA template and RNase H activity. Integrase catalyses the
incorporation of the double stranded viral DNA into the host chromosomes so that a
provirus is established. Once the viral genome is integrated, transcription of viral
genes occurs and new viruses are produced.
The Env gene encodes gp120 (surface subunits) and gp41 (transmembrane subunits).
Together these proteins instigate the entry of HIV by binding to the host cell
9receptors CD4. The gp120 and gp41 proteins are linked by non-covalent bonds and
three of the gp120-gp41 heterodimers make up the envelope glycoprotein knob.
Both the subunits are heavily glycosylated and these sites are conserved between
viral isolates signifying their importance in infectivity.
Tat and Rev are regulatory proteins that bind viral RNA. Tat is a transcriptional
activator that enhances processivity of RNA polymerase II so that longer viral
transcripts are produced. Tat has also been implicated in interfering with cellular
processes such as proliferation and apoptosis. Rev is a protein involved in the
nuclear transport of RNA. It promotes the nuclear export of unspliced and singly
spliced viral transcripts (Seelamgari et al., 2004).
Nef is a multi functional protein that plays a role in the down regulation of CD4,
enhancing virion infectivity and signal transduction in T cells. CD4 is
downregulated on the surface of infected cells to prevent immune recognition.
Virions produced in the absence of Nef exhibit a severe defect in viral entry and viral
synthesis is impaired (Jere et al., 2010;Glushakova et al., 2001;Piguet et al., 2000).
The accessory proteins Vpr, Vpu and Vif are expendable for virus replication in vitro
(Trono, 1995). Vpr is an accessory protein that is involved in infectivity, apoptosis,
cell cycle control, viral transcription and nuclear import of the pre integration
complex (Romani and Engelbrecht, 2009). The main function of Vif is to interact
with the host proteins APOBEC 3G and APOBEC 3F. The APOBEC family induce
the deamination of cytidine to uridine resulting in hypermutation in the HIV-1
genome. The interaction of Vif to APOBEC induces its degradation by the
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proteosome and no hypermutation can occur (Malim, 2009;Henriet et al., 2009).
Vpu has two primary functions, degradation of CD4 in the endoplasmic reticulum
and the enhancement of virion release (Nomaguchi et al., 2008).
Figure 1.2 Stru
organisation of
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cture and organisation of the HIV-1 genome. A mature HIV-1 virion is shown in panel A. In panel B, the structural
the HIV-1 genome is illustrated. The genome is 9.2kb in length and codes for structural and non structural genes (figure
ed EO 2004).
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1.5 HIV life cycle
The steps of the HIV-1 life cycle are shown in figure 1.3. The first step involves
entry into the host cell, followed by release of the viral genome into cytoplasm where
reverse transcription occurs. The transcribed RNA genome is transported into the
nucleus where it is integrated into the host genome forming the provirus. The viral
proteins are translated and assembled at the plasma membrane before budding from
the cell.
1.5.1 Attachment and entry of HIV-1
Virus entry begins with binding of the viral envelope to the primary receptor CD4 on
host cells. The CD4 receptor interacts with class II MHC molecules to participate in
the signal transduction of T cell activating signals (Doyle and Strominger, 1987).
CD4 has four immunoglobulin domains D1 to D5 with gp120 binding to D1. The
HIV-1 viral membrane contains 14 +7 spikes of gp160 complexes (Zhu et al., 2006).
Each gp160 consists of three gp120 (surface glycoprotein) proteins that are linked to
the gp41 (transmembrane glycoprotein) protein in a tripod shape. The gp120 subunit
contains hypervariable regions V1 to V5, defined as areas where less than 30% of the
amino acids are conserved and conserved regions C1 to C6, where the amino acid is
relatively constant. The V3 region plays a major role in determining the cellular
tropism and which co-receptor the virus will bind to.
The chemokine co-receptors CCR5 and CXCR4 are a class of G protein-coupled
receptors that have a seven transmembrane architecture. During the early stages of
infection, CCR5 infecting viruses predominate whereas the progression to AIDS is
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associated with CXCR4 viruses (Deng et al., 1997). Other chemokine receptors have
been reported for HIV-1 including CCR2 (Frade et al., 1997) and CCR3 (Choe et al.,
1996). Mutations within the CCR5 co-receptor, namely a 32 base pair deletion at
position 32 (CCR5Δ32), result in a truncated CCR5.  Individuals who are 
homozygous for the deletion are resistant to HIV-1 infection and individuals who are
heterozygous for the deletion have a slower progression to AIDS (Dean et al., 1996).
Once gp160 binds to the CD4 receptor, a conformational change is triggered in
gp120 revealing the binding site of the chemokine co-receptors and depending on the
tropism of the virus, either CCR5 or CXCR4 becomes engaged (Gomez and Hope,
2005). Binding of the co-receptor instigates a series of conformational changes that
ensue with the formation of a six helical bundle that completes the fusion of the viral
envelope and the plasma membrane (Melikyan et al., 2000).
1.5.2 Uncoating
Once fusion has occurred, the HIV-1 core disassembles and leads to the generation of
the reverse transcription complexes (RTCs) and the preintegration complexes (PICs).
Recent studies have shown that uncoating is not a spontaneous process and that the
release of capsid proteins during uncoating, is triggered by cellular factors. This
includes the cellular factor cyclophilin A (CypA) which has been shown to bind to
capsid and aid the uncoating process (Auewarakul et al., 2005;Warrilow et al.,
2008;Aiken, 2006). A recent study showed that peptidyl-prolyl isomerase (Pin 1)
also assists in the uncoating process of the capsid core. Capsid is phosphorylated
after release from an infected cell and interacts directly with Pin1 after entry into the
host cell so that uncoating can take place. It has been shown that the depletion of
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Pin1 resulted in dysfunctional uncoating of HIV (Misumi et al., 2010). Viral proteins
such as integrase have also been shown to play a role in the uncoating process by
promoting capsid core stability (Briones et al., 2010).
1.5.3 Reverse transcription
The next stage in the life cycle is reverse transcription which results in synthesis of a
double stranded viral DNA molecule from a single stranded RNA template.
Initiation of reverse transcription occurs following fusion of the viral and host
membranes prior to nucleocapsid uncoating. The steps of reverse transcription are
shown in figure 1.4. Reverse transcription begins with the binding of a tRNA
molecule acquired from the host, to the primer binding site (PBS). Synthesis of the
minus strand DNA is initiated and proceeds towards the 3’ end of the RNA genome,
producing U5 and R sequences in a DNA-RNA hybrid. The RNase H activity of RT
degrades the U5 and R sequence of the RNA. The 3’ end of the RNA genome also
contains an R sequence and during the first strand transfer event, the newly
synthesized U5 and R DNA sequence are transferred to the 3’ end of the plus strand
RNA genome. The newly synthesised R sequence is complementary to the R
sequence at the 3’ end and the U5 and tRNA overhang at the 3’ end. Synthesis of the
minus stand continues towards the 5’ end of the RNA genome with the RNase H
activity of RT degrading the RNA template once as the DNA is synthesised. There
are two stretches of purine rich RNA sequences that are not degraded; the central
polypurine tract (cPPT) and the 3’ polypurine tract (3’ PPT). The cPPT and PPT are
used as priming sites for synthesis to occur towards the 5’ end of the plus strand
DNA, again RNase H activity degrades the PPT RNA and tRNA concomitantly. The
second transfer event involves the transfer of the plus strand DNA to the 3’ end of the
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minus strand DNA where complementary base pairing occurs between the PBS
sequences. Plus strand synthesis continues until it reaches the central termination
signal (CTS). At this point, the RT is ejected and a central DNA flap is created.
Minus and plus strand synthesis resumes, with each strand using the other as a
template until double stranded DNA which contains the LTR is produced. The
central flap is removed after integration by the host enzyme flap endonuclease 1
(FEN1). The DNA is now ready to be transported to the nucleus via the
preintegration complex (PIC) (Basu et al., 2008;Freed, 2001a;Jonckheere et al.,
2000).
1.5.4 Integration
The PIC contains viral DNA, RT, integrase, matrix and Vpr as well as cellular factors
such as LEDGF/p75 (Ciuffi and Bushman, 2006). The matrix protein contains two
nuclear localisation signals (NLS) enabling it to direct the PIC to the nucleus.
Although Vpr does not have a NLS, it also has a role in directing the PIC to the
nucleus by binding to members of the importin alpha family. The importin family
are involved in protein transport and recognises the NLS. Once the protein has
bound to importin alpha, it then binds to importin beta and together, this complex
docks at the nuclear pore and allows translocation through into the nucleus
(Nitahara-Kasahara et al., 2007;Gorlich et al., 1996). The cellular factor
LEDGF/p75 has been shown to bind to integrase and it contains a NLS, which drives
the translocation of the PIC across the membrane (Cherepanov et al., 2003).
Viral DNA can integrate into any sequence in the host but integration has been
shown preferentially to integrate into actively transcribed regions in order to promote
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efficient viral gene expression (Marshall et al., 2007). Integration can be divided into
two stages, 3’ processing and strand transfer. The first stage involves the recognition
of specific DNA sequences at the end of each LTR. Integrase catalyses the removal
of two nucleotides from the 5’ end exposing a 3’-OH group (Engelman et al., 1991).
In the strand transfer reaction, target sites on the host are cleaved via a nucleophilic
attack exposing a 5 base pair at each end. The viral DNA is integrated into host
genome at the 5’ end. The two nucleotides at the 5’ end of the viral DNA removed
and the gaps are filled by cellular repair enzymes. The integrated viral DNA is now
called a provirus and serves as the template for the synthesis of structural, regulatory
and accessory proteins required for viral production (Delelis et al., 2008;Jegede et
al., 2008).
1.5.5 Gene expression
The provirus is transcribed to produce the full RNA genome as well as shorter RNA
products that are produced through splicing. The two regulatory proteins Tat and
Rev are required for viral gene expression. The expression of the viral genome is
regulated by enhancer and promoter elements found within the 5’ LTR. The TATA
box is a key sequence where transcription is initiated.
A key interaction of Tat is with the positive transcriptional elongation factor b (P-
TEDb) which aids the initiation of transcription by binding to a RNA stem loop
structure known as the tat response element (TAR), located at the 5’ end of viral
transcripts. The interaction between TAR and the P-TEDb complex result in the
phosphorylation of the C terminal domain of RNA polymerase II which enhances the
processivity of polymerase II complex so that full length transcripts are produced
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(Zhu et al., 1997). In the absence of Tat, shorter transcripts are produced and it has
been suggested that this is due to the poor processivity of RNA polymerase II
(Pagans et al., 2005;Strebel, 2003b).
When levels of Rev reach a specific level, the production of single spliced and
unspliced transcripts is initiated. The transcription of the longer transcripts occurs
when the Rev protein binds to a stem loop structure known as the Rev response
element (RRE) located in the env gene. Rev facilitates the export of RRE containing
RNA out of the nucleus before further splicing can occur. It has a nuclear export
signal (NES) and hijacks the host export pathway to export the transcripts out of the
nucleus (Groom et al., 2009;Strebel, 2003a). Host proteins including CRM-1 and
B23 are also involved in this process (Szebeni et al., 1997;Fukuda et al., 1997).
Once the transcripts enter the cytoplasm, they are ready to be translated by host
ribosomes. The gag and gag-pol polyproteins are translated by ribosomes in the
cytoplasm whereas the env polyprotein is translated on ribosomes in the endoplasmic
reticulum. The gag and gag-pol proteins are modified with the addition of the 14-
carbon fatty acid myristate at the N terminus end of matrix. This modification is
important for promoting membrane association of gag and particle formation
(Gottlinger, 2001;Resh, 2005;Zhou et al., 1994).
1.5.6 Assembly, release and budding
The assembly of gag particles requires nucleocapsid, capsid and matrix and occurs at
the membrane in areas that are rich in lipids. Matrix targets assembly of viral
proteins towards regions that are cholesterol and sphingolipid rich so that the virus
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can acquire a plasma membrane that is rich in cholesterol and lipids. This is
important, as cells that are depleted of these lipids are more likely to have an
impaired infectivity and viral particle production (Ono et al., 2007).
In order for the virus to bud from the cell membrane, HIV-1 exploits the endosomal
sorting complex required for transport (ESCRT) machinery. The ESCRT machinery
is comprised of 3 subunits, ESCRT-I, ESCRT-II and ESCRT-III. Short sequences in
gag, known as the late domain (L domain) are involved in binding to Tsg101 and
ALIX of ESCRT-I and ESCRT-III respectively. Through a series of interactions with
subunits of the ESCRT machinery, the virion envelope is detached from the cell
membrane (Roxrud et al., 2010;Bieniasz, 2009;Strack et al., 2003;VerPlank et al.,
2001).
Before transport to the cell membrane, host enzymes add sugar side chains to env
producing monomers of gp160, which aggregate to form oligomers. The oligomers
are transported to the Golgi apparatus where further processing of the sugar side
chains occurs, and eventually gp160 is cleaved into gp120 and gp41 by the host
enzyme furin. Once the gp120-gp41 complex arrives at the cell surface, it is
internalised. The incorporation of the env proteins into a budding particle is not well
understood but matrix is thought to play an important role (Freed, 1998).
1.5.7 Maturation
The final stage of the cell cycle is virion maturation which involves the cleavage of
the gag and gag-pol polyproteins by protease. The cleavage of gag takes place at five
different sites, all of which are important for infectivity. The order of cleavage
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occurs in the following sequence, NC-SP1, MA-CA, SP2-p6, NC-SP2 and CA-SP1.
This cleavage results in a dramatic change in virion morphology, with immature
virions appearing doughnut shaped by electron microscopy and mature virions
containing conical cores (Pornillos et al., 2009;Freed, 2001b).
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Figure 1.3 The stages of the HIV-1 life cycle. The life cycle begins with binding of the gp120 to the CD4 receptor. Through a series
of conformational changes, gp41 is exposed and the V3 region of gp41 binds to the chemokine co receptor CCR5 or CXCR to initiate
fusion of the viral membrane and the host cell membrane. The viral genome is uncoated and reverse transcription transcribes the RNA
to DNA followed by production of a second complementary DNA strand. The double stranded viral DNA is transported into the nucleus
via the pre integration complex. The viral DNA is integrated into the host chromosome and the provirus is established. The provirus
serves as a template for the production of new viral proteins and RNA genomes. The newly transcribed transcripts are transported out of
the nucleus and they assemble at the cell membrane, where the viral particle is released. The final stage is maturation of the viral
particle, characterised by the processing of viral polypetides into discrete proteins.
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1.6 Transmission routes
HIV can be transmitted horizontally through sexual contact or via infected blood or
blood products, and vertically from mother to child during pregnancy, at delivery or
through breastfeeding. The most common route of transmission is via sexual contact
(UNAIDS 2007, ). The transmission of HIV from other bodily fluids such as salvia
is very rare (Campo et al., 2006).
1.7 Pathogenesis of HIV-1
HIV-1 infection is acquired across the mucosal membrane during sexual and
perinatal transmission. The transmission of HIV from an infected to an uninfected
individual is correlated with the concentration of HIV-1 in the bodily fluid that is the
source of the infection. In a retrospective study carried out in Uganda, HIV
transmission was studied among couples. Individuals with a plasma HIV-1 RNA
level of <3,500 copies per millilitre did not transmit the virus onto their partner.
Individuals with a plasma HIV-1 RNA level between 10,000 and 49,999 copies per
millilitre showed a 40% rate of transmission to their partner (Quinn et al., 2000). A
Swiss meta-analysis of heterosexual discordant couples showed that the risk of HIV
transmission from the positive partner to the negative partner was reduced by 92% if
the positive partner was treated with antiretroviral therapy and had a suppressed HIV-
1 RNA level in plasma (Attia et al., 2009). A similar reduction in risk of transmission
as a result of HIV suppression with antiretroviral therapy was recently reported
among discordant heterosexual couples in Africa (Donnell et al., 2010).
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Since dendritic cells are located within the mucosal and the lymphoid tissues, it had
been suggested that they are among the first cells that encounter HIV-1 and are
responsible for transmitting the virus onto CD4+ T cells (Embretson et al., 1993;Wu
and KewalRamani, 2006). There are three stages of HIV-1 infection, the acute phase,
the chronic phase and AIDS as shown in figure 1.5. During the acute phase of the
infection, HIV-1 replicates within the host producing a viraemia over a period of a
few weeks since initial exposure. The viraemia is partially controlled by the host
immune system. The acute phase of the infection may occur asymptomatically or in
the presence of symptoms together forming the Acute Seroconversion Syndrome.
This typically includes flu-like symptoms, rash, fever, sore throat, fatigue and
lymphadenopathy for a couple weeks. During the acute phase, antibodies to HIV-1
may not be detected although the level of infectious virus within the patient is very
high. The development of a negative to positive antibody response is known as
seroconversion and this usually occurs within a few weeks following infection. The
acute phase is characterised by a significant depletion of CD4+ T cells, followed by a
partial recovery once the initial burst of virus replication subsides. The viral load
level decreases to a nearly stable level known as the viral set point. The set point has
been shown to predict the rate of disease progression and varies between individual
to individual (Mellors et al., 1996). The range of the viral set point is usually
between 103 and 105 RNA copies per millilitre.
The next stage is the chronic phase of infection, which comprises a generally long
asymptomatic phase before the development of AIDS. Despite this phase being
clinically silent or nearly silent, virus replication continues at high level accompanied
by chronically high levels of immune activation. This leads to progressive immune
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dysfunction and depletion of CD4+ T cells, leading to the onset of the clinical
manifestations of AIDS. The time between infection and development of AIDS is
approximately seven to ten years, but progression can be more rapid in
approximately 10% of patients (rapid progressors) and conversely delayed for over
10 years in about 5-10% of patients (slow progressors and long-term non
progressors).
The immune deterioration that occurs during the chronic phase eventually results in
the appearance of opportunistic conditions. This stage is known as AIDS and is
characterised by diseases such as Pneumocystis carnii pneumonia and Kaposi’s
sarcoma.
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Figure 1.5 Typical course of HIV-1 infection. The acute phase of infection is
characterised by the depletion of CD4 T cells and a high viraemia. The chronic
phase is characterised by a generally long asymptomatic phase during which virus
replication continues at high level while immune deterioration progresses. The final
stage is AIDS which is characterised by the appearance of opportunistic conditions,
ultimately resulting in death. Figure taken from (Feinberg and Moore, 2002).
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1.8 HIV-1 reverse transcriptase
1.8.1 Discovery of HIV-1 RT
Before the 1970’s, the central dogma of molecular biology was that genetic
information proceeded from DNA to RNA to protein. The discovery of RT in 1970
by Temin and Baltimore contradicted this central dogma since it was shown that RT
could allow genetic information to proceed from RNA to DNA. Temin worked on
Rous sarcoma virus to prove that the RNA genome could be converted into a
provirus and in doing so, the virus could lie dormant in cells (Temin and Mizutani,
1970). Baltimore worked on virus replication and looked for the presence of RNA
and DNA in virions of Rauscher murine leukaemia virus. Together, these
experiments showed that DNA could be synthesised from a DNA template
(Baltimore, 1970). Their discoveries of RT lead to their receiving the Nobel Prize for
Physiology and Medicine in 1975.
1.8.2 Functions of RT
RT is a key enzyme in the life cycle of HIV-1 as shown in step 3 of the virus life
cycle in figure 1.3. RT has three functions; an RNA dependent DNA polymerase
activity to synthesize a single stranded DNA copy from the RNA template, an DNA
dependent DNA polymerase activity to complete the synthesis of the newly
transcribed cDNA and an RNase H activity is required to degrade the RNA template
from the RNA-DNA hybrid (Sluis-Cremer et al., 2000b).
1.8.3 Structural features of RT – fingers/palm/thumb domains
The HIV-1 RT is a heterodimer composed of two subunits, p66 (66kDa) and p51
(51kDa) as shown in figure 1.6. The p51 subunit carries out essentially a structural
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role by serving as a scaffold to stabilize p66. It is initially processed as a polyprotein
that has both a pol and RNase H domain. Subsequent cleavage of the polyprotein
cleaves the RNase H domain producing subunits with and without a RNase H
domain corresponding to p66 and p51 respectively. The p66 subunit is responsible
for the catalytic activities of the enzyme and its structure is said to resemble a human
hand in that it contains five subdomains named thumb, fingers, palm, connection and
RNase domain. The p51 subunit shares the same subdomains as p66 except the
RNase sub domain (Shafer, 2002).
The palm and connection subdomains consist of five beta sheets with two alpha
helices on one side, the thumb subdomain consists of a four helical bundle. The
fingers subdomain consists of a beta sheet and three alpha helices. The beta strands
of the palm subdomain form hydrogen bonds with the beta strands at the base of the
thumb subdomain that results in hydrogen bonding to the connection beta sheet
(Kohlstaedt et al., 1992).
Despite the fact that subunits p51 and p66 share the same amino acid sequence, there
are some significant differences on how the subunits are folded. The p51 subunit has
no cleft and the residues that are involved in the catalytic functions of the enzyme are
buried. In the p51 subunit, the finger subdomain is positioned towards the palm
subdomain and the palm subdomain is situated further away from the fingers and
palm subdomains then in p66. A vital difference between these subunits is observed
in the connection domain. The p66 connection subdomain contacts the RNase H, the
bottom of the thumb and the connection subdomain of p51. The p51 subunit on the
other hand contacts the other subdomains and like p66, also contacts the connection
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subdomain of p66 (Kohlstaedt et al., 1992). It is interesting to consider why the
RNase H subdomain is cleaved from one of the subunits. It has been suggested that
there is an evolutionary pressure to increase the amount of information of viral
genomes. Therefore, the ability of the HIV-1 to encode two protein subunits from
the same gene through proteolytic cleavage gives the virus the ability to produce
proteins that can adopt more than one structure and function (Castro et al., 2006).
1.8.4 Comparison to other RT’s
The genomic organisation of HIV-2 is similar to that of HIV-1 with the two viruses
sharing between 60-70% sequence homology in the RT gene (Le Grice et al.,
1988;Shaharabany and Hizi, 1992). Similar to other retroviral RTs, the HIV-2 RT has
a RNA dependent DNA polymerase activity as well as an RNase H activity. The
HIV-2 RT is composed of a heterodimer consisting of p68, which is equivalent to p66
in HIV-1 RT and p55, which is equivalent to p51 in HIV-1 RT (Muller et al., 1991).
The connection domain in HIV-2 is much longer than that of HIV-1 RT and this has
been attributed to the specificity of the protease (Fan et al., 1995). A significant
difference between HIV-1 RT and HIV-2 RT is in the RNase H activity. HIV-2 RT
has a ten times slower RNase H activity than HIV-1 RT although the pattern of
cleavage is the same in both enzymes (Sevilya et al., 2001).
Moloney murine leukaemia virus RT (MoMLV RT) shares functional and sequence
similarities to the HIV-1 RT. An important site on RT is the polymerase active site.
Similar to HIV-1 RT, which has three aspartate in its catalytic active site at positions
Asp110, Asp185 and Asp186, MoMLV RT also shares these aspartate residues in its
active site at positions Asp150, Asp224 and Asp225 (Kohlstaedt et al., 1992;Boyer et
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al., 2001a). Furthermore, the dNTP binding site in HIV-1 RT requires residues K65
and R72 whereas in MoMLV RT, the corresponding residues are K103 and R110.
As mentioned previously, the HIV-1 RT is a heterodimer composed of 560 amino
acids and contains a fingers, palm, thumb, connection and RNase H subdomains.
Structurally, the MoMLV RT is a monomer of 671 amino acids and consists of the
same subdomains as HIV-RT, namely fingers, palm, thumb, connection and RNase H
(Roth et al., 1985;Tanese and Goff, 1988). Within the fingers and palm subdomains,
there is a 25% sequence identity between HIV-1 RT and MoMLV RT and the
connection domain has the least sequence identity with only 6% homology (Cote and
Roth, 2008).
The fidelity of RT can be defined as the accuracy at which the template strand is
copied. Enzyme processivity can be defined as the number of nucleotides
incorporated by RT before the RT dissociates from the template. The fidelity and
processivity of HIV-1 RT, HIV-2 RT and MoMLV RT have been compared and it was
found that the MoMLV RT had a higher fidelity, than both HIV-1 RT and HIV-2 RT,
which both had a similar fidelity (Bakhanashvili and Hizi, 1992b;Bakhanashvili and
Hizi, 1992a;Bakhanashvili and Hizi, 1993). The processivity of HIV-2 RT was
shown to be less than that of HIV-1 RT on a single stranded M13 DNA template
(Boyer et al., 2006).
The Escherichia coli Pol I Klenow fragment was also found to resemble a hand and
this likeness was extended to include the HIV-1 RT. However there does not appear
to be much sequence similarity but it can be said that these polymerases are related to
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each other to some extent in terms of structure. This conservation is particularly seen
in the subdomain that contains the catalytic site (Ollis et al., 1985).
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Figure 1.6 The structure of HIV-1 RT. The two domains p66 (in colour) and p51
(in grey) are shown. Within the p66 domain, the subdomains are shown as fingers
(red), palm (yellow), thumb (orange), connection (cyan) and RNase H (blue). The
DNA template (light green) and primer (dark green) strands are also shown. Figure
taken from (Kohlstaedt et al., 1992).
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1.9 Drug resistance
1.9.1 Current drug targets
The principal goals of antiretroviral therapy are to reduce morbidity, prolong
survival, improve quality of life, restore and preserve immunological function and
prevent transmission. Suppression of HIV-1 RNA in plasma (the “viral load”) is
used as a surrogate marker for these desired outcomes. Antiretroviral therapy,
typically combinations of three antiretroviral agents, can suppress the viral load to
below the detection limits of routine viral load assays (typically 50 copies per
millilitre) and this is considered to be the measure of successful therapy (Hammer et
al., 2008).
Following the introduction of highly active antiretroviral therapy (HAART), it was
thought that a ‘hit early hit hard’ approach could reduce morbidity and mortality,
prevent immune deterioration, and even eradicate the disease (Ho, 1995). The
rationale behind early treatment was that it would prevent damage to the immune
system and by controlling virus replication and lead to HIV eradication within
estimated three years of treatment (Ho, 1995). However, this approach was
mitigated by the following considerations. Firstly, HIV-1 infection cannot be
eradicated due to its persistence in latently infected T cells; the viral load rebounds
rapidly after stopping suppressive antiretroviral therapy, and treatment must therefore
be regarded as life-long. This raises concerns about the patient’s ability to maintain
adherence long-term, the risk of treatment failure with accumulating resistance and
exhaustion of treatment options, and long-term toxicity of antiretroviral drugs.
However antiretroviral therapy has evolved over time and is currently safer and
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simpler than in the past. A large number of options are available that allow a tailored
treatment, improving both adherence and tolerability. Emerging clinical data have
clearly shown the benefit of starting therapy earlier than it was recommended until
recently, in terms of improved morbidity and mortality. The beneficial effect of
treatment is seen not only in terms of reduced incidence of opportunistic conditions,
but also incidence of numerous co-morbidities that are triggered by HIV-associated
immune activation and inflammation (Baker et al., 2010). Thus, treatment guidelines
have been recently revised to recommend earlier initiation of therapy, before the CD4
cell counts declines below 500 cells per microliter in developed countries (Thompson
et al., 2010) and 350 cells per microliter in resource-limited settings (WHO 2009,
2010). The benefit of treating patients with a CD4 cell count above 500 cells per
microlitre is unclear (Volberding and Deeks, 2010;Gazzard et al., 2008). In all
guidelines however, emphasis is placed on the fact that treatment should be
considered in patients with CD4 cell counts above the recommended threshold for
therapy initiation in the presence of specific circumstances. These include for
example hepatitis B or hepatitis C infection, high cardiovascular disease risk, renal
disease, age >50 years, high viral load, or a rapid CD4 cell decline.
Currently antiretroviral therapy targets viral proteins at six main stages in the HIV-1
life cycle. This includes RT, protease and integrase, which inhibit reverse
transcription, proteolytic cleavage during maturation, and integration of proviral
DNA into the host genome respectively. The viral protein gp41 and the host cell
proteins CCR5, which are involved in virus entry, are also targeted.
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Novel therapeutic approaches to inhibit HIV-1 replication include targeting lipid
rafts, uncoating, RNase H activity, matrix, capsid, nucleocapsid, p6, accessory
proteins such as Vif, Vpu and Nef and also the host protein LEDGF/p75 which is
involved in the nuclear import of the PIC. The plasma membrane has regions of
microdomains that rich in cholesterol and lipids. Studies have shown that HIV-1
uses lipid rafts as platforms for viral particle assembly and release (Ono et al.,
2007;Waheed and Freed, 2009). Using compounds such as amphotericin B methyl
ester (AME) that bind to the virion lipid bilayer, viral particle production and
infectivity have been shown to be inhibited (Waheed et al., 2008;Waheed et al.,
2006).  The process of uncoating has also been investigated.  The TRIM5α protein 
targets partially uncoated incoming capsid resulting in either premature disassembly
or by recruiting the virion for proteasomal degradation.  Therefore TRIM5α like 
molecules that could restrict HIV-1 could be developed (Adamson and Freed,
2010;Wilkin et al., 2010).
The introduction of antiretrovirals and in particular HAART has vastly improved the
outcome of HIV infected patients. However, there is a significant risk of emergence
of resistance to these antiretrovirals and there are many factors that contribute to the
surfacing of resistance. Firstly, the RT is highly error prone and lacks a proofreading
ability, introducing an average of one to two mutations for each viral genome
transcribed (Bebenek et al., 1989;Ji and Loeb, 1992). Furthermore HIV-1 has a very
high replication rate, reaching up to 109-1012 virus particles produced daily in
untreated patients (Perelson et al., 1996). Therefore HIV infected patients harbour
numerous virus variants known as the quasispecies that can vary in their sensitivity
to antiretrovirals. Within the quasispecies, certain strains dominate and this
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represents the dynamic equilibrium between escape for selective pressure (e.g.
immune responses, drug therapy) and preserved ability to replicate and infect.
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Figure 1.7 Structure of nucleoside and nucleotide RT inhibitors (NRTIs).
Nucleosides include zidovudine (AZT), stavudine (D4T), zalcitabine (DDC),
didanosine (DDI), lamivudine (3TC), abacavir (ABC) and emtricitabine (FTC) and
one nucleotide tenofovir (TDF).
37
1.10 RT Inhibitors
Inhibitors of RT can be divided into two groups, nucleoside and nucleotide RT
inhibitors (NRTIs) and non-nucleoside RT inhibitors (NNRTIs).
1.10.1 NRTIs
The first NRTI to be developed was zidovudine (AZT). It was originally developed
in 1964 to treat cancer but was found to be ineffective in killing tumour cells. A
collaboration with the National Cancer Institute and the Burroughs Wellcome
Company led to finding that AZT could inhibit HIV-1 replication (Mitsuya et al.,
1985). NRTIs are competitive inhibitors that compete with the natural dNTP
substrate for incorporation into the growing DNA chain. NRTIs therefore share a
similar structure to dNTP’s in that they both have a nitrogenous base and are attached
to a ribose sugar. The discriminating feature is that the 3’ hydroxyl group of dNTPs
is absent which prevents further bonding and thus results in DNA chain termination
(El et al., 2007;Zdanowicz, 2006). There are currently 8 NRTIs, comprising seven
nucleosides, zidovudine (AZT), stavudine (D4T), zalcitabine (DDC), didanosine
(DDI), lamivudine (3TC), abacavir (ABC) and emtricitabine (FTC) and one
nucleotide tenofovir (TDF) as shown in figure 1.7. Once NRTIs enter cells they need
to be phosphorylated by cellular kinases to become active. The nucleoside analogues
are administered in an unphosphorylated form and require triphosphorylation. TDF
is administered as a monophosphate and requires biphosphorylation. The first
phosphorylation event is the rate-limiting step for all nucleosides except for AZT
where the second phosphorylation event is the rate-limiting step (Balzarini et al.,
1989;Furman et al., 1986).
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1.10.2 Mechanisms of resistance to RT inhibitors
There are at least two mechanisms of resistance to the NRTIs. The first mechanism
is mediated by mutations that interfere with binding and/or incorporation of the
NRTI figure 1.8. Examples include M184V, Q151M, L74V, K70E, and K65R. The
second mechanism is known as NRTI excision figure 1.9. Examples include the
thymidine analogue mutations (TAMs).
1.10.2.1 Binding and incorporation
The M184V mutation is selected by treatment with 3TC and FTC. This mutation is
situated close to the active site of the enzyme in the palm subdomain, which is highly
conserved among retroviral RTs. The change of amino acid from methionine to
valine causes steric hindrance between the oxathiolane ring of the 3TC and the side
chain of valine. Mutant RT containing M184V decreases the catalytic efficiency of
incorporation of the 3TC triphosphate however whether this is attributed to the KD
(dissociation constant) or kpol (polymerisation rate) is not known, but both are
thought to be important (Huang et al., 1998;Sarafianos et al., 1999a;Krebs et al.,
1997;Deval et al., 2004b).
The Q151M mutation is located within the palm subdomain of RT and interacts with
the nitrogen base of the dNTP resulting in the altered recognition and a reduced
incorporation of the NRTI. It is selected by multiple NRTIs, typically by
combinations such as AZT and DDI, and confers resistance to all available NRTIs,
albeit less so to 3TC and TDF (Sluis-Cremer et al., 2000a).
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The L74V mutation is located within the fingers sub domain and is selected by DDI
or ABC. The DDI resistance effects of L74V are related to the incorporation rates of
the inhibitor whereas ABC resistance is related to differences in the discrimination of
the inhibitor and natural substrate (Deval et al., 2004a;Winters et al., 1997)
The K70 residue is located in the β3-β4 hairpin loop of RT and is associated 
primarily with TDF resistance. Nucleotide discrimination appears to be the major
mechanism of resistance conferred by K70E, in particular a decreased incorporation
rate of the inhibitor (Sluis-Cremer et al., 2007).
The K65 residue interacts with the γ-phosphate of the incoming dNTP. The K65R 
mutation is selected by TDF, ABC and DDI and is located in the fingers subdomain.
The K65R mutation mediates nucleotide discrimination by decreasing the kpol for the
incorporation of the inhibitor (Huang et al., 1998;Selmi et al., 2001).
Several of these mutations, typically M184V, but also K65R and L74V reduce viral
replication capacity or fitness (Vivet-Boudou et al., 2006).
1.10.2.2 NRTI excision
The second mechanism of resistance is NRTI excision or primer unblocking. This
mechanism involves the selected removal of the incorporated NRTI from the end of
the growing DNA chain and is demonstrated by a group of mutations known as the
thymidine analogue mutations (TAMs), which are selected by the thymidine
analogues AZT and D4T. The evolution of TAMs can be divided into two pathways;
the TAM-1 pathway consists of M41L, L210W, T215Y and sometimes D67N. The
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TAM-2 pathway consists of D67N, K70R, T215F and K219Q/E. The first pathway
is associated with greater levels of AZT resistance and significant NRTI cross-
resistance than the second pathway (Marcelin et al., 2005;Miller, 2004;Hu et al.,
2006). The TAMs emerge in sequential order and their accumulation over time is
associated with increasing levels of resistance to AZT and D4T, as well as ABC, DDI
and TDF. The first TAM to appear is usually K70R followed by T215Y/F which
arises with M41L and L210W and D67N, K219Q/E can appear after either K70R or
T215Y/F (Garcia-Lerma, 2005).
The NRTI excision mechanism mediated by the TAMs occurs through a
pyrophosphorolysis reaction using cellular pyrophosphate or ATP as an acceptor.
The T215Y or T215F mutations are selected because the aromatic ring of the side
chain stacks with the adenine ring of ATP enhancing the ability of RT to bind to ATP
(Boyer et al., 2001b;Dharmasena et al., 2007).
The efficiency of the excision reaction is influenced by many factors including
whether the template strand is DNA or RNA, the specific NRTI blocking synthesis
and the presence of other resistance mutations. NRTI excision is less efficient when
the template strand is RNA rather than DNA (Nikolenko et al., 2005). The
thymidine analogues AZT and D4T are very efficiently removed whereas the cytidine
analogues 3TC and DDC are not very efficiently removed (Boyer et al.,
2001b;Meyer et al., 2000;Meyer et al., 1999). Other NRTI resistance mutations such
as K65R, L74V, M184V and the NNRTI resistance mutation Y181C are able to
enhance susceptibility to AZT and frequently also D4T in the presence of TAMs.
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These mutations have been shown inhibit excision of AZT (Gotte et al., 2000;Selmi
et al., 2003;White et al., 2006;Miranda et al., 2005).
A growing body of evidence has emerged implicating a role in drug resistance for
mutations in the connection and RNase H domains. These mutations have been
demonstrated to augment AZT resistance by altering the balance between NRTI
excision and RNase H activity. The mutations specifically reduce the RNase H
activity of RT, allowing more time for the RT to excise AZT from the terminated
primer template. Connection domain mutations such as E312Q, G335C/D, N348I,
A360I/V, A371V, V365I and A376S have been shown to increase resistance to AZT
(Nikolenko et al., 2007;viks-Frankenberry et al., 2007;viks-Frankenberry et al.,
2008;Yap et al., 2007). Mutations in the RNase H domain have also been shown to
increase AZT resistance including H539N, D549N and Q509L. These mutations are
also associated with TAMs (Brehm et al., 2007;Brehm et al., 2008;Nikolenko et al.,
2005).
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Figure 1.8 Mechanisms of NRTI resistance. Binding and incorporation. A drug sensitive virus has its replication blocked when the
NRTI binds. A virus containing the mutations M184V, L74V, K70E or K65R interfere the binding and incorporation of the NRTI.
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Figure 1.9 Mechanisms of NRTI resistance. NRTI excision mediated by the TAMs. A drug sensitive has its replication blocked
despite the presence of ATP. The virus containing TAMs excises the bound NRTI using ATP as a pyrophosphate donor, allowing chain
synthesis to continue.
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1.10.3 NNRTIs
Currently there are four approved NNRTIs for treating HIV-1 infection. Nevirapine
(NVP), efavirenz (EFV) and delavirdine (DLV) are first generation NNRTIs with
largely overlapping resistance pathways. Second generation NNRTIs can retain
activity against certain virus strains resistant to first generation NNRTIs (e.g.,
K103N) and include etravirine (ETV), which is already licensed, and rilpivirine
which is in advanced stages of development (figure 1.10). NNRTIs are non-
competitive inhibitors of RT. They bind to a hydrophobic pocket in the p66 subunit
that is close but distinct from the enzyme active site and NRTI binding site. The
NNRTI binding pocket can only form once the NNRTI is bound. Once the NNRTI
is bound, conformational changes occur in the RT that impact the catalytic ability of
the enzyme (Sluis-Cremer et al., 2004). All NNRTIs bind at the same site in RT and
this binding site is located in the palm subdomain of p66 approximately 10Ǻ from 
the catalytic active site. The hydrophobic pocket is lined with aromatic, hydrophobic
and hydrophilic residues. Binding of the NNRTI induces a conformational change
that rotates the side chains of residues Y181 and Y188 (Hsiou et al., 1996). NNRTIs
are highly specific inhibitors of HIV-1 and have no activity against HIV-2 (Tucker et
al., 1996).
Single amino acid substitutions are usually sufficient to confer high-level resistance
to the NNRTIs. These mutations are often clustered around the NNRTI binding
pocket, in particular, mutations at positions K103, Y181, Y188 and G190 cause
significant effects on resistance. These mutations effect the stacking interactions
between their aromatic side chains and the pyridine group of the NNRTI (Ren et al.,
2001). The K103N mutation is located at the rim of the NNRTI binding pocket and
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its side chain protrudes out. A hydrogen bond between the Y188 hydroxyl group and
the amide group of K103N is formed which creates an energy barrier reducing drug
potency (Ren et al., 2000). Mutations at positions L100, K101, V106, V108 and
E138 have also been shown to contribute to NNRTI resistance. Second generation
NNRTIs such as ETV have been developed to be effective against viruses containing
K103N, but are vulnerable to the effect of mutations at positions E138 (Tambuyzer et
al., 2010) and Y181 (Andries et al., 2004).
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Figure 1.10 Structure of the non-nucleoside RT inhibitors (NNRTIs).
Nevirapine (NVP), efavirenz (EFV), delavirdine (DLV) and etravirine (ETV).
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1.11 Protease Inhibitors
HIV-1 protease is involved in the maturation of the HIV-1 particle. It cleaves the
Pr55gag and Pr160gag-pol polyproteins to release structural and functional proteins,
including matrix, capsid, nucleocapsid, RT, protease and integrase. Protease
recognises the asymmetric shape of the peptide substrate rather than specific amino
acid sequences and consequently the amino acid sequence of all cleavage sites differ
(Prabu-Jeyabalan et al., 2002). Protease belongs to the family of aspartic proteases
and has an aspartic acid at position 25 in the active site. It is composed of two
identical subunits of 99 amino acids per monomer. Three main domains of protease
are often described, the active site cavity, the dimerisation domain and the flaps
(Navia et al., 1989).
Protease inhibitors (PIs) are competitive inhibitors and have been designed to bind to
the viral protease with high affinity. Once bound, they result in the production of
immature HIV particles that lack infectious abilities (Craig et al., 1991;Vacca, 1994).
Currently there are nine PIs in clinically use, saquinavir (SQV), ritonavir (RTV),
indinavir (IDV), nelfinavir (NFV), lopinavir (LPV) (co-formulated with ritonavir),
fosamprenavir (FPV) (as a prodrug of amprenavir), atazanavir (ATV), tipranavir
(TPV) and darunavir (DRV) (Mastrolorenzo et al., 2007). PIs are metabolised via the
cytochrome P450 enzyme system (CYP450) in the liver and gastrointestinal tract.
These pathways both act in different ways to restrict drug exposure. Processing in
the gastrointestinal tract reduces the proportion of the PI in the blood stream while
processing in the liver clears the PI already present in the blood stream. Hence the
half-life of the PI is reduced. To improve the bioavailability of PIs, a cytochrome
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P450 enzyme inhibitor known as ritonavir is used to ‘boost’ the plasma levels and
therefore the action of the PIs (Barry et al., 1997). PI can be divided into three
groups, first generation inhibitors (IDV, SQV, NFV and RTV), second generation
inhibitors (FPV, LPV, and ATV) and third generation inhibitors (TPV and DRV). The
first generation inhibitors were poorly adaptable to mutations in protease and
consequently the presence of a one or a few mutations caused resistance (Velazquez-
Campoy et al., 2002). In contrast the newer PIs have a higher affinity for the enzyme
active site and can tolerate the presence of a few resistance mutations without loss of
activity (Ohtaka et al., 2004).
The development of PI resistance is a stepwise process whereby mutations in the
substrate binding cleft are usually first to appear and this includes mutations at
positions D30, V32, M46, I47, V48, I50, I54, T74, L76, I84, V82 and N88. These
mutations cause an increase in the size of the catalytic site and as a result, there is
decreased binding of the PI. These mutations are known as primary or major
mutations. Secondary or minor mutations emerge later and although in isolation they
do not have a significant effect on resistance, in combination with primary or major
resistance mutations, these mutations contribute to an increased resistance and fitness
(Nijhuis et al., 1999;Mammano et al., 2000).
49
1.12 Integrase inhibitors
Integrase is required for the integration of the viral genome into the host
chromosome so that viral proteins can be produced. The process of integration can
be divided in to two stages, 3’ processing and strand transfer (Pommier et al., 2005).
Raltegravir is the first integrase inhibitor to be licensed for use in the treatment of
HIV infected patients. It is an inhibitor of the strand transfer step of integration. It
binds tightly to integrase and chelates the metal ions in the catalytic triad resulting in
sequestration of the crucial metal ion cofactors required for integrase to function
(Grobler et al., 2002). When integrase is inhibited, host enzymes circularise the viral
DNA and 2-long terminal repeats accumulate within the nucleus (Svarovskaia et al.,
2004).
Resistance to integrase inhibitors has been described as occurring in residues
surrounding the catalytic core and can be divided into three main pathways. The first
pathway consists of the N155H mutation, the second pathway consists of the
Q148K/R/H mutation and the third pathway consists of the Y143C/R mutation.
These mutations are primary resistance mutations and are associated with secondary
mutations that restore viral fitness (Delelis et al., 2009;Marinello et al.,
2008;Kobayashi et al., 2008).
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1.13 Fusion inhibitors
HIV-1 entry into the target cells is initiated through binding of the viral gp120
envelope glycoprotein to the CD4 host cell surface receptor. Following binding,
gp120 undergoes a conformational change enabling its interaction with a chemokine
co-receptor. The gp41 subunit is responsible for fusion of the viral and cell
membranes. It contains two heptad repeats, HP1 and HP2 and three monomers of
gp41 lie parallel to one another to make a six helical bundle. The formation of the
six helical bundle brings the two membranes closer together so that the fusion
peptide region capable of piercing the cell membrane is brought forward to form a
pore (Chan et al., 1997).
Enfuvirtide is the only fusion inhibitor that is currently in clinical use. Enfuvirtide
binds to the HR1 region gp41 and blocks the formation of the six helical bundle and
consequently fusion is blocked. Resistance to enfuvirtide is associated with changes
in a conserved triad of amino acids at positions 36-45 in HR1 of gp41 (Wei et al.,
2002;Mink et al., 2005).
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1.14 Entry inhibitors
CCR5 and CXCR4 are the major chemokine co-receptors that HIV-1 uses for entry
and their distribution on CD4 positive cells determines viral tropism. Entry
inhibitors targeting the chemokine co-receptor represent the first example of an
antiretroviral drug that targets a host cell protein rather than a viral protein.
Maraviroc was the first and to date the sole co-receptor antagonist approved for use
in the treatment of HIV (Macarthur and Novak, 2008). It is a non-competitive
inhibitor of the CCR5 co receptor. Maraviroc binds within a cavity in the membrane
spanning regions of the CCR5 helices, resulting in conformational changes within
the CCR5 receptor that prevents interaction with the V3 crown of gp120 (Watson et
al., 2005;Dragic et al., 2000).
Given the high variability in the envelope gene of HIV, it is not surprising that the
development of resistance to CCR5 is complex. Two mechanisms of resistance have
been suggested. The first mechanism involves the more efficient use of inhibitor free
CCR5. The second mechanism involves emergence of changes in the V3 loop that
allow the virus to bind the CCR5 co-receptor despite the presence of the antagonist.
These resistant variants retain the use of the natural CCR5 receptor as well as
binding to the altered inhibitor bound CCR5 (Westby et al., 2007;Pugach et al.,
2007). The use of CCR5 antagonists has raised concerns about whether there will be
an evolution towards CXCR4-using viruses. Emergence of CXCR4-using viruses has
been observed in patients experiencing virological failure during CCR5 antagonist
therapy as a result of the selection of pre-existing variants. This however has not
been associated with a negative impact on CD4 cell counts. In addition, the selected
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CXCR4-using variants are rapidly outgrown by R5 strains once the drug selective
pressure is discontinued, indicating a lack of intrinsic fitness advantage of CXCR4-
using strains under conditions of relatively preserved immunity and cell target
availability (Westby and van der, 2010).
53
1.15 Phenotypic assays
The development of drug resistance is a contributory factor that leads to treatment
failure (Alcorn and Faruki, 2000). To address this problem, resistance testing has
been used to help design new regimens for patients who harbour drug resistant
viruses (Hirsch et al., 2000). There are two types of resistance assays, genotypic and
phenotypic assays.
Genotypic assays involve amplification and sequencing of genes such as protease,
RT or integrase. Regions are reverse transcribed in vitro and amplified by either a
single or nested PCR reaction. Automated DNA sequencing is used to obtain the
sequence, which is compared to a wild type reference sequence such as HXB2.
Mutations are designated as those differing from the wild type reference sequence.
Drug resistance mutations are classified according to interpretation systems such as
the Stanford HIV Drug Resistance Interpretation Algorithm, French National Agency
for AIDS Research, International AIDS Society-USA and Rega Institute (Grant and
Zolopa, 2009).
For reliable amplification from plasma, most resistance assays require a viral load
between 500 to 1000 copies per millilitre, although amplification at viral loads less
than 500 copies per millilitre is possible. However, whether this would be an
accurate representation of the viral population within the patient is debatable (Alcorn
and Faruki, 2000). Nonetheless use of resistance testing at viral load of just a few
hundred copies has been shown to provide clinically useful information (Mackie et
al., 2010). It should also be noted that the population sequencing only detects viral
populations that represent more than 20% of the population (Schmidt et al., 2002a).
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In the absence of drug pressure, wild type virus tends to rapidly outgrow drug
resistant variants, which may thus become a minor species in the viral population.
Drug resistant variants may also be archived within proviral DNA in latently infected
cells. Once treatment is resumed, reselection of the resistant variants can occur
rapidly. Drug resistance should therefore be regarded as long lived. Although a
resistant mutant may be undetectable by routine resistance testing, it may be
detectable by more sensitive research methods. At least in the case of NNRTI
resistant mutants, these low frequency variants have been shown to impact
significantly on therapeutic responses. This concept has been well illustrated in
studies of single dose nevirapine to prevent mother to child transmission, patients
experiencing virological failure and patients with transmitted drug resistance
(Lecossier et al., 2005;Flys et al., 2005). Research tools that can achieve increased
sensitivity of detection include allele specific PCR, ultra deep sequencing and single
genome sequencing (SGS) (Johnson et al., 2008;Metzner et al., 2009;Paredes et al.,
2009;Johnson and Geretti, 2010;Geretti et al., 2009;Palmer et al., 2005). While with
some of these assays it is possibly to obtain a sensitivity well below 1%, cut-offs are
usually applied to aid interpretation and circumvent the issue of detection of the
natural background of resistant variants in the quasispecies and technical errors
intrinsic to the methodologies.
Phenotypic assays are another method of analysing the effect that resistance
mutations have on drug susceptibility. In their most common format, they involve
inserting a particular gene of interest, e.g. RT or protease into a defective vector to
produce a replicating recombinant virus. The virus and a wild type control are then
passaged into cells in varying concentrations of antiretrovirals. The drug
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concentration required to inhibit virus replication by 50% (IC50) or 90% (IC90)
relative to a control virus is calculated. The fold difference (fold change) between
the wild type and mutant virus are used as a measure of drug susceptibility
(Sebastian and Faruki, 2004).
Previously, phenotypic assays were performed on peripheral blood mononuclear cells
(PBMCs) in the presence of increasing concentrations of drug. The patient virus and
PBMCs were isolated and cultivated for 2-8 weeks. The readout for this assay was
typically p24 antigen production in the supernatant. Although this method has the
advantage of using cells and virus from the patient, there are major disadvantages.
These include the fact that the assay is time consuming, that given that the virus is
cultured for more than two weeks drug resistance mutations can be selected during
passage, and that reproducibility can be a problem due to natural biological
variations (Schmidt et al., 2002b;Japour et al., 1993). Therefore, a simpler
phenotypic method was developed based on the recombinant virus technique. The
assay involves amplifying the gene of interest and co transfecting with a defective
molecular clone to produce a recombinant virus. The readout for this assay was
initially a tetrazolium colorimetric assay that measured cell death (Kellam and
Larder, 1994).
The recombinant virus assay was subsequently modified into two different types of
assays, a single cycle assay and a multiple cycle assay. The single cycle assay allows
a single cycle of replication to occur whereas the multiple cycle allows multiple
cycles of replication. The single cycle has the advantage that it is a fairly rapid assay
compared to the multiple cycle assay, and results of replicate experiments generally
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show smaller variation. A commercial assay utilising the single cycle approach for
measuring drug susceptibilities is provided by Monogram Biosciences in the United
States. The multiple cycle assay has the advantage of the multiple cycle method is
the fact that the virus has multiple rounds of replication and therefore mimics more
closely the conditions that the virus experiences in vivo. However, the assay is more
complex and time consuming than the single cycle assay and retains the potential that
the virus may mutate during passage. Virco in Belgium provides a commercial assay
utilising the multiple cycle approach for measuring drug susceptibilities (Youree and
D'Aquila, 2002;Demeter and Haubrich, 2001).
To compare drug susceptibilities, the fold change is used. To aid interpretation, cut
offs are frequently used in routine diagnostics. The technical cut off is generated by
measuring the variation seen with repeat testing of the same samples. The biological
cut off represents the phenotypic variability observed within treatment naïve patients.
The clinical cut off represents the value that discriminates between treatment
responders and non responders among treatment experience patients. It should be
noted that phenotypic assays do not take into account drug-drug interactions which
may influence resistance (Hsu et al., 1998) and do not take into account the effect of
drug combinations as they assay each drug independently.
Despite the limitations of both genotypic and phenotypic assays, both methods have
been used to correlate virological failure with resistance (Deeks et al., 1999;Lorenzi
et al., 1999). It is accepted that resistance testing improves the virological outcome
of patients who have the benefit of its use and therefore, resistance testing is an
integral component of the management of HIV infected patients.
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1.16 Virus Fitness
Virus fitness can be defined as the ability of a virus to replicate and produce progeny
(Domingo et al., 1997). There are two stages to describe the evolution of viral fitness
whilst on therapy. The first stage is characterised by viruses that not only have
reduced drug susceptibility but an impaired replicative capacity relative to the wild
type. During the second stage, additional mutations arise that alone do not confer
drug resistance but in combination with the primary mutations enhance the
replicative capacity of the virus. These mutations are known as accessory mutations
(Nijhuis et al., 1999). It can be said that the natural evolution of HIV under drug
pressure is towards increasing levels of resistance, cross resistance and fitness.
There are a number of ways to measure virus fitness and these methods can be
divided into either in vivo or ex vivo methods. In vivo methods include calculating
fitness by comparing the amount of wild type and mutant viruses detectable in raw
sequence electropherogram data (Devereux et al., 2001). This method has also been
used to estimate the viral dynamics of CMV (Emery et al., 1999).
There are also many ex vivo methods that are employed to measure fitness, including
monoinfection assays, enzymatic assays and growth competition assays.
Monoinfection assays involve quantifying virus replication. This includes measuring
specific viral proteins such as p24 by ELISA or RT activity. Enzymatic assays that
measure enzyme activity such as protease processing or maturation or RT RNase H
activity offer good insights into the effect drug resistance mutations can have on
enzyme functioning (Martinez-Picado and Martinez, 2008). Another method to
measure virus replication is to use a reporter gene like luciferase for instance in a
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single cycle assay (Dykes and Demeter, 2007). Advantages of using a single cycle
system to measure fitness include the fact that they are rapid and reproducible (Deeks
et al., 2001b;Petropoulos et al., 2000b). One drawback to single cycle assays is that
they do not measure significant differences in fitness between viruses that may differ
by only a single nucleotide.
Growth competition assays are regarded as the gold standard for assessing virus
fitness in vitro. They measure the relative fitness between two virus strains. The two
strains are mixed together at specific ratios and passaged into cells. The outgrowth
of one strain is a reflection of greater fitness. These assays are accurate but time
consuming. They have the advantage that small changes in fitness can be detected
and that they provide as close as possible a reproduction of conditions in vivo. A
major challenge when setting up growth competition assays is developing the
appropriate technique to differentiate between mutant and wild type strains. Previous
studies have used sequencing, real time PCR or a recombinant marker assay
(Quinones-Mateu and Arts, 2002).
Generally drug resistance mutations are associated with a lower fitness compared to
wild type virus in the absence of drug. An interesting question is whether the drug
resistant mutations can affect likelihood of transmission from person to person. In
support of this hypothesis, studies have demonstrated that the 3TC mutation M184V,
which has a significant impact on viral fitness, has a high prevalence among treated
patients but is rarely seen in drug naive patients (Catucci et al., 1999). However the
older studies relied on population sequencing as a way of detecting resistance.
Recent studies using ultrasensitive methodologies have found a relatively high
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frequency of M184V among treatment naive patients (Geretti et al., 2009;Johnson et
al., 2008;Johnson and Geretti, 2010;Metzner et al., 2009;Paredes et al., 2007).
Given the fact that an unfit virus would replicate less efficiently, it is also reasonable
to speculate that if an unfit virus was transmitted, a lower viral load set point could
be established. A recent study found the drug-naive patients with the M184V
mutation (detected by routine resistance testing) had indeed a lower viral load than
patients without the mutation (Harrison et al., 2010). Since the viral load set point
has been directly associated with disease progression, it is not unreasonable to
speculate that viral fitness could also be associated with disease progression. One
study examined the impact of fitness on CD4+ T cell counts and viral load in acutely
infected HIV-1 infected patients (Barbour et al., 2004). Using the single cycle fitness
assay provided by ViroLogic, the fitness of the wild type viruses varied widely with
only 11/191 (6%) attributed to the presence of drug resistance mutations. No
correlation was seen between fitness and the viral load level recorded at baseline.
Furthermore, a threshold value of 42% (compared to the reference control) appeared
to be the best predictor of the baseline CD4+ T cell count. Patients showing fitness
over 42% having an average CD4+ T cell count of 512 cells per microlitre compared
to patients showing a fitness of less than 42% having an average CD4+ T cell count
of 663 cells per microlitre. It should be noted that the assay variability was high, with
95% confidence intervals of 12% to 93%. The same group studied viral fitness in
acutely infected HIV-1 patients using the multiple cycle system by Monogram. They
found no correlation between fitness and viral load or CD4+ T cell counts at baseline
(Barbour et al., 2006). It should be noted that these studies do not take into
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consideration other determinants of fitness such as the contribution of Env and
immunological escape.
In a study looking at viral fitness in long-term non progressors, a reduced fitness was
seen in 2/4 (50%) of patients. This study used virus and PBMCs isolated from the
patients and measured fitness by monitoring p24 antigen levels. These patients
showed evidence of HIV specific cellular immune responses and high tires of
neutralising antibodies, which may account for the attenuated severity of the disease
(Cao et al., 1995). A similar study using long-term non progressors also showed that
their viruses had a reduced fitness (Blaak et al., 1998).
The influence of drug resistance mutant with a reduced fitness may influence clinical
outcome. However, larger studies that take into account confounding variables such
as the immune response and host genetic factors need to be done to provide more
information regarding the impact of virus fitness on clinical outcomes.
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1.17 Accessory mutations
When therapy fails to suppress viral replication, resistance mutations emerge that
generally reduce virus fitness relative to wild type virus. If replication continues to
occur, new mutations emerge alongside major resistance mutations, which may either
further augment resistance or restore virus fitness. The mutations have mainly been
identified through statistical analyses of large databases, comparing the frequency of
different mutations in untreated and treated persons and identifying clinical
correlates. As a result the individual in vitro effects of the mutations are often
unknown and the mutations are not generally included in the routine interpretation of
genotypic resistance.
Currently, 61 novel mutations at 44 positions have been associated with NRTI
resistance (Perno et al., 2006) (tables 1.1 and 1.2). These mutations can be classed
into two groups. The first group includes mutations that that are present in treatment
experienced patients and very rarely present in drug naïve patients, and are usually
observed with major NRTI resistance mutations. Two conclusions can be inferred
from these observations, firstly that they require drug pressure to emerge and
secondly, that they emerge after prolonged exposure to NRTIs. Therefore these
mutations could contribute to increasing resistance and/or fitness (Gonzales et al.,
2003;Rhee et al., 2005). One example includes the K20R mutation, which was found
in 1/47 (2%) treatment naïve patients and in 29/47 (62%) patients that were treatment
experienced. K20R has been shown to confer a reduced susceptibility to 3TC
(Saracino et al., 2006;Svicher et al., 2006). Another example includes the E40F and
K43E mutations, which cause resistance and have effects on viral fitness.
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Introduction of these mutations on a M41L + T215Y RT backbone resulted in a 135
fold increase in resistance to AZT compared to HXB2. Growth competition
experiments showed that the virus containing M41L, T215Y, E40F and K43E was
more fit than the M41L and T215Y virus (Huigen et al., 2008).
The second group includes mutations that are common polymorphisms in drug naïve
patients but their prevalence increases further in treatment experienced patients.
Unlike the mutations in the first group, these mutations may not contribute
significantly to fitness but may have an effect on drug resistance (Ceccherini-
Silberstein et al., 2005;Gonzales et al., 2003;Rhee et al., 2005). This group includes
the G196E mutation, which was found in 88/551 (16%) of treatment naïve patients
and 120/417 (29%) of treatment experienced patients and found to contribute to AZT
and 3TC resistance (Stoeckli et al., 2002;Svicher et al., 2006). Another example is
the K122E mutation, which was found in 121/551 (22%) of treatment naïve patients
and 175/417 (42%) of treatment experienced patients and found to confer an
increased resistance to AZT, D4T and TDF (Svicher et al., 2006).
These two groups of mutations have been shown to contribute to NRTI resistance in
a positive way in that their presence increases resistance. However, there are
mutations that have been associated with a negative impact on NRTI resistance.
Characteristics of these mutations include that they are commonly observed in drug
naïve patients and their prevalence decreases in treatment experienced patients, in
particular those who have experienced virological failure. Furthermore, these
mutations are rarely observed with NRTI resistance mutations and if they are present
together, these mutations confer an increased susceptibility to the NRTIs. Examples
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include V35I and R83K. The V35I mutation was found in 127/551 (23%) of
treatment naïve patients and 58/417 (14%) treatment experienced patients. Similarly,
the R83K mutation was found in 182/551 (33%) of treatment naïve patients and
83/417 (20%) of treatment experienced patients. R83K has also been associated with
AZT, DDI and D4T resistance (Svicher et al., 2006;Ceccherini-Silberstein et al.,
2005).
Novel mutations associated with the NNRTIs have also been identified, with 33
novel mutations at 22 positions associated with NNRTI exposure (table 1.3). The
majority of these mutations are found within the hydrophobic binding pocket. The
I132M has been shown to contribute to an increased susceptibility to AZT, 3TC and
TDF but a decreased susceptibility to NVP, EFV and DLV (Nissley et al.,
2007;Ambrose et al., 2009).
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Table. 1.1 Accessory mutations associated with NRTIs exposure.
Table. 1.2 Accessory mutations associated with NRTIs exposure.
aPositions highlighted in bold indicate residues that can also show major mutations associated with NRTI resistance. NRTI accessory
mutations were classified according to (Svicher et al., 2006;Perno et al., 2006;Cane et al., 2007).
NRTI Associated Accessory Mutationsa
K
20
R
V
35
M
T
39
A
E
40
F
K
43
EN
Q
N
57
H
V
60
I
S
68
GR
D
113
EG
Y
115
HN
K
122
E
Q
145
LM
P
157
S
S
162
A
S
163
N
G
196
E
T
200
AE
IK
I
202
V
E
203
K
Q
207
ED
H
208
Y
R
211
KG
S
NRTI Associated Accessory Mutationsa
F
214
L
D
218
E
K
219
R
K
223
Q
L
228
HM
R
G
333
DE
G
335
C
N
348
I
R
356
K
G
359
S
A
360
I
T
369
I
A
371
V
T
377
L
E
399
D
L
469
T
Q
509
L
H
539
N
D
549
N
K
558
R
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Table. 1.3 Accessory mutations associated with NNRTIs exposure.
NNRTI Associated Accessory Mutationsa
1
3
L
E
6
K
V
35
L
E
40
K
S
48
T
A
62
V
L
74
V
V
90
I
K
101
Q
V
106
I
I
134
A
M
I
135
KL
MR
TV
V
179
FI
Y
181
HS
W
G
196
R
H
221
Y
K
223
EQ
F
227
C
L
228
HR
L
283
I
N
348
I
T
369
I
T
386
A
E
399
D
aPositions highlighted in bold indicate residues that can also show major mutations associated with NNRTI resistance. NNRTI
accessory mutations were classified according to (Svicher et al., 2006;Perno et al., 2006;Cane et al., 2007).
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1.18 H208Y
It has been suggested that the H208Y mutation is an accessory mutation that arises in
order to increase resistance and or viral fitness. H208Y is located in the fingers
subdomain of RT.
The H208Y mutation was identified following passage of recombinant HIV-1 in the
presence of foscarnet. Foscarnet is a pyrophosphate analog that demonstrates a
broad activity against both RNA and DNA viruses including CMV, HSV-1 and HIV-
1. It binds to the pyrophosphate binding site on RT and blocks HIV-1 replication
(Crumpacker, 1992). After 13 passages the foscarnet resistant virus demonstrated an
8.5 fold foscarnet resistance and also an increased susceptibility to AZT. Sequencing
the RT gene showed the emergence of G161L and H208Y, which were suggested to
be responsible for foscarnet resistance (Tramontano et al., 1998).
Further work carried out on HIV patients who had been treated with various
antiretrovirals including NRTIs, NNRTIs and PIs demonstrated a strong association
of H208Y with the TAMs M41L and T215Y. M184V was not a prerequisite for the
presence of H208Y. Site directed experiments showed that the triple mutant
H208Y/R211K/L214F in the background of TAMs resulted in a 21-fold AZT
resistance (Sturmer et al., 2003). These findings were supported by the study carried
out by Svicher et al. 2006. This study also showed that H208Y in the presence of
M41L/L210W/T215Y conferred resistance to all NRTIs including AZT and D4T.
Despite these findings indicating a role of H208Y conferring resistance to AZT, a
contradictory study showed that H208Y when present in isolation decreased
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susceptibility to AZT and NNRTIs. This study also showed using a single cycle
replicative capacity assay, that the H208Y mutation had a similar replicative capacity
to the wild type strain (Clark et al., 2006). Currently however, the H208Y mutation
is not recognised as a major NRTI mutation.
The H208Y mutation has been suggested to play a role in NRTI resistance for many
reasons. Firstly, the incidence of H208Y in treatment naïve patients is very low at
0.3% (n=2347) compared to treatment experienced patients where it is 4.1%
(n=4005) (Nebbia et al., 2007). The low incidence in naïve patients compared to
treatment experienced patients suggests that the H208Y requires drug selective
pressure to arise. Furthermore, H208Y has been shown to appear alongside other
known major resistance mutations such as M184V and TAMs suggesting that it may
further increase the level of resistance associated with NRTI exposure, or possibly
increase the replicative capacity of a heavily mutated NRTI resistant virus. This is
consistent with the finding that the H208Y mutation is rarely observed in the absence
of major NRTI mutations M184V and TAMs (Cane et al., 2007;Sturmer et al.,
2003;Nebbia et al., 2007;Stoeckli et al., 2002).
In this thesis the H208Y mutation has been characterised to test the hypothesis that
H208Y is an accessory mutation. In order to test this hypothesis, three main aspects
were investigated. Firstly, the association of H208Y to major resistance mutations
and other accessory mutations was examined. Also, the contribution of H208Y to
conferring drug resistance and viral fitness was explored.
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Chapter two
2 Materials and Methods
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2.1 Materials
2.1.1 Bacteria
HB101: F–, thi-1, hsdS20 (rB–, mB–), supE44, recA13, ara-14, leuB6, proA2, lacY1,
galK2, rpsL20 (strr), xyl-5, mtl-1.
TOP10F’: F´ {lacIq Tn10 (TetR)} mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
ΔlacΧ74 recA1 araD139 Δ(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG
XL1 blue supercompetent cells: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac
[F´ proAB lacIqZΔM15 Tn10 (Tetr)].
2.1.2 Mammalian cell lines
MT4: human T cells isolated from patient with T-cell leukaemia (Harada et al.,
1985).
2.1.3 Bacterial Media
LB: 10 g tryptone, 5 g yeast extract, 5 g sodium chloride and deionised water to a
final volume of 1 litre. Ampicillin and IPTG were added at a concentration of 50
ug/ml and 100 mM respectively. LB agar was made by adding 1.5% agar.
Terrific broth: 12 g tryptone, 24 g yeast extract, 4 ml glycerol, 100 mL of 0.17M
KH2PO4 and 0.72M K2HPO4 and deionised water to a final volume of 1 litre.
NZY broth: 10 g of NZ amine (casein hydrolysate), 5 g of yeast extract, 5 g of
sodium chloride, 12.5 ml of 1M magnesium chloride, 12.5 ml of 1M magnesium
sulphate, 10 ml of 2M glucose and deionised water to a final volume of 1 litre. The
pH was adjusted to 7.5 using sodium hydroxide.
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S.O.C: 20 g tryptone, 5 g yeast extract, 0.5 g sodium chloride, 2.5 ml 1M potassium
chloride, 20mls 1M glucose and deionised water to a final volume of 1 litre. The pH
was adjusted to 7 with sodium hydroxide.
2.1.4 Cell culture
Cells were grown in RPMI (GIBCO, Invitrogen, Paisley, UK) supplemented with
100 U/ml of penicillin, 100 ug/ml of streptomycin and 10% fetal bovine serum (FBS)
(BioSera, Ringmer, UK).
2.1.5 Antiretrovirals
NRTIs: zidovudine, abacavir, lamivudine, tenofovir and didanosine.
NNRTIs: nevirapine, efavirenz and etravirine.
All antiretrovirals were obtained through the AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH.
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Table. 2.1 Primer sequences
Primer name Sequence 5’-3’ Position inHXB2
Res 1 GAAGAAATGATGACAGCATGTCAGGG 1822-1844
Res 2 TAATTTATCTACTTGTTCATTTCCTCCAAT 4173-4199
Pin 2 GGCTGTACTGTCCATTTATCAGG 3254-3276
Pin 18 CAGTATTAGTAGGACCTACACC 2472-2493
Pout 3 AAGGGCTGTTGGAAATGTGG 2019-2038
PK pout 3 CATTGCTCTCCAATTACTGTGATATTTCTCATG 4263-4295
PK pout 5 GGTACAGTATTAGTAGGACCTACACCTGTCAACAT 2469-2503
PK pin 3 TCTATTCCACAAAAATAGTACTTTCCTGATTCC 4212-4246
PK pin 5 AATTTTCCCATTAGTCCTATTGAAACTGTACCAG 2544-2577
Res 3 ATGGYTCTTGATAAATTTGATATGTCC 3559-3582
Res 4 AGACAGGCTAATTTTTTAGGGA 2077-2095
Seq 1 CAAGGCCATTGACAGAAG 2616-2634
Seq 2 GGATCACCAGCAATATTCCA 3012-3031
Seq 3 CAAGGCCAATGGACATATCA 3549-3568
Seq 4 CTTCTATGTAGATGGGGC 3866-3883
Seq 5 TGGGCCATCCATTCCTGGCTT 2586-2606
Seq 6 CATCCCTGTGGAAGCACATT 2998-3007
Seq 7 TCTGCTATTAAGTCTTTTGAT 3512-3532
Seq 8 GGAAAGTACTATTTTTAGATGGAATAGA 4219-4246
Pyro forward ATGGAAAGGATCACCAGCAA 3005-3024
Pyro reverse TGTTGAGGTGGGGACTTACC 3175-3194
Pyro seq 1 CAAAAATAGAGGAG 3148-3161
Pyro seq 2 GAGGAGCTGAGACAA 3156-3170
Pyro seq 3 AAAATAGAGGAGCTGAGACA 3150-3169
TaqMan forward GACATAGTTATCTATCAATACAT 3078-3100
TaqMan reverse GATAAATGGACAGTACAGCC 3258-3277
ASPCR mt st A GCATAGAGCAAAAATAGAAGAGTTAAGAGGTT 3140-3171
ASPCR wt st A CATAGAGCAAAAATAGAAGAGTTAAGAGGTC 3141-3171
ASPCR mt st B CATAGAGCAAAAATAGAGGAACTRAGACGAT 3141-3171
ASPCR mt st B CATAGAGCAAAAATAGAGGAACTRAGACGAC 3141-3171
SDM st B
forward
GAACAAAAATAGAGGAGCTGAGACAACATCTGTTGAG
GTGGGG
3145-3187
SDM st B
reverse
CCCCACCTCAACAGATGTTGTCTCAGCTCCTCTATTTTT
GTTC
3145-3187
SDM st A
forward
GAGCAAAAATAGAAGAGTTAAGAGCTCATCTATTGAGC
TGGGG
3145-3187
SDM st A
reverse
CCCCAGCTCAATAGATGAGCTCTTAACTCTTCTATTTTT
GCTC
3145-3187
SDM stA
V184M forward
CCAGAAATAATTATCTATCAATATATGGATGATTTGTATGT
AGGATC
3075-3121
SDM stA
V184M reverse
GATCCTACATACAAATCATCCACATATTGATAGATAATTA
TTTCTGG
3075-3121
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Table. 2.2 Probe sequences
Probe Name Sequence Position inHXB2
ASPCR ATGGGTTATGAACTCCATCCTGA 3237-3259
TaqMan mt CTAAGACAATATCTGTT 3162-3178
TaqMan wt CTAAGACAACATCTGTT 3162-3178
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2.2 Methods
2.2.1 Identification of patients
All HIV-1 infected patients that attend the Royal Free Hospital for drug resistance
testing have their pol gene sequences and genotypic profile entered into a database.
This database also includes treatment regimens, plasma HIV-1 RNA load and HIV-1
subtype. In March 2010, this database contained approximately 8500 pol sequences.
Upon examination of the database 17 patients harbouring H208Y were identified.
From these 17 patients, 12 were treatment experienced and 5 were treatment naïve.
Ethics approval for use of HIV infected patient samples in phenotypic studies was
obtained prior to beginning the study.
2.2.2 Molecular Biology
2.2.2.1 Extraction of viral RNA
All nucleic acid extraction methods are based on the Boom extraction method (Boom
et al., 1990). Both automated and manual extraction methods were used. The
automated method was carried out by the EasyMag automated extractor (Nuclisens,
Biomerieux, Boxtel Netherlands).  Nucleic acid was extracted from 500μl of patient 
plasma according to the manufacturer’s instructions.  RNA was eluted into 55μl 
elution buffer and stored at -80ºC until required.
Manual RNA extractions were done using the Qiagen QIAamp Viral RNA kit
(Qiagen, Crawley, UK).  Briefly, 200 μl of HIV infected culture supernatant was 
lysed under denaturing conditions using guanidine thiocyanate and bound to the
silica membrane in the spin column thorough centrifugation. Contaminants and
proteins in the sample were removed by washing with specific buffers. Viral RNA
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was eluted into 60 μl of RNase-free water containing 0.04% sodium azide.  RNA was 
stored at -80ºC until required.
2.2.2.2 Random priming
10 μl of eluted RNA was denatured at 65°C for 30 seconds followed by 5 minutes at 
42°C.  10 μl of reverse transcription mix was added to the RNA.  The mix consisted 
of 5XRT buffer containing 1.5 mM MgCl2, (Promega, Southampton, UK), 250 uM of
each dNTP, 500 ng random primers (Promega, Southampton, UK), 200 units of
MMLV reverse transcriptase (Promega, Southampton, UK) and 20 units of RNase
inhibitor (Promega, Southampton, UK). Cycling conditions were 42°C for 60
minutes followed by 99°C for 5 minutes.
2.2.2.3 One step RT-PCR
The Qiagen one step RT-PCR kit (Qiagen, Crawley, UK) was used to amplify codons
1-345 of the HIV-1 RT gene. The RT-PCR mix contained primers res 1 and res 2
(table 2.1) at a final concentration of 600 uM each, 400 μM of each dNTP, 5X RT-
PCR buffer containing 1.25 mM MgCl2, 2 μl of RT-PCR enzyme, 10 μl of RNA and 
made up to a final reaction volume of 50 μl with water.  Reaction conditions were 
one cycle of 50ºC for 35 minutes, 95ºC for 15 minutes, 95ºC for 30 seconds, 65ºC for
45 seconds, 72ºC for 3 minutes, 95ºC for 30 seconds, 60ºC for 45 seconds. 72ºC for 3
minutes, followed by 45 cycles of 95ºC for 30 seconds, 58ºC for 45 seconds, 72ºC
for 3 minutes, finally 72ºC for 10 minutes and a hold at 4ºC.
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2.2.2.4 Amplification of codons 1-335 of the reverse
transcriptase gene
20 μl of cDNA was used to amplify codons 1-335 of the reverse transcriptase (RT) 
gene. The PCR mix consisted of 10Xbuffer containing 2.5 mM MgCl2, 250 uM of
each dNTP, 5U AmpliTaq Gold Polymerase (Applied Biosystems, UK) and 200 uM
of primers pin 18 and pout 3 (table 2.1). PCR cycling conditions were 35 cycles of
95°C for 15 minutes, 95°C for 30 seconds, 54°C for 45 seconds, 72°C for 2 minutes
followed by 72°C for 10 minutes and a hold at 4°C.
2.2.2.5 Amplification of codons 1-560 of the reverse
transcriptase gene
Codons 1-560 of the reverse transcriptase gene were amplified using 20 μl of cDNA 
in a 100 μl PCR mix which consisted of 10Xbuffer containing 1.5 mM MgCl2, 375
uM of each dNTP, 150 uM of primers and 2.5units of PfuUltra high fidelity DNA
Polymerase (Stratagene, Cheshire, UK). PCR cycling conditions were 35 cycles of
95°C for 3 minutes, 90°C for 1 minute, 55°C for 30 seconds, 72°C for 3 minutes
followed by 72°C for 10 minutes and a hold at 4°C. Primers PK pout 3/5 were used
in the 1st round PCR and PK pin 3/5 were used in the nested PCR (table 2.1).
Nested PCR was done using 10 μl of the first round PCR product.  Cycling and reagent 
conditions were the same as the first round PCR conditions.
2.2.2.6 Gel electrophoresis
Agarose gel electrophoresis was used to confirm the correct size of the PCR product.
1.5 g of agarose was dissolved in TAE buffer in a microwave and once cooled, 10
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mg/ml ethidium bromide was added. PCR products were mixed with 5Xloading dye
and loaded onto the gel with the DNA mass ladder hyperladders I-IV (Bioline,
London, UK). Gels were run for approximately 1-2 hours at 100 volts, depending on
the size of the band expected. All gels were visualised using a UV transilluminator
(Biorad, Hertfordshire, UK)
2.2.2.7 Purification of PCR product
PCR products were visualised using ethidium bromide staining and agarose gel
electrophoresis. The desired product was either excised using the QIAQuick Gel
Extraction Kit (Qiagen, Crawley, UK) or purified using the QIAQuick PCR
Purification kit (Qiagen, Crawley, UK) in accordance with the manufacturer’s
instructions. Briefly, the PCR product was added to the buffer containing the
chaotropic agent guanidine thiocyanate and bound to the silica membrane in the
QIAquick spin column through centrifugation for 1 minute at 13,000rpm. Impurities
and contaminants were removed through washing with an ethanol containing buffer
and DNA was eluted into a low salt and pH containing buffer.
2.2.2.8 A-tailing
To enable efficient TA cloning of products generated with high fidelity polymerases,
purified PCR products were added to a mix of 250 uM dATP, 10Xbuffer containing
2.5 mM MgCl2, and 2.5 units of Amplitaq Gold Polymerase. The mix was heated to
95oC for 10 minutes followed by 20 minutes at 72oC.
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2.2.2.9 PCR cloning
The TOPO TA cloning kit (Invitrogen, Paisley, UK) was used to clone the HIV
reverse transcriptase gene. TOPO TA cloning uses Topoisomerase I to ligate the
PCR product with an A nucleotide overhang into the vector which contains the T
nucleotide overhang. All PCR products were cloned into pCR 2.1-TOPO. The
ligation reaction consisted of 4 ul PCR product, 1 ul salt solution and 1 ul TOPO
vector. Ligation reactions were incubated at room temperature for 5 minutes and
then stored on ice ready for transformation. 2 ul of the ligation reaction was
transformed into a vial of 50ul TOP10F’ E. coli cells and incubated on ice for 5-30
minutes. Cells were then heat shocked at 42ºC for 45 seconds and cooled on ice for
2 minutes. 250 ul of SOC medium (Invitrogen, Paisley, UK) was added to the cells
and incubated in a 37ºC orbital shaker for 1 hour. Cells were plated onto LB agar
plates containing 50 ug/ml ampicillin and 100mM IPTG and incubated overnight at
37ºC.
2.2.2.10 Site directed mutagenesis
Site directed mutagenesis was carried out using Quickchange Muliti/Site Directed
Mutagenesis Kit (Stratagene, Cheshire, UK) to insert desired mutations. All primer
combinations were designed specifically to incorporate the desired mutation and are
shown in table 2.1. 50 ng plasmid and 125 ng of the primers containing the required
mutation were used in the following PCR, 12-18 cycles of 95°C for 30 seconds, 90°C
for 30 seconds, 55°C for 1 minute, 72°C for 2 minutes and a hold at 4°C. In order to
degrade the parental DNA plasmid, the PCR product was incubated at 37ºC for at
least one hour with the restriction enzyme Dpn1. The digested PCR product was
then transformed into XL1-blue supercompetent cells and plated onto LB agar plates
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containing 50 ug/ml ampicillin, 80 ug/ml Xgal and 20 mM IPTG. Plates were
incubated overnight at 37ºC. The desired mutations were confirmed by sequencing
the full RT gene using Sanger sequencing.
2.2.2.11 Minipreps
Plasmid DNA was extracted from bacterial cells using the methodology described by
(Birnboim and Doly, 1979).
Plasmid DNA was extracted from bacterial cells using the QIAPrep Spin Miniprep
Kit (Qiagen, Crawley, UK). in accordance with the manufacturer’s instructions.
Briefly, DNA was extracted from 2 mls of LB broth containing 50 ug/ml ampicillin
overnight cultures, inoculated using a single transformed white colony. Bacterial
cells were resuspended and lysed under alkaline conditions. The lysate was then
neutralised with acetic acid and bound to the silica membrane of the QIAprep spin
column through centrifugation for 1 minute at 13,000rpm. Remaining impurities
were washed away using an ethanol based buffer. The plasmid DNA was then eluted
under low salt conditions into RNase-free water.
Maxipreps of the vectors was done using the JETstar plasmid purification kit
(Genomed-DNA, Löhne, Germany) according to the manufacturer’s instructions.
Briefly, DNA was extracted from 100 mls of LB broth containing 50 ug/ml
ampicillin overnight cultures. Bacterial cells were resuspended and neutralised with
acetic acid. The plasmid was bound to the anion exchange resin and all impurities
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were washed away using an alcohol based buffer. The plasmid DNA was eluted and
concentrated by alcohol precipitation.
2.2.2.12 Restriction digest
5 ul of miniprep were digested with 1ul EcoRI (Invitrogen, Paisley, UK), 2ul buffer
containing 1 mM MgCl2, and 12ul RNase free water. Digests were incubated for 1
hour at 37ºC and visualised using ethidium bromide staining and agarose gel
electrophoresis. Positive clones were identified as those harbouring the correctly
sized inserts.
2.2.2.13 Sequencing
All DNA was sequenced using Sanger sequencing. Plasmids identified as containing
the PCR insert were then sequenced using the BioDye Sequencing mix v1.1. Primers
seq 1 to seq 8 (table 2.1) were used to get an overlapping readable sequence. The
sequencing PCR conditions were as follows, 25 cycles of 96°C for 10 seconds, 50°C
for 5 seconds and 60°C for 4 minutes and a hold at 4°C. Sequences were analysed
using a 3100-Avant Genetic Analyzer (Applied Biosystems, UK).
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2.2.3 Cell Culture
2.2.3.1 Passaging cells
MT4 cells are adherent cells derived from lymphocytes. They were passaged twice a
week in RPMI 1640 + 10%FCS + 100 U/ml penicillin and 100 μg/ml streptomycin 
in 5% CO2 at 37ºC.
2.2.3.2 Construction of recombinant viruses
The recombinant virus assay was used to create a fully replicative competent virus.
The molecular clone pHIVΔRTBstEII contains the complete HIV-1 genome except 
for a 1.4kb deletion in the reverse transcriptase gene. It also contains the T7 RNA
polymerase promoter, a BstEII restriction site, ampicillin and β-galactosidase 
markers. This clone in not infectious but once it is transfected into MT4 cells with
full-length reverse transcriptase PCR product, a replicative virus is produced through
homologous recombination.
pHIVΔRTBstEII was linearised by incubation with BstEII at 60ºC for at least 2
hours. The linearised plasmid was purified using the QIAQuick Purification kit
(Qiagen, Crawley, UK) as described previously. 10 µg of the molecular clone was
used per transfection. MT4 cells were split 1:2 (volume:volume) the day before the
transfection. For each transfection, 2x106 MT-4 cells and 12 µl of the transfection
reagent DMRIE-C ((1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium
bromide) and cholesterol) (Invitrogen, Paisley, UK) were used. MT4 cells were
resuspended at a concentration of 7.5x105 /ml. Serum free OptiMEM medium was
added to 6 well plates followed by DMRIE-C and 2 µg DNA. Following an
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incubation of 15-30 minutes at room temperature, MT4 cells were added and the
plates were incubated at 37ºC with 5% CO2 for 5 hours. Cells were observed for
CPE and each day and fresh medium was added. Once CPE was observed, the cell
free supernatant was harvested and stored in aliquots at –80°C.
2.2.3.3 MTT titration assay
Virus titres were obtained in MT4 cells and 3-(4,5-dimethylthiazol)-2,5-
diphenyltetrazolium bromide (MTT) was used to determine cell viability. 2x106 MT-
4 cells were used per titration at a concentration of 7.5X105/ml. Viruses were serially
diluted (0.5 log10 ) in RPMI (no phenol red). MT4 cells were resuspended in
supplemented RPMI (no phenol red) and 50 µl was added to the wells. Each dilution
was performed in quadruplicate.
Following a 5 day incubation, 20 µl of MTT (Sigma-Aldrich, Dorset, UK-Aldrich) (5
mg/ml in PBS) was added and the plates were incubated for 2 hours. 170 µl of
acidified isopropanol (86% Isopropanol, 11% dH2O, 2.7% NP-40 and 0.3%
concentrated HCl) was added and the absorbance was measured at 595nm and the
TCID50 (Tissue culture infectivity dose) determined by the Spearman-Karber
method.
2.2.3.4 Cytopathic effect titration assay
100 µl of supplemented RPMI was added to a 96 well plate. 23 µl of neat virus was
added to the plate and nine serial fivefold dilutions were made. 50 µl of MT4 cells
were added to the wells at a concentration of 6X105 per ml. Plates were left to
incubate for five days. After five days, all wells were scored for the presence of
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CPE. TCID50 was calculated using the Reed and Muench method. The equation
used was as follows; M = inv log{x1 + [(x2 - x1)((y1 - 50) / y1 - y2)]}, where y1 =
percent of well scored positive closest to, but higher than 50% at a certain virus
dilution, y2 = percent of well scored positive closest to, but lower than 50% at a
certain virus dilution, x1 = the log (dilution of the virus where was observed), x2 = the
log (dilution of the virus where was observed).
2.2.3.5 Drug susceptibility assays
All drug susceptibility assays required 2X106 MT4 cells per assay. Cells were
washed first with PBS and then with supplemented RPMI (no phenol red). The cell
pellet was resuspended using the virus supernatant and volumes were equalised with
medium so that the same volume of liquid was added to each of the assays. Cells
and virus were incubated for two and a half hours at 5% CO2 at 37ºC. 50 µl of
supplemented RPMI (no phenol red) was added to each of the wells and 50 µl of
concentrated drug (4X) was added to one column. 10 serial dilutions of the drug
were done to give a 1X concentration of drug (following the addition of 50 µl of
MT4 cells). Infected cells were resuspended in supplemented RPMI (no phenol red)
at a concentration of 7.5x105 /ml and 50 µl of these cells were added to all the wells.
Uninfected MT4 cells and infected MT4 cells containing no drug controls were also
set up. Plates were left to incubate at 5% CO2 at 37ºC for 4 days. On day four MTT
was used to analyse results as described previously. All assays were done in
quadruplicate and the average of the four was used to calculate the IC50.
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2.2.3.6 Growth competition assay
Growth competition assays were set up according to (Harrigan et al., 1998). Briefly,
7.5x105 MT4 cells were used per growth competition assay. For each assay 750
TCID50 units total of 2 viruses were added to MT4 cells. Cells and viruses were left
to incubate for 2 hours at 5% CO2 at 37ºC and cells were resuspended every 30
minutes. After 2 hours, cells were spun down and washed twice with PBS. Infected
cells were then resuspended in 5 ml of supplemented RPMI and incubated for 6 days.
On day 6, aliquots of virus supernatant were collected and stored at –80°C. 50 µl of
virus supernatant was used to re-infect fresh MT4 cells and resuspended in 5ml of
supplemented RPMI. This was continued for four passages. For competitions done
in the presence of antiretrovirals, 1ml of virus supernatant was used to start a new
passage. The antiretroviral drug was added to 5 ml of supplemented RPMI.
Controls of monoinfections and uninfected MT4 cells were also set up. RNA was
extracted from 200 µl of virus supernatant and used in a quantitative real time PCR
to assess proportions of mutant and wild type viruses.
2.2.4 Pyrosequencing
2.2.4.1 Pyrosequencing – preparation of PCR product
For pyrosequencing a 200bp fragment encompassing codons 176-242 of the reverse
transcriptase gene was amplified using primers Pyro forward and reverse (table 2.1).
The PCR mixture contained 50 ng DNA, 200 uM of primers, 250 uM of each dNTP,
10X enzyme buffer and 2.5 units of PfuUltra high fidelity DNA Polymerase
(Stratagene, Cheshire, UK) in a total volume 50 µl. The reverse primer was
biotinylated at the 5’ end to allow capture onto the streptavidin beads. PCR cycling
conditions consisted of 40 cycles of 95°C for 5 minutes, 95°C for 30 seconds, 55°C
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for 30 seconds, 72°C for 30 seconds followed by 72°C for 5 minutes and a hold at
4°C. The correct sized fragment was confirmed by gel electrophoresis.
2.2.4.2 Pyrosequencing – sample preparation
A mixture of 0.3 µM sequencing primer in 40 µl of annealing buffer was made for
each of the samples and aliquoted into the pyrosequencing plate. 20 µl of
biotinylated PCR product was added to 3 µl of streptavidin sepharose beads, 37 µl of
binding buffer and 20 µl of high purity water. The PCR product-bead mix was added
to a single well in a 96 well plate. To enable the biotinylated product to be captured
onto the streptavidin beads, the plate was mixed at 1000rpm for 10 minutes. To
secure the single stranded biotinylated PCR DNA onto the filter probe, a vacuum
pump was used. The beads were then washed with 70% ethanol, denatured and
given a final wash with the washing buffer to remove the non biotinylated strand.
The DNA was then released into the plate containing the sequencing and annealing
buffer mixture. To allow binding of the DNA to the sequencing primer, the mixture
was heated at 80ºC for 2 minutes and allowed to cool. Samples were run on the
PSQ96 MA (biotage) and analysed using the allele quotient mode in order to
determine the proportion of mutant and wild type nucleotide at position 208.
2.2.5 Quantitative real time PCR – Taqman PCR
Primer3 software was used to design two taqman PCR probes that would specifically
bind to mutant and wild type DNA (table 2.2). Primers TaqMan forward and reverse
(table 2.1) amplified a 200bp fragment encompassing the region of interest. 200 ng
of DNA was added to a 50 µl PCR mix containing 150 nM primers, 100 nM taqman
probe, and 12.5 µl of 2 X superscript platinum qRT-PCR mix (Invitrogen, Paisley,
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UK). Cycling conditions were as follows, 50°C for 15 minutes, 95°C for 2 minutes,
40 cycles of 95°C for 15 seconds and 60°C for 30 seconds.
2.2.6 Allele specific PCR (ASPCR)
Mutant and wild type forward primers were specifically designed with incorporated
G nucleotide two base pairs away from the SNP. Primers were designed to be
subtype specific. To amplify subtype B sequences, primers ASPCR st B mt and wt
were used and to amplify subtype A sequences, primers ASPCR st A mt and wt were
used (table 2.1).
300 ng of total RNA was used in the real time PCR with a PCR mix containing 150
nM primers, 100 nM of probe ASPCR, and 12.5 µl of 2X superscript platinum qRT-
PCR mix. Cycling conditions for the real time PCR were 95°C for 11 minutes, 45
cycles of 95°C for 30 seconds, 50°C for 30 seconds and 60°C for 32 seconds.
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Chapter three
3 Clonal analysis of H208Y
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3.1 Introduction
The HIV-1 reverse transcriptase (RT) is a heterodimer composed of two subunits,
p66 (66kDa) and p51 (51kDa). The p51 subunit carries out essentially a structural
role whereas the p66 subunit is responsible for the catalytic activities of the enzyme.
The p66 subunit contains five subdomains named thumb, fingers, palm, connection
and RNase domain. RT is one of the major drug targets of antiretroviral therapy and
the majority of RT associated resistance mutations are located within the fingers and
palm domain (Sarafianos et al., 1999b;Sluis-Cremer et al., 2000b). However,
mutations within the connection and RNase H domain have also been shown to
contribute to NRTI (nucleos(t)ide RT inhibitors) and NNRTI (non-nucleoside RT
inhibitors) resistance (Brehm et al., 2007;Brehm et al., 2008;Ehteshami et al.,
2008;Nikolenko et al., 2007;Yap et al., 2007).
When antiretroviral therapy fails to suppress HIV replication, mutations emerge that
confer drug resistance but generally reduce virus fitness relative to wild type virus. If
replication continues to occur, new mutations emerge alongside major resistance
mutations, which may either augment resistance or restore virus fitness. These
mutations are called accessory mutations and are associated with major resistance
mutations. Although some accessory mutations may occur spontaneously in drug
naïve persons, their frequency increases significantly in treated persons (Cane et al.,
2007;Perno et al., 2006;Svicher et al., 2006). These mutations have mainly been
identified through statistical analyses of large resistance databases, comparing the
frequency of different mutations in untreated and treated persons and identifying
clinical correlates. As a result, the individual and cumulative in vitro effects of the
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mutations are often unknown and the mutations are not generally included in the
routine interpretation of genotypic resistance.
To date, accessory mutations associated with NRTI treatment and major NRTI
resistance mutations have been identified at 40 positions in RT and this includes the
H208Y mutation (Cane et al., 2007;Gonzales et al., 2003;Perno et al., 2006;Sturmer
et al., 2003;Svicher et al., 2006). The thymidine analogue mutations (TAMs) are a
group of major NRTI resistance mutations that confer resistance to stavudine (D4T)
and zidovudine (AZT). TAMs can be divided into 2 pathways, the TAM-1 pathway
includes M41L, L210W and T215Y and the TAM-2 pathway includes D67N, K70R,
T215F and K219Q/E. The TAM-1 pathway is known to confer a higher level of
resistance and cross-resistance than the TAM-2 pathway (Miller, 2004). The
accessory mutation H208Y has been shown to cluster preferentially with the TAM-1
pathway (Cane et al., 2007;Gonzales et al., 2003;Sturmer et al., 2003;Svicher et al.,
2006).
Previous studies examining the phenotypic effect of the H208Y mutation have
reported conflicting results. Some studies have shown that in the presence of TAMs,
H208Y confers a decreased susceptibility to AZT (Sturmer et al., 2003;Svicher et al.,
2006). Despite these findings indicating a role for H208Y in conferring resistance to
AZT, another study showed that H208Y in isolation could confer an increased
susceptibility to AZT (Clark et al., 2006).
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The aim of the study described in this chapter was to investigate which major NRTI
resistance mutations and recognised accessory mutations co-exist with H208Y on the
same viral genome.
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3.2 Methods
3.2.1 Identification of patients
In the Virology Diagnostic Department at the Royal Free Hospital, the HIV-1 pol
sequences (protease codons 1-99 and RT codons 1-335) of patients attending for
routine care are routinely examined for the presence of drug resistance mutations by
automated population sequencing. The sequences are obtained from plasma samples
using either the ViroseqTM HIV-1 genotyping system (Celera Diagnostics, USA)
according to the manufacturer's instructions or an in-house methodology, and
analysed using a 3100-Avant Genetic Analyzer (Applied Biosystems, UK). All
sequences are stored in the local HIV Genotyping Drug Resistance Database. This
database also contains information about HIV-1 subtype, antiretroviral treatment
history, HIV plasma RNA load and CD4 cell counts at the time of testing. In March
2010 there were 8500 pol sequences stored in the database. The database was
searched to identify patients who harboured the H208Y mutation in their genotypic
resistance test.
3.2.2 RNA extraction
Nucleic acid from plasma samples were extracted using the EasyMag automated
extractor (Nuclisens, Biomerieux, Boxtel Netherlands).  RNA was eluted into 55μl 
elution buffer and stored in aliquots at -80ºC until required.
3.2.3 Amplification of viral RNA
Random priming was used to convert RNA to cDNA. Codons 1-560 and 1-335 of
RT were amplified by nested PCR using 20μl of cDNA. 
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3.2.4 Cloning of the RT gene
The PCR product from each patient was purified and cloned into the commercial
vector pCR 2.1-TOPO. Positive clones were identified as those harbouring inserts of
the correct size after a restriction digest.
3.2.5 Sequencing the RT gene
All DNA was sequenced using Sanger sequencing. Plasmids identified as containing
the PCR insert were then sequenced using the BioDye Sequencing mix v1.1 (Applied
Biosystems, UK). Four forward and reverse primers were used to obtain overlapping
sequences. Sequences were analysed using a 3100-Avant Genetic Analyzer (Applied
Biosystems, UK).
3.2.6 Nomenclature
Sequences were analysed for the presence of mutations relative to HXB2 wild type.
Mutations were classed into the following groups: major RT (NRTI and NNRTI)
resistance mutations (http://hivdb.stanford.edu/), accessory NRTI mutations in the
polymerase domain and connection domain (Cane et al., 2007;Perno et al.,
2006;Svicher et al., 2006;Torti et al., 2004) and other mutations with unknown
effects on drug susceptibility or viral fitness. Accessory mutations in the RNase H
domain were not investigated.
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3.3 Results
3.3.1 Database Analysis
The HIV Genotyping Database was searched for patients with H208Y present in their
genotypic resistance test. Samples with missing treatment status were excluded from
the analysis. A total of 5087 patients were identified, with 1304 being treatment
experienced and 3783 being treatment naive. Upon examination of the database,
17/5087 (0.3%) patients harbouring the H208Y mutation were identified. A total of
12/17 (71%) patients had an extensive treatment history and had experienced NRTIs,
NNRTIs and PIs (protease inhibitors). However, 5/17 (29%) patients were
antiretroviral treatment naïve. The prevalence of H208Y was 5/3783 (0.1%) in
treatment naïve patients and 12/1304 (0.9%) in treatment experienced patients. The
majority of treatment experienced patients harbouring H208Y (8/12, 67%) were
infected with subtype B virus followed by subtype C (2/12, 17%), subtype A (1/12,
8%) and subtype G (1/12, 8%) virus (table 3.1). Similarly, the majority of treatment
naïve patients (2/5, 40%) had a subtype B virus and one each with subtype C,
CRF02_AG and CRF06_cpx.
From these 17 patients, 5 were selected for further analysis as shown in table 3.2.
Since the majority of patients harbouring H208Y had a subtype B virus, both a
treatment naive patient and a treatment experienced patient with subtype B were
chosen for further analysis. Two treatment experienced patients harbouring the
highly prevalent subtype A and subtype C virus were also chosen to assess whether
there could be any subtype related differences associated with H208Y.
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Table. 3.1 Prevalence of H208Y according to treatment status and HIV-1 subtypea
Subtype
Treatment Experienced Patients Treatment Naïve Patients
Number of
patients
analysed
Patients with
H208Y, n (%)
Number of
patients
analysed
Patients with
H208Y, n (%)
A 104 1 (1.0) 258 0
B 514 8 (1.6) 1621 2 (0.1)
C 415 2 (0.5) 1134 1 (0.1)
G 34 1 (2.9) 105 0
CRF01_AE 25 0 309 1 (0.3)
CRF06_cpx 8 0 33 1 (3.0)
Other subtypes 204 0 323 0
All 1304 12 (0.9) 3783 5 (0.1)
aPatients with H208Y were identified from the HIV-1 drug resistance database held at
the Royal Free Hospital.
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Table. 3.2 RT population sequencing results in patients with H208Ya
Patient Subtype Major NRTIResistance
Mutations
Major NNRTI
Resistance
Mutations
NRTI Accessory
Mutations Other RT Mutations
1 B None None G196E, H208Y
D123E, D177E, I178M,
I195T, R211K, A272P,
K277R, A288T, I293V,
E297K, Q334L
2 B
M41L, D67N,
V75M, V118I,
L210W, T215Y,
K219DN
A98G, G190Q
K43E, V60I,
K122E, I135V,
T200A, H208Y,
V35L, E40F, W88C,
I94L, I178L, R211K
3 A
D67N, T69N,
K70KR,
M184V, T215F,
K219E
None
K20KR, V60I,
K122E, I135T,
V179I, H208HY,
T200A,
E6K, V35T, D123S,
K173L, Q174K, D177E,
Q207A, R211S, V245Q,
A272S, T286A, E291D,
I293V, E312D, Q334E
4 C
M41L, E44D,
D67N, L74V,
V118IV,
M184V, L210W,
T215Y, K219R
A98G, K101H,
V108I, Y181C,
G190A
E203K, H208Y,
T200A, D218E,
K223Q
V35L, T39E, V111I,
K122P, D123N, A158S,
S162N, K173T, Q174K,
D177E, L205F, Q207E,
R211K
5 B
M41L, E44D,
T69N, L74I,
V118IV,
M184V, L210W,
T215Y, K219R
A98G, K103N,
V108I, F227L
K43Q, K122E,
I135L, V179I,
G196EG, T200A,
E203K, H208Y,
K223DE, L228H,
E6K, V111I, E194EQ, ,
R211K, Q242H, V245Q,
I293V, P294Q, V317A
aMutations that were present in bulk sequences spanning codons 1-335 of the RT gene
from five patients that harboured the H208Y mutation, including one treatment naïve
(no 1) and 4 treatment experienced (no 2-5) patients. Major NRTI and NNRTI resistance
mutations were classified according to the Stanford HIV Drug Resistance Interpretation
Algorithm. NRTI accessory mutations associated with TAMs were classified according
to (Cane et al., 2007;Perno et al., 2006;Svicher et al., 2006). Other RT mutations were
classified as differing from the HXB2 wild type reference strain. NRTIs =
Nucleos(t)ide RT inhibitors; NNRTIs= non-nucleoside RT inhibitors.
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Patient 1 was treatment naïve and did not have any major RT resistance mutations.
Among the treatment experienced individuals, patients 2, 4 and 5 showed TAM-1
mutations (M41L, L210W, T215Y) accompanied by one or more TAM-2 mutations
(D67N, K219D/N/R), with or without the lamivudine (3TC) associated resistance
mutation M184V. Patient 3 showed TAM-2 mutations with M184V. In addition,
patients 2, 4 and 5 showed V118I and/or E44D which are mutations typically seen in
NRTI-experienced patients with TAMs, while patients 4 and 5 showed L74V/I,
which confers resistance to didanosine (DDI) and abacavir (ABC). Patient 2 had the
V75M mutation, which is associated with resistance to DDI and D4T. Patients 2, 4
and 5 also showed major NNRTI mutations conferring resistance to nevirapine
(NVP), efavirenz (EFV) and etravirine (ETV).
NRTI accessory mutations other than H208Y were detected in all patients and
comprised G196E in patient 1, K43E, V60I, K122E, I135V and T200A in patient 2,
K20K/R, V60I, K122E, I135T, V179I and T200A in patient 3, T200A, E203K,
D218E and K223Q in patient 4, and K43E, K122E, I135L, V179I, G196E, T200A,
E203K, K223DE and L228H in patient 5.
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3.3.2 Cloning and sequencing of the RT gene encompassing codons
1-335
Population sequencing that occurs routinely in clinical settings can only identify
virus variants that represent over 20% of the viral population (Alcorn and Faruki,
2000), and since it produces a consensus sequence from all dominant variants it
cannot be used to examine linkage of mutations. To examine which mutations were
linked to H208Y at the genomic level, codons 1-335 of the RT gene from patients 2,
4 and 5 were cloned and 35 clones from each patient were sequenced from one PCR
reaction.
Table 3.3 shows the major RT resistance mutations and NRTI accessory mutations
found within the clones. For the major resistance mutations, in all three patients, all
clones showed a combination of TAM-1 and TAM-2 mutations. These comprised
M41L and L210W together with mutations at codon 215 (T215Y, T215N or T215C)
and codon 219 (K219G, K219E, K219N or K219R) with or without D67N. The
major resistance mutations M184V with mutations at codon 74 (L74I or L74V) were
found in all clones from patients 4 and 5; E44D was present in all clones from patient
4 and in 34/35 (97%) clones from patient 5; all patients had V118I present in all
clones except for patient 4 who had V118I present in 10/35 (29%) clones.
NRTI accessory mutations other than H208Y were also found in the clones. Patients
2 and 5 had mutations at codon 43 (K43E or K43Q), codon 135 (I135L or I135V)
and K122E present in all clones. Patients 2 and 5 had all clones with T200A and
patient 4 had 33/35 (94%) of clones with T200A. Patients 4 and 5 had mutations at
codon 203 (E203D or E203K) and codon 223 (K223E or K223Q) present in their
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clones. Patient 4 had 19/35 (54%) clones with E203K and 3/35 (9%) with E203D
and patient 5 had 34/35 (97%) clones with E203K. Patient 4 had 19/35 (54%) clones
with K223Q and patient 5 had 21/35 (60%) clones with K223Q and 6/35 (17%)
clones with K223E. Other NRTI accessory mutations present in the clones included
V60I for patient 2, D218E for patient 4, and G196E/D, and L228H in clones from
patient 5.
NNRTI accessory mutations other than H208Y were also found in the clones. Patient
4 had all clones with V35L and patient 2 had all clones with V35I, and patient 5 had
all clones with E6K and V179I.
Table. 3.3 Mutations detected in RT clones spanning amino acids 1-335a
Patient
Major NRTI
Resistance Mutations
NNRTI
Accessory Mutations
NRTI
Accessory Mutations
M
41
L
E
44
D
D
67
N
L
74
I
L
74
V
T
69
N
T
69
D
V
75
M
V
118
I
M
184
V
L
210
W
T
215
Y
T
215
N
T
215
C
K
219
G
K
219
E
K
219
N
K
219
R
E
6
K
V
35
L
V
35
I
V
179
I
K
43
E*
K
43
Q
V
60
I
K
122
E*
I
135
V
I
135
L
G
196
E
G
196
D
T
200
A
E
203
D
E
203
K*
H
208
Y*
D
218
E*
K
223
E
K
223
Q*
L
228
H*
2
4 10 1 34 33 3 19 19
5 34 34 1 33 1 1 1 28 1 34 28 1 34 6 21 20
aMajor RT resistance mutations and accessory mutations that were detected in clones generated from three patients that harboured the
H208Y mutation. The clones spanned RT amino acids 1-335. For each patient, 35 clones were sequenced. White boxes indicate absence of
the mutation in all 35 clones; shaded boxes indicate presence of the mutation in either all 35 clones (no number), or in a subset of clones
(number given in the box). * indicates accessory mutations associated with exposure to both NRTIs and NNRTIs.
3.3.3 Cloning and sequencing of full-length RT gene
Recent studies have shown that mutations within the C terminus of RT also
contribute to NRTI resistance (Brehm et al., 2007;Brehm et al., 2008;Ehteshami et
al., 2008;Ehteshami and Gotte, 2008;Nikolenko et al., 2007;Yap et al., 2007;Hachiya
et al., 2008). Therefore, in order to examine associations of H208Y and mutations in
the C terminus of RT, the full RT gene was cloned and sequenced in four patients. In
order to improve sampling of the viral quasispecies, more than one PCR reaction was
used to amplify the RT gene in each patient, excluding patient 3. The PCR products
were then pooled prior to cloning. Clinical details, the number of PCR reactions
used for the amplification reactions and the number of clones sequenced from each
patient are shown in table 3.4.
Table. 3.4 Number of PCR reactions used for amplification and number of
clones sequences in each patient
Patient Subtype
Viral load
(log10 copies/ml)
Treatment history Number of PCRreactions
Number of
clones sequenced
1 B 5.5 None 2 10
2 B 4.4 DDI, TDF, LPV/RSQV 2 11
3 A 6 3TC, LPV/r, SQV 1 6
4 C 5.2 3TC, TDF, FPV,SQV/R, T-20 3 20
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3.3.3.1 Full-length RT clones from patient 1 (n=10)
Patient 1 was treatment naïve and infected with subtype B, and harboured no major
RT resistance mutations by population sequencing. This was confirmed in the clonal
analysis of full-length RT. Figure 3.1 shows the NRTI accessory mutations present
within the 10 clones from this patient. Consistent with the results of population
sequencing, all 10 clones showed the NRTI accessory mutations G196E and H208Y
in the polymerase domain. In the connection domain all 10 clones showed the
G359S mutation, which has been previously associated with TAMs (Cane et al.,
2007). However this patient did not have TAMs. Within the RNase H domain, all 10
clones had the Q509K mutation. In combination with D67N, K70R and T215F, the
Q509L mutation has been shown to increase AZT resistance by 7.4 fold (Brehm et
al., 2007).
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Figure 3.1 Clonal analysis from patient 1. The p66 subunit of RT is shown with
the 5 subdomains; fingers (blue), palm (red), thumb (green), connection (orange) and
RNase H (purple). The full-length RT gene from patient 1 was cloned and
sequenced. The proportions (%) of clones (n=10) with mutations are shown.
Sequences were analysed for the presence of mutations relative to HXB2 wild type.
Mutations were classified according to the Stanford Genotypic Resistance
Interpretation Algorithm Version 6.0.8. Bars in red denote mutations in the
polymerase domain, bars in orange represent mutations in the connection domain and
bars in purple represent mutations in the RNase H domain.
102
3.3.3.2 Full-length RT clones from patient 2 (n=11)
Patient 2 was treatment experienced and infected with subtype B and both population
sequencing and clonal analysis of RT codons 1-335 showed several major RT
resistance mutations and NRTI accessory mutations. Figure 3.2 shows the mutations
present within the 11 full-length RT clones from this patient. They comprised as
major NRTI resistance mutations the TAMs M41L, D67N, L210W, T215Y and
K219N as well as V75M and V118I in all clones. The major NNRTI resistance
mutations A98G and G190Q were also present in all clones.
Within the polymerase domain, patient 2 had the NRTI accessory mutations K43E,
V60I, K122E, I135V and T200A in all clones with H208Y. Within the connection
T377I was present in 1/11 (9%) clones. No known resistance or accessory mutations
were found within the RNase H domain.
There was however variability in the clones relative to the HXB2 reference strain
with several other mutations detected alongside H208Y that have unknown effects on
drug susceptibility and viral fitness. In the polymerase domain these other mutations
comprised of L310I, which was present in 2/11 (18%) clones. Within the connection
domain, K350R was present in 8/11 (73%) clones, K390R was present in 7/11 (64%)
clones and T386I was present in 4/11 (36%) clones. Within the RNase H domain, all
clones had the mutations D460N, S468P, Q480E, H483N, L491P and K512Q.
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Figure 3.2 Clonal analysis from patient 2. The p66 subunit of RT is shown with
the 5 subdomains; fingers (blue), palm (red), thumb (green), connection (orange) and
RNase H (purple). The full-length RT gene from patient 2 was cloned and
sequenced. The proportions (%) of clones (n=11) with mutations are shown.
Sequences were analysed for the presence of mutations relative to HXB2 wild type.
Mutations were classified according to the Stanford Genotypic Resistance
Interpretation Algorithm Version 6.0.8. Bars in grey denote major NRTI resistance
mutations in the polymerase domain, bars in red denote mutations in the polymerase
domain, bars in orange represent mutations in the connection domain and bars in
purple represent mutations in the RNase H domain.
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3.3.3.3 Full-length RT clones from patient 3 (n=6)
Patient 3 was treatment experienced and infected with subtype A and both population
sequencing and clonal analysis of RT codons 1-335 showed several major RT
resistance mutations and NRTI accessory mutations. Figure 3.3 shows the mutations
present within the 6 full-length RT clones from this patient. They comprised as
major NRTI resistance mutations the TAMs D67N, T215F and K219E, as well as
T69N and M184V present in all clones. K70KR was seen a mixture in the
population sequencing but was not found in any of the 6 clones. No major NNRTI
resistance mutations were found within the clones from patient 3.
Within the polymerase domain, patient 3 had the NRTI accessory mutations K20R,
V60I, K122E, V179I and T200A in all clones with H208Y. H208Y was present in
1/6 (17%) of clones whereas in the population sequencing, patient 3 showed a
mixture of H208HY. Within the connection domain, three NRTI accessory mutations
associated were found, G359A, A371V and T377L which were present in all clones
with H208Y.
There was however variability in the clones relative to the HXB2 reference strain
with several other mutations detected alongside H208Y that have unknown effects on
drug susceptibility and viral fitness. In the polymerase domain these other mutations
comprised of I2L, which was present in 1/6 (17%) clones. Within the connection
domain T369A was present in 1/6 (17%) clones. Within the RNase H domain,
K454R and V466I were present in 2/6 (33%) of clones and T477A was present in 4/6
(67%) of clones.
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Figure 3.3 Clonal analysis from patient 3. The p66 subunit of RT is shown with
the 5 subdomains; fingers (blue), palm (red), thumb (green), connection (orange) and
RNase H (purple). The full-length RT gene from patient 3 was cloned and
sequenced. The proportions (%) of clones (n=6) with mutations are shown.
Sequences were analysed for the presence of mutations relative to HXB2 wild type.
Mutations were classified according to the Stanford Genotypic Resistance
Interpretation Algorithm Version 6.0.8. Bars in grey denote major NRTI resistance
mutations in the polymerase domain, bars in red denote mutations in the polymerase
domain, bars in orange represent mutations in the connection domain and bars in
purple represent mutations in the RNase H domain.
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3.3.3.4 Full-length RT clones from patient 4 (n=20)
Patient 4 was treatment experienced and infected with subtype C and both population
sequencing and clonal analysis of RT codons 1-335 showed several major RT
resistance mutations and NRTI accessory mutations. Figure 3.4 shows the mutations
present within the 20 full-length RT clones from this patient. They comprised as
major NRTI resistance mutations the TAMs M41L, D67N, L210W, T215Y and
K219R as well as E44D, L74V, V118I and M184V present in all clones with H208Y.
The major NNRTI resistance mutations A98G, K101H, Y181C and G190A were also
present in all clones and V108I was present in 10/20 (50%) of clones with H208Y.
Within the polymerase domain, patient 4 had the NRTI accessory mutations T200A,
E203K and K223Q present in clones with H208Y. E203K was found in 14/20 (70%)
of clones, T200A were present in all clones and K223Q was present in 12/20 (60%)
of clones. The G335D, R356K and T377L mutations were also found within the
connection domain and present in all clones. The G335D mutation has been
associated with contributing to AZT resistance in the context of TAMs (Zelina et al.,
2008).
There was however variability in the clones relative to the HXB2 reference strain
with several other mutations detected alongside H208Y that have unknown effects on
drug susceptibility and viral fitness. In the polymerase domain these other mutations
comprised of D123N and L205F, which were present in 8/20 (40%) of clones.
Mutations S162N, R206K, H221Y, A272P and K277R were present in 2/20 (10%) of
clones. Within the connection domain T386I mutation was present in 4/20 (20%) of
clones, K390R was present in 6/20 (30%) of clones and G436E was present in 2/20
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(10%) of clones. Within the RNase H domain mutations Q500L and K558I were
present in 2/20 (10%) of clones and K527N was present in 8/20 (40%) of clones.
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Figure 3.4 Clonal analysis from patient 4. The p66 subunit of RT is shown with
the 5 subdomains; fingers (blue), palm (red), thumb (green), connection (orange) and
RNase H (purple). The full-length RT gene from patient 4 was cloned and
sequenced. The proportions (%) of clones (n=20) with mutations are shown.
Sequences were analysed for the presence of mutations relative to HXB2 wild type.
Mutations were classified according to the Stanford Genotypic Resistance
Interpretation Algorithm Version 6.0.8. Bars in grey denote major NRTI resistance
mutations in the polymerase domain, bars in red denote mutations in the polymerase
domain, bars in orange represent mutations in the connection domain and bars in
purple represent mutations in the RNase H domain.
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3.4 Discussion
There have been two separate studies looking at the prevalence of H208Y in
treatment naive and treatment experienced patients. The first study reported a
prevalence of 7/2347 (0.3%) in treatment naïve patients and 165/4005 (4.1%) in
treatment experienced patients (Nebbia et al., 2007). The other study reported a
prevalence of 0.1% in treatment naïve patients and 12.8% in patients who had >4
TAMs (Cane et al., 2007). The HIV Drug Resistance Database maintained by
Stanford University USA (http://hivdb.stanford.edu/) reports a prevalence of
24/18812 (0.1%) in treatment naïve patients and 2119/23212 (9%) in treatment
experienced patients. It should be noted that although the prevalence of H208Y
reported by the Stanford Database in treatment experienced patients is higher than
that reported by published studies, the numbers used in the Stanford database are
much larger than those used by (Nebbia et al., 2007) or (Cane et al., 2007).
Furthermore, the treatment history and perhaps the HIV-1 subtype are also likely to
influence prevalence estimates as the Stanford database contains many sequences
from treatment experienced patients and subtype B viruses. It should also be taken
into account that the studies by Gaia et al. and Cane et al. both used sequences from
the UK HIV Drug Resistance Database and therefore they reflect similar patient
populations in terms of treatment history and distribution of HIV-1 subtypes. Upon
examination of the HIV Resistance Database held at the Royal Free Hospital, 17
patients harboured H208Y. The prevalence of H208Y in treatment experienced
patients was 12/1304 (0.9%) and higher than that found in treatment naïve patients
5/3783 (0.1%) and was in agreement with the previously mentioned reports from the
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UK. These observations support the hypothesis that the H208Y mutation is an
accessory mutation that emerges as a result of drug pressure.
Regarding subtype differences, Nebbia et al. 2007 reported that in the 165 treatment
experienced patients who harboured H208Y, H208Y was most commonly observed
in subtype B patients with a prevalence of 118/165 (71.6%), followed by 26/165
(15.6%) in subtype C patients. The Stanford Database showed that in patients who
had been exposed to RT inhibitors, H208Y was most common in subtype F with a
prevalence of 60/461 (13%). This was followed by 1959/17806 (11%) in subtype B,
20/751 (2.7%) in subtype G, 48/1831 (2.6%) in subtype C and 13/560 (2.3%) in
subtype A. In treatment naïve patients, the prevalence reported by the Stanford
Database for subtypes B, C, D and CRF02_AG was similarly low at 0.1-0.2%.
Similar to the study by Nebbia et al., in the treatment experienced population
described in this study, 8/12 (67%) of patients with H208Y had a subtype B virus,
followed by 2/12 (17%) of patients with a subtype C virus. The remaining two
patients had a subtype A and subtype G virus. Although these findings are not
consistent with those from the Standard Database, it should be noted that the number
of samples used to calculate prevalence in the Stanford Database and in this study
varies considerably between subtypes and therefore, the prevalence reported may be
biased. For instance the total number of patients with subtype F and subtype G
viruses in the HIV Database held at the Royal Free Hospital was 16 and 139
respectively, compared to 461 subtype F and 751 subtype G samples from the
Stanford Database. Analysis of the prevalence of H208Y in people with different
subtypes should keep in mind one important caveat. The increased prevalence of the
mutation in people with multiple TAMs suggests selection through prolonged drug
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pressure with the thymidine analogues AZT and D4T. This is more likely to have
occurred in resource-rich regions where antiretroviral therapy has been available for
many years and where subtype B predominates.
The H208Y mutation results from a single nucleotide change from CAT to TAT. To
examine the sequence variation at codon 208 between subtypes, consensus sequences
for subtypes A, B, C, D, F, G, CRF01_AE and CRF02_AG were obtained from the
Los Alamos Database (http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html
The nucleotide sequence at codon position 208 was examined and for all subtypes,
the nucleotide sequence was always CAT at codon 208. This argues against a
sequence related preferential selection of H208Y and indicates a high degree of
conservation at this position.
Consistent with previous observations (Cane et al., 2007;Gonzales et al.,
2003;Sturmer et al., 2003;Svicher et al., 2006), population RT sequencing of the
treatment experienced patients with the H208Y mutation demonstrated that it
occurred with multiple major RT resistance mutations, particularly multiple TAMs.
The results from the clonal analysis of RT codons 1-335 confirmed the linkage with
TAMs. Importantly, the clones from the treatment experienced patients were found to
be homogenously resistant. The clonal analysis was extended to full-length RT to
assess the presence of mutations in the C terminus of the gene which may contribute
to NRTI resistance (Brehm et al., 2008;Ehteshami and Gotte, 2008;Nikolenko et al.,
2007;Yap et al., 2007;Hachiya et al., 2008). In order to minimise the chances of over
sampling the same clone, multiple PCR reactions were used to generate clones for
each patient. Again the full-length RT clones were homogenous within each patient
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with regard to the proportion of clones that contained major NRTI resistance
mutations. This may be expected in heavily treated persons in whom selective
pressure leads to a highly mutated quasispecies becoming dominant. Population
sequencing in routine use in clinical practice can only identify virus variants that
represent over 20% of the population (Alcorn and Faruki, 2000). The clones selected
for analysis also represent the dominant quasispecies within each patient.
The subtype A virus from the treatment experienced patient showed a mix of
H208HY in the population sequence, indicating a mixture was present in the
dominant quasispecies and indeed the clonal analysis identified 1/6 clones that
contained the H208Y mutation with the remaining 5/6 clones with H208. It should
be noted that only six clones were sequenced for this patient. The remaining patients
had all clones with the H208Y mutation indicating it is present in the dominant
quasispecies of these patients.
The plasma HIV-1 RNA load of the sample is an important factor that will influence
sampling of the viral quasispecies. This is because if the viral load is low, it is
unlikely that the subsequent PCR and cloned sequence will have been derived from
different RNA templates and therefore a true representation of the genetic diversity
within the patient will not be obtained (Liu et al., 1996).
All the patient samples had a viral load over 400,000 copies per millilitre and the
results from the sequencing analysis showed that there was variability in the patient
clones. Excluding the treatment naïve patient, who had identical clones, the clones
from the three treatment experienced patients showed more variability. The clones
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from the treatment experienced subtype B and A patients had 11% of clones that
were unique. The clones from the treatment experienced subtype C patient had 26%
of clones that were unique. This demonstrates that although there was not large
variability between clones, a representation of the quasispecies was sampled for each
patient, as the clones were not all identical to one another. It should also be noted
that only a small number of clones were sequenced for each patient.
In order to obtain a wider representation of low frequency variants within the
quasispecies, a large number of clones would need to be sequenced or alternative
sequencing methods (e.g., ultra-deep pyrosequencing) employed, which was beyond
the scope of these studies. Clonal analysis of the dominant quasispecies however
allows an analysis of the linkage of mutations at the genomic level. Given that
H208Y is a mutation that usually emerges following the appearance of major NRTI
resistance mutations, it is most likely to be present within the dominant quasispecies
of a patient once major resistance mutations have evolved.
Another important consideration is that PCR amplification may introduce errors
though the incorporation of incorrect nucleotides. Errors introduced during the early
round of PCR amplification will result in the subsequent clones containing the PCR
induced sequencing errors (Varghese et al., 2010). This problem can be overcome to
an extent by using a proof-reading polymerase such as Pfu high-fidelity polymerase
which has 3’-5’ exonuclease activity, as done in this study. An alternative way to
address this issue is to perform limiting dilution of the cDNA so that a single
template is used in the PCR and sequencing reactions. By using this technique, even
if an error is introduced during the early stages of PCR, the error will not be present
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at greater than 25% of the bases at that position in the mixture and therefore will not
result in an erroneous base call when the DNA is sequenced (Learn, Jr. et al., 1996).
The TAMs are a group of major NRTI resistance mutations that confer resistance to
D4T and AZT (Miller, 2004). The mechanism of NRTI resistance mediated by the
TAMs is known as NRTI excision or pyrophosphorolysis. In the presence of ATP or
pyrophosphate, the TAMs can mediate the excision of the incorporated NRTI through
a nucleophilic attack on the phosphodiester bond between the NRTI and the DNA.
This results in the removal of the NRTI and allows chain synthesis to continue
(Acosta-Hoyos and Scott, 2010;Clavel and Hance, 2004a).
The H208Y mutation has previously been associated with TAMs and this association
is augmented with an increasing number of TAMs. The TAM-1 pathway (M41L,
L210W and T215Y) has been predominantly associated with the H208Y mutation
(Cane et al., 2007;Nebbia et al., 2007;Saracino et al., 2006;Svicher et al., 2006). The
findings of this study show that there is a strong genetic linkage with TAMs within
viruses that are highly drug resistant. Among the treatment experienced patients, the
TAMs were the predominant group of mutations that were associated with the
H208Y mutation and were present in all clones for all patients. Two of these patients
had clones containing the TAM-1 pathway mutations and one patient had clones
containing the TAM-2 pathway mutations. The TAMs that were always detected
with H208Y in the clones from treatment experienced patients included D67N,
T215Y or F and various mutations at codon 219. Based upon these observations, it
can be speculated that H208Y may have a role in augmenting NRTI resistance by
aiding the pyrophosphorolysis effect of T215Y or T215F. A key mutation in
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pyrophosphorolysis is T215Y/F. The aromatic ring of the ATP interacts with the
aromatic ring of the tyrosine amino acid through π-π interactions.  This interaction 
changes the binding of ATP and affects its orientation enabling more efficient
binding (Singh et al., 2010;Chamberlain et al., 2002;Meyer et al., 2002;Arion et al.,
1998;Sarafianos et al., 2009).
The H208Y mutation did not show a consistent linkage with M184V. The M184V
mutation causes high level resistance to 3TC and emtricitabine (FTC) by decreasing
the incorporation of the two NRTIs and allowing DNA synthesis to continue.
M184V has been reported to be present in approximately 44% of patients that
already harbour the H208Y mutation (Nebbia et al., 2007). This is consistent with the
findings reported in this study, showing that half of the patients with H208Y had the
M184V mutation, but also implying that M184V is not a prerequisite for the H208Y
mutation. M184V carries a significant fitness cost for the virus, for which
compensatory mechanisms have not been yet clearly identified (Diallo et al., 2003),
possibly because of its positioning near the catalytic site of the enzyme (Perno et al.,
2006). M184V has also been shown to antagonise NRTI pyrophosphorolysis
mediated by mutations at position T215, partially restoring susceptibility to AZT,
D4T and TDF (Gotte et al., 2000;Menendez-Arias, 2008). It would be tempting to
speculate that H208Y either counterbalances the fitness reduction caused by M184V
or interferes with its antagonists effects on NRTI susceptibility, but the fact that
H208Y occurs independently of M184V at both the population and clonal level does
not support the hypothesis.
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There were a number of other NRTI and NNRTI resistance associated mutations that
were consistently present in the clones with H208Y, including the NRTI resistance
mutations E44D, T69N/D, L74V, V75M and V118I. The V118I mutation was
present in clones from two treatment experienced patients. Several of these mutations
(E44D, T69N/D and V118I) also tend to occur in NRTI-experienced patients in
combination with TAMs (Miranda et al., 2005;Girouard et al., 2003;Zaccarelli et al.,
2007). NNRTI resistance mutations present were A98G, K101H, V108I, Y181C and
G190A/Q. Among the three treatment experienced patients, A98G and G190A/Q
were present with H208Y in all clones from two patients. The presence of NRTI and
NNRTI resistance mutations reaffirms that patients with H208Y usually have had
extensive treatment exposure.
Some NNRTI resistance mutations have been shown to increase susceptibility to the
NRTIs and this includes I132M and Y181C. The Y181C mutation confers high-level
resistance to NVP and delavirdine (DLV) and low-level resistance to EFV (Johnson
et al., 2009;Balzarini et al., 1994). It has also been shown to confer an increased
susceptibility to AZT when present with M41L and T215Y (Baldanti et al.,
2003;Byrnes et al., 1994;Larder, 1992). The mechanism of this increased
susceptibility is a reduced ability of the RT to excise AZT-monophosphate from
chain-terminated primers (Selmi et al., 2003).
The I132M mutation also confers high-level resistance to NVP and DLV and low-
level resistance to EFV (Nissley et al., 2007). It has also been shown to confer an
increased susceptibility to 3TC and TDF and have a lower fitness compared to the
wild type virus. The mechanism of increased susceptibility to 3TC and TDF is
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different to that mediated by Y181C and is based on the ability of the mutant RT to
discriminate between the natural nucleotide and the nucleoside analogue (Ambrose et
al., 2009).
Among the treatment experienced patients, Y181C and H208Y were present in all
clones from the subtype C patient. No previous studies have looked at the
association of H208Y with Y181C and looking at the patient clones within this study,
no strong association of these mutations appear to occur since Y181C is not a
prerequisite for H208Y. Furthermore, since the hypothesis remains that H208Y is
associated with the TAM group of mutations which mediate NRTI excision, it is
perhaps not surprising that there is no association of these mutations together since
Y181C causes re-sensitisation to AZT.
Many studies have showed the importance of mutations within the connection and
RNase H domains in resistance, which confer resistance to NRTIs and NNRTIs.
Mutations in the connection domain that have confer NRTI and NNRTI resistance
includes N348I which confers resistance to AZT, DDI and NVP (Yap et al., 2007),
A371V which confers resistance to AZT, 3TC and ABC (Brehm et al., 2007), G335D
which confers resistance to AZT and 3TC (Zelina et al., 2008) and Q509L which
confers resistance to AZT, 3TC and ABC (Brehm et al., 2007;Hachiya et al.,
2008;Nikolenko et al., 2007;Roquebert and Marcelin, 2008a).
In this study, two connection domain mutations were found in clones with H208Y,
G335D and A371V. The G335D mutation has been demonstrated to confer AZT and
3TC resistance in two ways. Firstly in combination with M184V, G335D confers an
118
increased level of discrimination of the NRTI compared to the natural dNTP.
Secondly, in combination with TAMs and M184V, the G335D mutation can help to
increase the excision of the NRTI from the DNA chain and thus allow chain
synthesis to resume (Roquebert and Marcelin, 2008b;Zelina et al., 2008). The two
patients with this mutation also showed M184V and TAMs, which is in agreement
with these findings. The A371V mutation in combination with TAMs has been
demonstrated to increase AZT resistance (Hachiya et al., 2008;Santos et al., 2008).
The patient with A371V had TAMs but also the M184V mutation, which has not
been associated with A371V (Brehm et al., 2007).
Three mutations in the RNase H domain have been shown to confer resistance to
AZT, H539N, D549N and Q509L (Brehm et al., 2008;Roquebert and Marcelin,
2008a). None of these mutations was found within the clones from treatment
experienced patients, although all clones from the treatment naïve patient had
Q509K. To develop into Q509L, Q509K would require multiple nucleotide changes
(from AAA or AAG to CTC, CTT, CTA, CTG, TTA or TTG), and its detection has
therefore unclear significance in terms of potential effects on drug susceptibility.
Other NRTI accessory mutations previously associated with TAMs were also found
within all patient clones. These were E40F and K43E, which were found within all
clones with H208Y from patient 2. Recent data have further indicated that E40F
confers resistance to AZT up to 187 fold if present in the background of TAMs
(Huigen et al., 2008). The K43E mutation, when present in isolation does not show
significant effects on drug susceptibility or viral fitness. In combination with E40F
in a background of TAMs, however K43E increases resistance to AZT by up to 135
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fold. The virus replicative capacity as a measure of viral fitness is also increased
(Huigen et al., 2008).
There were three NRTI associated accessory mutations within the polymerase
domain that were consistently present in the clones with H208Y. These were found
at codon positions V35, K122 and T200 (Cane et al., 2007;Perno et al., 2006). All
three treatment experienced patients from whom RT clones were generated had
mutations present at RT position V35 comprising V35L and V35T. The V35M
mutation has been identified as an NRTI accessory mutation, which is associated
with ABC and TDF resistance. Interestingly, the V35I mutation is not associated with
NRTI resistance and is a common polymorphism in treatment naïve patients (Perno
et al., 2006;Svicher et al., 2006). Patient 3 had the V35T mutation present in all its
clones with H208Y whereas patients 2 and 4 had the V35L mutation present with
H208Y in all their clones, which has not been associated with resistance. All three
treatment experienced patients from whom RT clones were generated had mutations
present at RT position K122 comprising K122E and K122P. The K122E mutation
has been identified as an NRTI accessory mutation, which is associated with AZT,
D4T and TDF resistance (Perno et al., 2006;Svicher et al., 2006). Patients 2 and 3
had the K122E mutation present in all its clones with H208Y whereas patient 4 the
K122P mutation present with H208Y in all their clones, which has not been
associated with resistance. All three treatment experienced patients had clones with
H208Y and T200A.
There were a number of NRTI associated accessory mutations within the connection
domain that were consistently present in the clones with H208Y. These were
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G359A/R/S and T377L (Cane et al., 2007;Torti et al., 2004). Mutations at position
G359 were present in all clones with H208Y from the treatment naïve patient and the
subtype A and C treatment experienced patients. Mutations at position T377 were
present in all clones with H208Y from the treatment experienced subtype A and C
patients and in 1/11 (9%) of clones from the subtype B treatment experienced patient.
The presence of H208Y and mutations within the connection and RNase H domain
that have been associated with contributing to NRTI resistance does not indicate that
H208Y is linked to other NRTI resistance mutations. However, the presence of these
additional mutations in some of the patients is consistent with the general
observation that these viruses have been subjected to prolonged drug pressure with
NRTIs and have evolved multiple mechanisms for coping with this pressure.
In summary, the findings showed that H208Y was associated with TAMs, in
particular mutations at positions D67, T215 and K219. The clones from the
treatment experienced patients had H208Y always present with accessory mutations
at positions V35, K122 and T200 and other mutations with unknown effects on drug
susceptibility and fitness at positions V245, A272, I293, T377, K390, E404, V435,
H483 and L491. Since there is a strong association with H208Y and the TAMs, it
can be speculated that H208Y works in two ways. Firstly, H208Y could further
augment NRTI resistance to NRTIs conferred by the TAMs and secondly, H208Y
could increase the fitness of the TAM virus.
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Chapter four
4 Phenotypic impact of H208Y on drug susceptibility
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4.1 Introduction
In the previous chapter, the RT gene from patients harbouring H208Y was cloned and
sequenced. The results from the clonal analysis showed that the H208Y mutation
was always associated with mutations at codon positions D67, T215 and K219.
These mutations are members of the thymidine analogue mutation (TAM) group of
mutations, which are known to contribute significantly to NRTI resistance (Johnson
et al., 2009). The results were consistent with previous observations that the H208Y
mutation is most often observed in patients who have an extensive treatment history
and harbour TAMs (Cane et al., 2007;Sturmer et al., 2003;Svicher et al., 2006). It
was therefore hypothesized that H208Y is an accessory mutation that arises in a
background of major resistance mutations in order to increase drug resistance or
improve viral fitness. In order to test this hypothesis, recombinant viruses containing
patient derived RT genes with and without H208Y were constructed. These
recombinant viruses were used in drug susceptibility assays to determine whether
H208Y had an impact on resistance to the RT inhibitors NRTIs and NNRTIs. Based
upon the observed association with TAMs, it was hypothesised that the H208Y
mutation would confer an increased resistance to the NRTIs, and particularly to the
thymidine analogues AZT and D4T.
There are two main methods to measure drug susceptibilities in vitro, a single and
multiple cycle system. Both methods involve cloning the gene of interest into a
defective molecular clone to produce a recombinant virus. This virus is then
incubated in the presence of increasing concentrations of drug, and the drug
concentration required to reduce replication of the recombinant virus by 50% relative
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to a control virus (IC50) is calculated. The main difference between these assays is
that the single cycle system only allows one cycle of virus replication to occur
whereas the multiple cycle assay allows continuous rounds of replication (Quinones-
Mateu and Arts, 2002). In this study, the multiple cycle method was used in order to
determine the drug susceptibilities of the viruses constructed. The reasons for
choosing this method were to gain a close as possible reproduction of conditions in
vivo and obtain viruses that could be used in growth competition experiments.
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4.2 Methods
4.2.1 Patient group
Plasma samples from four patients with H208Y were used for further analysis. This
included a subtype B treatment naïve patient, a subtype B treatment experienced
patient, a subtype A treatment experienced patient and a subtype C treatment
experienced patient. The treatment naïve subtype B patient harboured no major
resistance mutations. The treatment experienced subtype B patient harboured the
TAMs M41L, D67N, L210W, T215Y and K219N together with V75M, A98G and
G190Q. The treatment experienced subtype A patient harboured the TAMs D67N,
K70R, T215F and K219E together with T69N, A98G and G190Q. The treatment
experienced subtype C patient harboured the TAMs M41L, D67N, L210W, T215Y
and K219R together with E44D, L74V, A98G, K101H, V108I, Y181C and G190A/Q.
The treatment experienced subtype A and C patients also harboured M184V which
was back mutated to eliminate its effect in the drug susceptibility assay.
4.2.2 Site directed mutagenesis
The most commonly occurring clone from each patient was selected for further
analysis. These clones all had H208Y and were reverted to the wild type codon 208
amino acid (tyrosine to histidine) by site directed mutagenesis. All site directed
mutants underwent Sanger sequencing to confirm the correct amino acid was present.
4.2.3 Production of recombinant viruses
Patient derived PCR product containing the RT gene with and without H208Y and
the molecular clone pHIVΔRTBstEII were transfected into MT4 cells.   Cells were 
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monitored for CPE and once peak CPE was observed, the virus supernatant was
aliquoted. RNA was extracted from the virus supernatant and Sanger sequencing
was used to confirm the correct mutations were present.
4.2.4 Virus titrations
Once the recombinant viruses were constructed two methods were used to determine
their viral titre. These were the CPE titration method and the 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide (MTT) titration method
(table 4.1). The CPE titration method was a qualitative assay that involved scoring
wells based on whether any CPE was present. The MTT titration method was a
quantitative assay that used MTT as a cell viability marker to measure the number of
live cells present. The Reed and Muench equation was used to calculate the tissue
culture infectious dose (TCID50) of each virus. All virus titrations were done in
MT4 cells. For MTT titrations, 2-3 independent replicate experiments were
performed and CPE titrations were done once.
4.2.5 Optimisation of incubation time in drug susceptibility assay
Drug susceptibility assays were performed in quadruplicate and the average of the
four was used to calculate the IC50. Results are presented as mean IC50 of 3-5
replicate experiments for each virus/drug combination. HXB2 was used as a wild
type control in all assays.
4.2.6 Alignment of sequences
The RT amino acid sequences from patients were aligned using ClustralW2. Subtype
A and C sequences were obtained from the Los Alamos Database
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(http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html) and used to create
consensus sequences. To create the consensus subtype A and C sequence, 153
subtype A and 761 subtype C sequences were used. The consensus sequences were
compared to corresponding patient sequence. For the subtype B sequences, HXB2
was used as the consensus sequence.
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4.3 Results
4.3.1 Virus titrations
Table 4.1 shows the virus titres determined using the two different methods. The
titres obtained with both methods were comparable as they lied within a 2-fold
difference of each other. The MTT titres were used for the drug susceptibility assays.
4.3.2 Optimisation of incubation period in drug susceptibility assay
As shown in figure 4.1 the IC50 values obtained over the three days were variable
between the different days. There was over a 5-fold difference in the IC50 value
obtained on day 3 and day 4, but there was less variability between values obtained
on day 4 and day 5 with only a 2 fold difference. Table 4.2 shows how the IC50
values for AZT obtained in this study compared to those available from published
studies. Table 4.2 also shows published IC50 values for other NRTIs and results
obtained with both HXB2 and TAM-containing viruses (Hertogs et al., 1998;Naeger
et al., 2001;Ross et al., 2001;Garcia-Lerma et al., 2003;Garcia-Perez et al.,
2007;Pernas and Lopez-Galindez, 2008;Taylor et al., 1999). It should be noted that
the IC50 values were obtained using different phenotypic assays.
The published AZT IC50 range for HXB2 using the MTT/MT4 assay ranges between
0.007µM and 0.1µM. In this study, the IC50 obtained on day 4 was within this range
and therefore day 4 post-infection was selected for the analysis of all drug
susceptibility assays.
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Table. 4.1 Recombinant virus titresa
aAverage of 2-3 independent replicate experiments. The TCID50 was calculated using
the Reed and Muench equation. The equation was as follows; M = inv log{x1 + [(x2 -
x1)((y1 - 50) / y1 - y2)]}, where y1 = percent of well scored positive closest to, but higher
than 50% at a certain virus dilution, y2 = percent of well scored positive closest to, but
lower than 50% at a certain virus dilution, x1 = the log (dilution of the virus where was
observed), x2 = the log (dilution of the virus where was observed). bViruses with H208Y
were reverted to H208 by side directed mutagenesis.
Virusb MTT TitrationTCID50/ml
CPE Titration
TCID50/ml
HXB2 Wild type 2.0X104 2.0X104
Subtype B naïve H208 6.3X104 6.0X104
Subtype B naïve H208Y 4.7X104 5.0X104
Subtype B experienced H208 3.6X103 7.0X103
Subtype B experienced H208Y 2.7X103 5.8X103
Subtype A experienced H208 2.4X104 2.0X104
Subtype A experienced H208Y 1.8X103 1.5X103
Subtype C experienced H208 2.5X104 5.0X104
Subtype C experienced H208Y 6.3X104 5.8X104
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Day IC50 (uM)
3 0.017
4 0.098
5 0.197
Figure 4.1 Drug susceptibility curves and IC50µM values for AZT obtained
against HXB2 on day 3, 4 and 5 post-infection.
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Table. 4.2 Published NRTIs IC50 values with HXB2 and TAM containing
viruses
Virus Assay Drug IC50 (μM) Reference
HXB2a Multiple cycleMTT/MT4
ABC
DDI
3TC
TDF
AZT
D4T
2.17
4.840
1.977
23.288
0.099
1.953
This study
HXB2 Multiple cycleMTT/MT4
ABC
DDI
3TC
TDF
AZT
D4T
1.36
0.75 - 10
0.91 - 7
0.48 – 4.4
0.007 – 0.1
1 – 8
Garcia-Lerma et al. 2003;
Hertogs et al. 1998;
Taylor et al. 1999;
Naeger et al. 2001;
Pernas et al. 2008
HXB2 + D67N,
K70R, T215F,
K219Q
MTT/MT4 AZT 0.6 Taylor et al. 1999
HXB2 + D67N,
K70R, T215Y
XTT/MT2 AZTTDF
3TC
5.1 ± 1.40
8.2 ± 1.2
7.4 ± 0.9
Naeger et al. 2001
HXB2 + ≥ 3 
TAMs
pNL4-3 +
≥ 3 TAMs
Virco
(multiple
cycle)
Phenosense
(single cycle)
D4T
D4T
6.7
2
Ross et al. 2001
pNL4-3 +
M41L, K70R,
T215F, K219R
pNL4-3 +
M41L, E44D,
D67N,V118I,
L210W,
T215Y, K219R
MT2
luciferase
(single cycle)
AZT
D4T
3TC
TDF
DDI
ABC
AZT
D4T
3TC
TDF
DDI
ABC
0.408
0.12
0.432
4.42
0.510
0.298
0.624
0.179
0.696
4.96
0.867
0.269
Garcia-Perez et al. 2007
aThe IC50 values obtained with the MTT/MT4 assay performed in this study using
HXB2 wild type and a panel of NRTIs are shaded.
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4.3.3 Impact of H208Y on drug susceptibility
We studied the plasma viruses from four patients. These comprised a treatment naïve
patient who unusually showed the presence of H208Y in the absence of major
resistance mutations in RT, and three treatment experienced patients who showed
H208Y in the presence of TAMs and other major resistance mutations. The RT gene
with H208Y and a SDM without H208Y derived from the former were cloned into
the subtype B molecular clone pHIVΔRTBstEII, and tested in quadruplicate in 3-5 
independent replicate experiments in the presence of RT inhibitors.
4.3.3.1 H208Y in the context of subtype B wild type virus from
a treatment naïve patient
Figure 4.2 shows the mean IC50 (µM) values obtained with a panel of NRTIs.
Compared to the H208 SDM, the presence of H208Y in the absence of major
resistance mutations increased susceptibility to 3TC, AZT, ABC, DDI and D4T, but
decreased susceptibility to TDF.
Hypersusceptibility is usually defined as a virus that has a fold change of at least 0.4
compared to the wild type control virus (Clark et al. 2006). The presence of H208Y
conferred hypersusceptibility to AZT by 0.24 fold, to ABC by 0.29 fold and to EFV
by 0.28 fold.
For 3TC, the IC50 values were 1.52µM and 1.84µM with and without H208Y, with a
fold change relative to the HXB2 wild type control of 0.77 and 0.93 (Δ +0.16) 
respectively. For AZT, the IC50 values were 0.024µM and 0.044µM with and
without H208Y, with a fold change of 0.24 and 0.44 (Δ +0.20) respectively.  For 
132
ABC, the IC50 values were 0.63µM and 2.14µM with and without H208Y, with a
fold change of 0.29 and 0.99 (Δ +0.70) respectively.  For DDI, the IC50 values were 
2.65µM and 4.83µM with and without H208Y, with a fold change of 0.55 and 1 (Δ 
+0.45) respectively. For D4T, the IC50 values were 1.32µM and 3.89µM with and
without H208Y, with a fold change of 0.67 and 2 (Δ +1.33) respectively. For TDF, 
the IC50 values were 15.75µM and 7.14µM with and without H208Y, with a fold
change of 0.68 and 0.31 (Δ -0.37) respectively.    
Figure 4.3 shows the drug susceptibility profile of the same virus with a panel of
NNRTIs that consisted of NVP, EFV and ETV. H208Y increased susceptibility to
NVP and ETV but reduced susceptibility to EFV.
For ETV, the IC50 values were 0.003µM and 0.004µM with and without H208Y,
with a fold change of 1.56 and 2.5 (Δ +0.94) respectively.  For NVP, the IC50 values 
were 0.130µM and 0.186µM with and without H208Y, with a fold change of 0.51
and 0.73 (Δ +0.22) respectively.  For EFV, the IC50 values were 0.007µM and 
0.002µM with and without H208Y, with a fold change of 0.28 and 0.1 (Δ -0.18) 
respectively.
From the replicate experiments, the IC50 values obtained for viruses without and
without H208Y in the subtype B treatment naïve patient between replicates
experiments were all within a 2.5-3 fold difference of each other. There were two
exceptions where a 4 fold difference was seen with AZT and NVP for the viruses
with and without H208Y respectively.
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Figure 4.2 NRTI Drug susceptibility profile from the subtype B treatment naive
patient. Virus was obtained from a treatment naïve patient with the RT mutation
H208Y in the absence of major resistance mutations, compared to a reference wild
type HXB2 and to a site directed mutant lacking H208Y. Mean values with range
were calculated from 3 to 4 replicate experiments each performed in quadruplicate.
Delta (Δ) indicates the difference in fold change measured for the virus with H208Y 
and without H208Y. The delta was calculated for each replicate experiment and then
averaged. *** indicates significant difference p<0.001 as determined by two tailed
ANOVA.
Drug HXB2IC50(µM)
H208Y H208 SDM Average Δ 
(standard
deviation)Mean IC50µM
(range IC50)
Mean fold
change
(range)
Mean IC50
µM
(range IC50)
Mean fold
change
(range)
AZT 0.099 0.02(0.01-0.04)
0.24
(0.1-0.36)
0.04
(0.03-0.06)
0.44
(0.30-0.61)
+0.20
(0.24)
ABC 2.173 0.63(0.35-0.83)
0.29
(0.16-0.38)
2.14
(1.84-2.35)
0.99
(0.85-1.08)
+0.70
(0.18)
3TC 1.977 1.52(0.83-2.48)
0.77
(0.42-1.25)
1.84
(1.45-2.82)
0.93
(0.73-1.43)
+0.16
(0.48)
D4T 1.953 1.32(0.75-2.18)
0.67
(0.38-1.1)
3.89
(2.57-4.67)
2
(1.32-2.39)
+1.33
(0.57)
DDI 4.840 2.65(2.29-3)
0.55
(0.47-0.62)
4.83
(4-6.14)
1
(0.83-1.27)
+0.45
(0.21)
TDF 23.288 15.75(10.16-20.4)
0.68
(0.44-0.88)
7.14
(6.84-7.58)
0.31
(0.29-0.33)
-0.37
(0.38)
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Figure 4.3 NNRTI Drug susceptibility profile from the subtype B treatment
naive patient. Virus was obtained from a treatment naïve patient with the RT
mutation H208Y in the absence of major resistance mutations, compared to a
reference wild type HXB2 and to a site directed mutant lacking H208Y. Mean values
with range were calculated from 3 to 4 replicate experiments each performed in
quadruplicate.  Delta (Δ) indicates the difference in fold change measured for the 
virus with H208Y and without H208Y. The delta was calculated for each replicate
experiment and then averaged.
Drug HXB2IC50(µM)
H208Y H208 SDM
Average Δ 
(standard
deviation)
Mean IC50
µM
(range IC50)
Mean fold
change
(range)
Mean IC50
µM
(range IC50)
Mean fold
change
(range)
NVP 0.256 0.130(0.072-0.164)
0.510
(0.28-0.64)
0.186
(0.102-0.306)
0.730
(0.4-1.2)
+0.22
(0.20)
ETV 0.0016 0.003(0.002-0.003)
1.560
(1.25-1.88)
0.004
(0.002-0.005)
2.500
(1.25-3.13)
+0.94
(0.44)
EFV 0.025 0.007(0.005-0.014)
0.280
(0.20-0.56)
0.002
(0.001-0.004)
0.100
(0.04-0.16)
-0.18
(0.22)
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4.3.3.2 H208Y in the context of subtype B virus from a
treatment experienced patient
Plasma virus from the subtype B treatment experienced patient harboured the
pathway 1 TAMs M41L, L210W and T215Y together with D67N, K219N and V75M
in all clones. The NNRTI resistance mutations A98G and G190Q were also present
in all clones.
Figure 4.4 shows the mean IC50 (µM) values obtained with a panel of NRTIs.
Compared to the H208 SDM, the presence of H208Y on a background of TAM-1
pathway mutations increased susceptibility to ABC and D4T, but reduced
susceptibility to 3TC, DDI and TDF.
For ABC, the IC50 was 37.50µM and 41.10µM with and without H208Y, with a fold
change of 17.26 and 18.91 (Δ +1.65) respectively.  For D4T, the IC50 was 11.53µM 
and 38.28µM with and without H208Y with a fold change of 5.9 and 19.6 (average Δ 
+13.70) respectively. For 3TC the IC50 was 45.13µM and 36.23µM with and
without H208Y respectively with a fold change of 22.83 and 18.33 (Δ –4.50) 
respectively. For DDI, the IC50 was 66.5µM and 56.23µM with and without H208Y
with a fold change of 13.74 and 11.62 (Δ –2.12) respectively. For TDF, the IC50 was 
404µM and 177µM with and without H208Y respectively with a fold change of 17.3
and 7.6 (Δ –9.70) respectively.  
Figure 4.5 shows the drug susceptibility profile of the same virus with a panel of
NNRTIs that consisted of NVP, EFV and ETV. H208Y also conferred an increased
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susceptibility to ETV. The IC50 was 0.004µM and 0.0097µM with and without
H208Y with a fold change of 2.5 and 6 (Δ + 3.8) respectively. 
From the replicates experiments, the IC50 values obtained for viruses with and
without H208Y in the subtype B treatment experienced patient were all within a 2.5
fold difference of each other.
Despite repeat attempts no IC50 values were obtained for AZT, EFV and NVP. For
AZT this was due to the fact the viruses were highly drug-resistant due to the
presence of multiple TAMs, and therefore the drug levels required to inhibit the
viruses exceeded the limit of the assay and were toxic to cells.
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Figure 4.4 NRTI Drug susceptibility profile from the subtype B treatment
experienced patient. Virus was obtained from a treatment experienced with the RT
mutation H208Y in the presence of M41L, D67N, V75M, A98G, V118I, G190Q,
L210W, T215Y and K219N compared to a reference wild type HXB2 and to a site
directed mutant lacking H208Y. Mean values with range were calculated from 3
replicate experiments each performed in quadruplicate.  Delta (Δ) indicates the 
difference in fold change measured for the virus with H208Y and without H208Y.
The delta was calculated for each replicate experiment and then averaged. ***
indicates significant difference p<0.001 as determined by two tailed ANOVA.
Drug HXB2IC50(µM)
TAM-1 H208Y TAM-1 H208 SDM
Average Δ 
(standard
deviation)
Mean IC50
µM
(range IC50)
Mean fold
change
(range)
Mean IC50
µM
(range IC50)
Mean fold
change
(range)
AZT 0.099 >10 NA >10 NA NA
ABC 2.173 37.50(21.2-51.5)
17.26
(9.8-23.7)
41.10
(34-53)
18.91
(15.6-24.4)
+1.65
(8.42)
3TC 1.977 45.13(36.8-51)
22.83
(18.6-25.8)
36.23
(28.2-43.9)
18.33
(14.3-22.2)
-4.50
(6.11)
D4T 1.953 11.53(6.8-16.3)
5.9
(3.5-8.4)
38.28
(23-53)
19.60
(11.8-27)
+13.70
(5.13)
DDI 4.840 66.50(52.5-79.4)
13.74
(10.8-16.4)
56.23
(39.2-67)
11.62
(8.1-13.8)
-2.12
(3.99)
TDF 23.288 404(294-500)
17.3
(12.6-21.5)
177
(150-196)
7.6
(6.4-8.4)
-9.70
(4.47)
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Drug HXB2IC50(µM)
TAM-1 H208Y TAM-1 H208 SDM
Average Δ 
(standard
deviation)
Mean IC50
µM
(range IC50)
Mean fold
change
(range)
Mean IC50
µM
(range IC50)
Mean fold
change
(range)
NVP 0.256 <0.01 NA <0.01 NA NA
ETV 0.0016 0.004(0.003-0.005)
2.5
(1.9-3.1)
0.01
(0.007-0.013)
6.3
(4.4-8.1)
+3.8
(2.53)
EFV 0.025 <0.01 NA <0.01 NA NA
Figure 4.5 NNRTI Drug susceptibility profile from the subtype B treatment
experienced patient. Virus was obtained from a treatment experienced patient with
the RT mutation H208Y in the presence of M41L, D67N, V75M, A98G, V118I,
G190Q, L210W, T215Y and K219N, compared to a reference wild type HXB2 and
to a site directed mutant lacking H208Y. Mean values with range were calculated
from 3 replicate experiments each performed in quadruplicate.  Delta (Δ) indicates 
the difference in fold change measured for the virus with H208Y and without H208Y.
The delta was calculated for each replicate experiment and then averaged.
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4.3.3.3 H208Y in the context of subtype A virus from a
treatment experienced patient
The subtype A patient harboured the pathway 2 TAMs D67N, K70R, T215F and
K219E. This patient also had the M184V and T69N mutations present in all clones.
The M184V mutation was back mutated to the wild type amino acid methionine by
side directed mutagenesis in order to eliminate its strong effects on drug
susceptibility, including high-level resistance to 3TC and FTC, and increased
susceptibility to ZDV, D4T and TDF. The NNRTI resistance mutations A98G and
G190Q were present in all clones.
Figure 4.6 shows the mean IC50 (µM) values obtained with a panel of NRTIs. The
presence of H208Y in the context of TAM-2 mutations increased susceptibility to
D4T, but reduced susceptibility to ABC, DDI and 3TC. No effects were seen for
TDF.
For 3TC, the IC50 was 12.54µM and 7.18µM with and without H208Y respectively,
with a fold change of 6.34 and 3.63 (Δ -2.71) respectively.  For ABC the IC50 was 
5.06µM and 3.48µM with and without H208Y respectively with a fold change of 2.3
and 1.6 (Δ -0.66) respectively.  For DDI the IC50 was 6.71µM and 3.74µM with and 
without H208Y respectively with a fold change of 1.39 and 0.77 (Δ -0.62) 
respectively. For D4T the IC50 was 2.05µM and 2.87µM with and without H208Y
with a fold change of 1.05 and 1.45 (Δ +0.42) respectively.   
From the replicates experiments, the IC50 values obtained for viruses with and
without H208Y in the subtype A treatment experienced patient were all within a 3
fold difference of each other. The two exceptions were with ABC and 3TC for the
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virus with H208Y, where a 3.4 fold difference was seen for both drugs. For both
these drugs, the number of replicates was increased to 4 and 5 for ABC and 3TC
respectively to obtain a more reproducible IC50 value. The subtype A viruses with
and without H208Y were not tested for their susceptibility to AZT and the NNRTIs
as the previous data indicated that due to the presence of TAMs in these viruses, no
reliable results would be obtained for AZT, EFV and NVP.
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Figure 4.6 NRTI Drug susceptibility profile from the subtype A treatment
experienced patient. Virus was obtained from a treatment experienced patient with
the RT mutation H208Y in the presence of D67N, T69N, T215F and K219E,
compared to a reference wild type HXB2 and to a site directed mutant lacking
H208Y. The patient’s virus also had the major RT mutation M184V which was back
mutated to the wild type amino acid methionine by site directed mutagenesis. Mean
values with range were calculated from 3 to 5 replicate experiments each performed
in quadruplicate.  Delta (Δ) indicates the difference in fold change measured for the 
virus with H208Y and without H208Y. The delta was calculated for each replicate
experiment and then averaged.
Drug HXB2IC50(µM)
TAM-2 H208Y TAM-2 H208 SDM
Average Δ 
(standard
deviation)
Mean IC50
µM
(range IC50)
Mean fold
change
(range)
Mean IC50
µM
(range IC50)
Mean fold
change
(range)
AZT 0.099 ND ND ND ND ND
ABC 2.173 5.06(1.9-6.6)
2.33
(0.9-3)
3.48
(2-5.9)
1.67
(0.92-2.7)
-0.66
(0.94)
3TC 1.977 12.54(5.7-19.3)
6.34
(2.9-9.8)
7.18
(5.8-8.8)
3.63
(2.9-4.4)
-2.71
(2.68)
D4T 1.953 2.05(1.1-3.0)
1.05
(0.6-1.6)
2.87
(1.7-4.3)
1.45
(0.9-2.2)
+0.42
(0.70)
DDI 4.840 6.71(6-8.54)
1.39
(1.2-1.8)
3.74
(2.8-5)
0.77
(1.6-1)
-0.62
(0.45)
TDF 23.288 12.17(8.4-18.9)
0.5
(0.4-0.8)
13.60
(6.9-21.6)
0.58
(0.3-0.9)
+0.08
(0.53)
ABC 3TC D4T DDI TDF
0
10
20
30
40
HXB2 TAM-2 +H208YTAM-2 +H208 SDM
NRTI
IC
50
(u
M
)
142
4.3.3.4 H208Y in the context of subtype C wild type virus from
a treatment experienced patient
The subtype C patient harboured the pathway 1 TAMs M41L, L210W and T215Y
with D67N and K219R. This patient also had the E44D, L74V and M184V
mutations present in all clones. The M184V mutation was back mutated to the wild
type amino acid methionine by side directed mutagenesis in order to eliminate its
strong effects on drug susceptibility. The NNRTI resistance mutations present were
A98G, K101H, V108I, Y181C and G190A/Q. All NNRTI mutations were present in
100% of clones except for V108I which was present in 50% (10/20) of clones.
Figure 4.7 shows the mean IC50 (µM) values obtained with a panel of NRTIs. The
presence of H208Y in the context of TAM-1 mutations increased susceptibility to
ABC, DDI, and 3TC and reduced susceptibility to D4T. No effects were seen for
TDF.
For DDI the IC50 was 23.01µM and 31.89µM with and without H208Y with a fold
change of 4.75 and 6.59 (Δ+1.84).  For ABC the IC50 was 23.53µM and 27.26µM 
with and without H208Y with a fold change of 10.83 and 12.29 (Δ+1.46). For 3TC 
the IC50 was 11.68µM and 13.97µM with and without H208Y respectively with a
fold change of 5.9 and 7.06 (Δ+1.16).   
For D4T the IC50 was 9.23µM and 8.63µM with and without H208Y respectively
with a fold change of 4.73 and 4.42 (Δ-0.31).   No effect was observed against TDF. 
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From the replicates experiments, the IC50 values obtained for viruses with and
without H208Y in the subtype C treatment experienced patient were all within a 2.5
fold difference of each other. The subtype C viruses with and without H208Y were
not tested for their susceptibility to AZT and the NNRTIs as the previous data
indicated that due to the presence of TAMs in these viruses no reliable results would
be obtained for AZT, EFV and NVP.
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Figure 4.7 NRTI Drug susceptibility profile from the subtype C treatment
experienced patient. Virus was obtained from a treatment experienced patient with
the RT mutation H208Y in the presence of M41L, E44D, D67N, L74V, A98G,
K101H, Y181C, G190A, L210W, T215Y and K219R, compared to a reference wild
type HXB2 and to a site directed mutant lacking H208Y. This patient’s virus also
had the major RT mutation M184V, which was back mutated to the wild type amino
acid methionine by site directed mutagenesis. Mean values with range were
calculated from 3 replicate experiments each performed in quadruplicate. Delta (Δ) 
indicates the difference in fold change measured for the virus with H208Y and
without H208Y. The delta was calculated for each replicate experiment and then
averaged.
Drug HXB2IC50(µM)
TAM-1 H208Y TAM-1 H208 SDM
Average Δ
(standard
deviation)
Mean IC50 µM
(range IC50)
Mean fold
change
(range)
Mean IC50 µM
(range IC50)
Mean fold
change
(range)
AZT 0.099 ND ND ND ND ND
ABC 2.173 23.53(18.8-26.4)
10.83
(8.6-12.1)
27.26
(16.5-36)
12.29
(7.6-16.6)
+1.46
(3.06)
3TC 1.977 11.68(7.4-14.5)
5.9
(3.7-7.3)
13.97
(8.9-21.5)
7.06
(4.5-10.9)
+1.16
(5.29)
D4T 1.953 9.23(8.1-10.5)
4.73
(4.2-5.4)
8.63
(7.3-10.8)
4.42
(3.8-5.5)
-0.31
(1.26)
DDI 4.840 23.01(18.8-28.6)
4.75
(3.9-5.91)
31.89
(25.4-36.8)
6.59
(5.2-7.6)
+1.84
(1.14)
TDF 23.288 47.88(32.7-56.5)
2
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49.36
(41.5-63.5)
2.12
(1.8-2.7)
+0.12
(0.48)
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Table. 4.3 Overall impact of the RT mutation H208Y on susceptibility to RT
inhibitors
Subtype MajorRT Mutations
RT Inhibitors
AZT ABC 3TC D4T DDI TDF NVP ETV EFV
B None
B
M41L, D67N, V75M,
A98G, V118I,
G190Q, L210W,
T215Y, K219N
ND ND ND
A D67N, T69N, K70R,T215F, K219E ND ND ND ND
C
M41L, E44D, D67N,
L74V, A98G, K101H,
Y181C, G190A,
L210W, T215Y,
K219R
ND ND ND ND
Delta (Δ) values were calculated as the difference in fold change (relative to the 
reference wild type HXB2) between virus with and without H208Y. For
interpretation purposes, a positive delta value was regarded as increased
susceptibility ( ); a negative delta value was regarded as decreased susceptibility
( ); ND= not done; *** indicates a significant difference p<0.001 as determined by
two tailed ANOVA.
***
***
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Table 4.3 summarises the overall impact of the H208Y mutation on drug
susceptibility in the four patients using the delta values obtained when comparing the
virus with and without H208Y (relative to the reference wild type HXB2). An
increased susceptibility was defined as a positive delta value and a decreased
susceptibility was defined as a negative delta value. For most of the drugs no
statistically significant effect was observed except from the reduced susceptibility to
TDF seen in the subtype B patients. Statistical analysis was performed using two-
tailed ANOVA.
In the absence of major resistance mutations in subtype B RT, H208Y increased
susceptibility to AZT, ABC, 3TC, D4T, DDI, NVP and ETV and reduced
susceptibility to TDF and EFV. The magnitude of the effect was such that it can be
concluded that H208Y conferred hypersusceptibility (at east 0.4 fold) to AZT, ABC
and NVP. In the presence of the TAMs M41L, D67N, L210W, T215Y, K219N and
V75M, A98G, V118I and G190Q in subtype B RT, H208Y increased susceptibility to
ABC, D4T and ETV and reduced susceptibility to 3TC, DDI and TDF. In subtype C,
with the same TAMs plus E44D, L74V, A98G, K101H, V108I, Y181C, G190A and
K219R RT, H208Y increased susceptibility to ABC, 3TC, TDF and DDI and reduced
susceptibility to D4T. In the presence of the TAMs D67N, T215F, and K219E
together with T69N, A98G and G190Q in subtype A RT, H208Y increased
susceptibility to D4T and TDF and reduced susceptibility to ABC, 3TC and DDI.
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4.3.4 Amino acid sequence alignment of RT sequences from the 4
patients
The presence of H208Y in RT from different HIV-1 subtypes showed variable results
regarding increased and decreased susceptibility to NRTIs and NNRTIs. However,
with TDF, a statistically significant effect was observed with the subtype B RT. In
this context, the presence of H208Y conferred a decreased susceptibility to TDF. In
order to gain insights into the different phenotypic effects seen for TDF with the
different viruses, the clonal RT amino acid sequences from the subtype A and
subtype C patients were compared with the subtype B sequences (figure 4.8).
The subtype B treatment naïve patient harboured no major RT resistance mutations.
Major resistance mutations shared between the three treatment experienced patients
were D67N, T215Y/F and K219E/N/R. Both the subtype B and C treatment
experienced patients had the A98G, G190A/Q, M41L and V118I mutations present.
Mutations not shared by the treatment experienced patients included V75M for the
subtype B patient, T69N for the subtype A patient and E44D, L74V, K101H, K103N,
V108I and Y181C for the subtype C patient.
Excluding major drug resistance mutations from this alignment, 12 amino acid
positions were identified that were the same in the two subtype B sequences but
different in the subtype A and C sequences. These positions are highlighted in red in
figure 4.8. Most of the mutations were found within the RNase H domain (6/12,
50%), followed by the polymerase domain (4/12, 33%) and the connection domain
(2/12, 17%). The majority of these changes were not mutations known to be
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associated with NRTI resistance. Of interest, two positions were identified that
appear to play a role in NRTI resistance involving codons 207 and 335. At position
207, both subtype B patients harboured Q (glutamine) whereas subtype A and
subtype C viruses harboured A (alanine) and E (glutamic acid) respectively. At
position 335, both subtype B patients harboured a G (glycine) whereas subtype A and
subtype C viruses harboured a D (aspartic acid).
To examine how the differences related to subtype, subtype A and subtype C
consensus sequences were downloaded from the Los Alamos Database
(http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html) in order to perform a
comparison of these 12 positions. This analysis showed that the majority of changes
were subtype-related differences with only 1/12 (8%) for subtype A and 4/12 (33%)
for subtype C having a mutation present (table 4.4). The positions at 335 and 207
were wild type for the respective subtype A and C patient sequences. No accessory
mutations were shared between the four patients.
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A PISPIETVPVKLKPGMDGPRVKQWPLTEEKIKALTEICTEMEKEGKISKIGPENPYNTPI 60
C PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALLEICEELEKDGKISKIGPENPYNTPV 60
Exp_B PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICTFLEEEGKISKIGPENPYNTPI 60
Naive PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPV 60
A FAIKKKNSNKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL 120
C FAIKKKNSTKWRKVVDFRELNKRTQDFWEVQLGIPHPGGLHKKKSVTVLDIGDAYFSIPL 120
Exp_B FAIKKKNSTKWRKLMDFRELNKRTQDFCEVQLGLPHPGGLKKKKSVTVLDVGDAYFSIPL 120
Naive FAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL 120
A DESFRKYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRLKNPEIII 180
C DPNFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPSIFQSSMTKILEPFRTKNPEIVI 180
Exp_B DEDFRKYTAFTIPSVNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDLVI 180
Naive DKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPEMVI 180
A YQYMDDLYVGSDLEIGQHRAKIEELRAYLLSWGFFTPDEKHQKEPPFLWMGYELHPDKWT 240
C CQYMDDLYVASDLEIGQHRAKIKELREYLWKWGFYTPERKHQQEPPFLWMGYELHPDKWT 240
Exp_B YQYMDDLYVQSDLEIGQHRAKIEELRQYLWKWGFYTPDNKHQKEPPFLWMGYELHPDKWT 240
Naive YQYMDDLYVGSDLETEQHRTKIEELRQYLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWT 240
A VQPIQLPEKDSWTVNDIQKLVGKLNWASQIYSGIKVKQLCKLLRGAKALTDVVPLTEEAE 300
C VQPIQLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTDIVPLTEEAE 300
Exp_B VQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIRVRQLCKLLRGTKALTEVVTLTREAE 300
Naive VQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKTLTEVVPLTKEAE 300
A LELAENREILKDPVHGVYYDPSKDLIAEIQKQGEDQWTYQVYQEPFKNLKTGKYARRKAA 360
C LELAENREILKEPVHGVYYDPSKDLIAEIQKQGDDQWTYQIYQEPFKNLKTGKYAKRRTA 360
Exp_B LELAENREILKTPVHGVYYDPSKELIAEIQKQGQGPWTYQIYQEPFKNLRTGKYARRKGA 360
Naive LELAENREILKEPVHGVYYDPSKDLIAEIQKQGLGQWTYQIYQEPFKNLKTGKYARMRSA 360
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A HTNDVKQLTEVVQKVVLEAIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTP 420
C HTNDVKQLTEAVQKIALESIVIWGKTPKFKLPIQKETWEAWWTDYWQATWIPEWEFVNTP 420
Exp_B HTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWETWWTDYWQATWIPEWEFVNTP 420
Naive HTNDVKQLTEAVQKIATESIVIWGKIPKFRLPIQKETWDTWWAEYWQATWIPEWEFVNTP 420
A PLVKLWYQLEKDPIIGAETFYVDGAANRETKLGKAGYVTDRGRQKVVSLNETTNQKAELH 480
C PLVKLWYQLEKEPIIGAETFYVDGAANRETRIGKAGYVTDRGRQKIVSLNETTNQKTELQ 480
Exp_B PLVKLWYQLEKEPIAEAETFYVDGAANRETKLGKAGYVTNRGRQKVVPLTDTTNQKTELE 480
Naive PLVKLWYQLETEPIVGAETFYVDGAANRDTKLGKAGYVTDRGRQKVVPLTDTTNQKTELQ 480
A AIYLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLINKERVYLSWVPAHK 540
C AIQLALQDSGSEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKERVYLSWVPAHK 540
Exp_B AINLALQDSGPEVNIVTDSQYALGIIQAQPDQSESELVSQIIEQLIKKEKVYLAWVPAHK 540
Naive AIHLALQDSGAEVNIVTDSQYALGIIHAKPDKSESELVSQIIEQLIKKEKVYLAWVPAHK 540
A GIGGNEQVDKLVSSGIRKVL 560
C GIGGNEQVDKLVSNGIRKVL 560
Exp_B GIGGNEQVDKLVSAGIRKVL 560
Naive GIGGNEQVDKLVSAGIRKVL 560
Figure 4.8 Amino acid sequence alignment of the RT derived from the plasma virus of four patients. Subtype B treatment naïve
(Naïve), subtype B treatment experienced (Exp_B), subtype A treatment experienced (A) and subtype C treatment experienced (C).
Amino acids in red represent positions that are conserved in the subtype B sequences but differ in the subtype A and subtype C
sequences. Amino acids in green represent major NRTI and NNRTI resistance mutations.
Table. 4.4 Subtype related sequence variationa
Subtype B
Amino Acid
Subtype A
Amino Acid
Subtype C
Amino Acid
K173 S173L A173T
Q174 K174 Q174K
Q207* A207 E207
K277R K277 R277K
E291 D291 D291
G335* D335 D335
T468P S468 S468
D471 E471 E471
S519 N519 N519
K530 K530 R530
A534 S534 S534
A554 S554 S554N
a12 amino acid positions were identified that were conserved in the two subtype B
sequences but differed in the subtype A and C sequences. The consensus sequences
for subtype A and C were obtained by aligning 153 and 761 subtype A and subtype C
sequences respectively from the Los Alamos Database. The consensus sequences
were compared to the patient sample of the corresponding subtype and mutations
were identified as those differing from the consensus sequence. * indicates positions
that have been proposed as playing a role in NRTI resistance.
Figure 4.9 Structural representation of the p66 subunit of the HIV-1 reverse
transcriptase gene. The arrows shows the position of H208Y and the three catalytic
aspartic residues A110, A185 and A186.
H208YA110,
A185,152
A186
153
4.3.5 Structure of RT with the H208Y mutation
Figure 4.9 shows a graphical representation of the HIV-1 RT p66 subunits backbone
secondary and tertiary structure. The H208 residue is shown in red and in yellow are
the catalytically important residues A110, A185 and A186. It can be seen that
residue 208 is located at a distal alpha-helix at the base of the palm subdomain, with
its side-chain protruding out into the surrounding solvent.
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4.4 Discussion
In this study, we determined the impact of the RT mutation H208Y on phenotypic
susceptibility to RT inhibitors using a multiple cycle recombinant virus assay. In the
context of subtype B RT without major resistance mutations and a subtype B RT with
the TAMs M41L, D67N, L210W, T215Y and K219N, the H208Y mutation conferred
a reduced susceptibility to TDF. This effect was not observed with subtype A RT
harbouring the TAMs D67N, K70R, T215F and K219E and with subtype C virus
harbouring the TAMs M41L, D67N, L210W, T215Y and K219R. The resistance
effects of H208Y were not seen with other NRTIs, rather the mutation was shown to
confer an increased susceptibility to some NRTIs and NNRTIs, although these effects
were not statistically significant when comparing virus with and without H208Y.
Phenotypic assays most commonly assess virus susceptibility to antiretroviral drugs
using recombinant viruses. The inhibitory concentration required to inhibit 50% of
the virus (IC50) is calculated and compared to a wild type laboratory strain as
reference. Currently there are two types of phenotypic assays which both utilise
recombinant virus. They involve cloning the gene of interest into either a replicative
competent vector (multiple cycle assay) or into a replication defective vector that
allows only one round of replication to occur (single cycle assay). The read out of
these two assays differs. The multiple cycle assay uses the MTT lysis method
whereas the single cycle method uses reporter genes such as luciferase or ß-
galactosidase.
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There are advantages and drawbacks with both methodologies. Advantages of the
single cycle assay include the fact that it is a fairly rapid assay compared to the
multiple cycle assay, and results of replicate experiments generally show smaller
variation. A commercial assay utilising the single cycle approach for measuring drug
susceptibilities is provided by Monogram Biosciences in the United States. The intra-
assay reproducibility of this test was evaluated by using duplicate aliquots of 9
clinical samples in a single experiment. The authors found that there was <2.5 fold
variability in the results given by 99% of tests (n=107) (Demeter and Haubrich,
2001). The major drawback to this method is that only a single round of replication
occurs and therefore it can be argued that the assay does not fully reproduce the in
vivo effects of resistance mutations.
Another commercial phenotypic assay is provided by Virco in Belgium. The assay
uses a multiple cycle approach to determine drug susceptibilities. The Virco assay
has been shown to be highly reproducible across independent experiments. The fold
change range compared to wild type virus was between 1.2 and 2.5 with 16 samples
tested in 10 independent experiments (Demeter and Haubrich, 2001). An advantage
of the multiple cycle method is the fact that the virus undergoes multiple rounds of
replication and therefore the assay conditions mimic more closely the conditions that
the virus experiences in vivo. This advantage is also a potential drawback in that it is
possible for the virus to mutate during passaging, particularly in the presence of
drugs, and therefore the input virus may not necessarily be the same virus at the end
of the assay. This is particularly true for drug susceptibility assays that are done over
a period of 2 to 3 weeks. The drug susceptibility assays presented in this study were
analysed following a short incubation of 4 days. The likelihood that the virus will
156
mutate significantly enough to cause a phenotypic effect in 4 days can be considered
low. An in vitro study showed that the selection of AZT resistant mutations in wild
type HXB2 appeared after a median of 54 days in culture in the presence of AZT.
The TAMs first to emerge were K70R and D67N (Garcia-Lerma et al., 2004).
When analysing independent replicate experiments in this study, variability was
usually within a 2.5 to 3 fold change range. There were some incidences however
where the range in fold change was greater than 3 and in this case the number of
replicate experiments was increased to give confidence in the results. Thus, when
testing the subtype A virus with H208Y for susceptibility to ABC and 3TC, the
replicate experiments showed initially a difference in the fold change range of 3.4
and therefore the number of replicates was increased to 5 and 4 respectively.
Differences in the fold change range were also seen with the subtype B virus with
H208Y when tested for susceptibility to AZT, and the subtype B virus with H208Y
when tested for susceptibility to EFV.
The majority of IC50 values obtained in this study were consistent with those
available in the literature. The variability observed between replicates is not overly
surprising given the fact that these were clinical samples tested in a multiple cycle
system. It is important to consider that although the same assay was used,
differences will occur resulting from the intrinsic variability of tissue culture
conditions. One important factor in reducing the impact of such variability is to use
fold changes in IC50 relative to the wild type virus tested under the same
experimental condition, rather than using absolute IC50 values. This is currently the
gold standard method of analysing phenotypic data.
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Previous studies examining the phenotypic effect of the H208Y mutation have
yielded conflicting results. These studies have reported both increased and reduced
susceptibility to AZT in the presence of H208Y. One study used the multiple cycle
assay and created site directed mutants to show that the triple mutant
H208Y/R211K/L214F in the context of the TAMs M41L, D67N, K70R, L210W,
T215Y and K219E resulted in a 21-fold reduced susceptibility to AZT (Sturmer et
al., 2003). These findings were supported by the study carried out by (Svicher et al.,
2006). This study sent samples to Virco for phenotypic testing. In the Virco
multiple cycle assay, in the presence of M41L, L210W and T215Y in the context of
subtype B RT, H208Y reduced susceptibility to all NRTIs including TDF. Despite
these findings indicating a role of H208Y in conferring resistance to AZT, another
study showed that in the absence of TAMs, H208Y caused increased susceptibility to
AZT, D4T, NVP and EFV, but reduced susceptibility to TDF. This study created site
directed mutants on subtype B RT backbone and used a single cycle assay to
determine drug susceptibility (Clark et al., 2006). The phenotypic data presented
here confirm that H208Y confers reduced susceptibility to TDF in both wild type
subtype B virus and subtype B virus containing the TAMs M41L, D67N, L210W,
T215Y and K219N. A novel finding was that the effect was not seen with subtype A
and subtype C virus showing the TAMs D67N, K70R, T215F and K219E and M41L,
D67N, L210W, T215Y and K219R respectively.
There are at least two mechanisms of resistance to the NRTIs. The first mechanism
is known as NRTI excision or primer unblocking. The excision is mediated by
TAMs, particularly T215Y. Excision occurs through a pyrophosphorolysis reaction
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using cellular pyrophosphate or more commonly ATP as an acceptor. This results in
the release of the incorporated NRTI and a free hydroxyl group enabling DNA
synthesis to resume (Goldschmidt and Marquet, 2004;Sluis-Cremer et al., 2000b).
The second mechanism is mediated by mutations that interfere with binding and/or
incorporation of the NRTI. Examples of these mutations are K65R and K70E, which
confer TDF resistance, and M184V which confers resistance to 3TC and FTC.
These mutations allow the enzyme to discriminate between the natural dNTP
substrate and the NRTI and consequently decrease incorporation of the NRTI,
allowing chain synthesis to continue (Sluis-Cremer et al., 2007). These mutations
are also known to have an antagonistic relationship with the TAMs. The side chain
of K65R interacts with the side chain of R72 (arginine) leading to the formation of a
bridge which restricts the movement of the RT. Consequently there is reduced NRTI
incorporation and NRTI excision (Sluis-Cremer et al., 2007;Das et al., 2009).
Neither of the subtype B clones harboured K70E or K65R, eliminating their role in
conferring TDF resistance. It can be speculated that the mechanism whereby H208Y
confers resistance to TDF is not the same as the traditional TDF resistance mutations.
Since the H208Y mutation was associated with TAMs, and consistently with
T215Y/F, the mechanism could be related to NRTI excision or primer unblocking.
This argument is further strengthened by the fact that H208Y was always associated
with mutations at position D67, T215 and K219. The T215Y/F mutation has been
suggested to increase the efficiency of ATP binding during pyrophosphorolysis
(Arion et al., 1998;Boyer et al., 2001b;Chamberlain et al., 2002;Meyer et al.,
2002;Sluis-Cremer et al., 2007;Boyer et al., 2002). These mutations also destabilise
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the RT allowing efficient release of the NRTI (Boyer et al., 2002;Meyer et al., 2003).
Therefore it is plausible that the mechanism of resistance of H208Y is related in
NRTI excision and perhaps aids the process.
There are several possible reasons why the phenotypic effect of H208Y on
susceptibility to TDF was observed only with the subtype B viruses. This includes
subtype-related or drug-induced sequence differences and possibly structural
differences in the enzyme. The TAMs present in the viruses from the three treatment
experienced patients were similar but not identical. The subtype B virus had the
TAMs M41L, D67N, L210W, T215Y and K219N alongside V75M, V118I and the
NNRTI resistance mutations A98G and G190Q. The subtype A virus had the TAMs
D67N, K70R, T215F and K219E alongside T69N and the NNRTI resistance
mutations A98G and G190Q, while the subtype C virus had the TAMs M41L, D67N,
L210W, T215Y and K219R alongside E44D, L74V, and the NNRTI resistance
mutations A98G, K101H, V108I, Y181C and G190A/Q. Thus the mutation profile
was similar albeit not identical for the subtype B and subtype C viruses, but rather
different for the subtype A virus. It is known that the pathway 1 TAMs M41L,
L210W and T215Y have stronger effects on NRTIs susceptibility than the pathway 2
mutations K70R, T215F and K219E/Q. Pathway 1 TAMs confer cross resistance to
DDI and TDF whereas pathway 2 TAMs do not (Hu et al., 2006;Marcelin et al.,
2005;Miller, 2004).
We also investigated whether other mutations were present that may explain the
differences observed between subtypes. Aligning the RT amino acid sequences from
the four patients showed that there were 12 positions which were the same in the two
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subtype B patients, but differed in the subtype A and subtype C patients. The
majority of these changes were polymorphisms with unknown effect on drug
susceptibility. However, differences were observed at codons 207 and 335. These
two positions are known to play a role in NRTI resistance. At codon 207, the
subtype B viruses harboured glutamine (Q), whereas the subtype A and subtype C
viruses harboured glutamic acid (E) and alanine (A) respectively. The Q207D
mutation has been shown to increase resistance by 2.7 fold to AZT when present in
an AZT-resistant RT but had no effect on AZT susceptibility when present in a wild
type RT (Lu et al., 2005). Therefore, it can be speculated that the mutation may have
played a role in conferring resistance, however it should be noted that none of the
patients had the Q207D mutation present and the phenotypic effect of Q207A/E have
not been investigated. Similarly, at position 335, the subtype B viruses harboured
glycine (G) whereas both the subtype A and C viruses had aspartic acid (D). The
G335D mutation has been shown to confer resistance to 3TC and AZT when present
alongside M184V and TAM-1 mutations respectively however, the phenotypic
impact of G335D alone has not been investigated (Zelina et al., 2008). The subtype
A and C viruses did not have the M184V present and they were not tested against
AZT however, the subtype A virus did show a decreased susceptibility to 3TC with a
average delta of Δ -2.71 but this effect was not statistically significant.  As a result it 
is difficult to make any assumptions regarding the impact of mutations at residues
Q207 and G335 when present with H208Y on phenotypic susceptibility.
It is also interesting to look at the wild type consensus sequences of subtype A and C
and compare the 12 differences found between subtype B and subtypes A and C. For
subtype A, only 1/12 positions were mutated in the patient virus relative to the
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subtype A consensus wild type sequence, this was S173L. For subtype C, 4/12
positions were mutated, these were A173T, Q174K, R277K and S554N. The
phenotypic effect of these mutations have not been investigated thus, available data
on these mutations do not explain the lack of a phenotypic effect of H208Y for TDF
with the non-B subtype viruses.
It is also important to remember that the same subtype B molecular clone was used to
generate all recombinant viruses and therefore it may be speculated that different
results may be obtained with a subtype-specific vector. HIV-1 subtypes differ from
one another by 10-12% on a nucleotide level and 5-6% in the protease and RT genes
on an amino acid level (Kantor et al., 2005). Therefore it is plausible that using
subtype specific molecular clones could have given a different result. However one
study used a subtype C RT in both a subtype B and C recombinant vector and
showed that there was not a significant difference in the drug susceptibility
measurements (Choe et al., 2007).
Looking at the structure of RT, residue 208 is located at a distal alpha-helix at the
base of the palm subdomain, with its side-chain protruding out into the surrounding
solvent. As this residue has minimal contact with other residues in the local tertiary
structure, it can be speculated that a mutation from histidine to tyrosine will not have
a significant direct effect on important residues in the surrounding region. However,
the mutation from a hydrophilic histidine to a hydrophobic tyrosine could be
speculated to have a slight impact on the tertiary structure of the local region, which
includes the catalytic residues of the active site (A110, A185 and A186). The
hydrophobic tyrosine could try to reorient itself to make contacts with surrounding
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hydrophilic residues such as 167. This could have an effect on the tertiary structure
of the active site, resulting in the drug not binding as well.
Previous studies have shown that hypersusceptibility is a common phenomenon in
treatment experienced patients with major drug-resistance mutations (Whitcomb et
al., 2002). Mutations in RT that are known to confer resistance to certain drugs while
increasing susceptibility to others include M184V, which confers resistance to 3TC
(and FTC) while increasing susceptibility to AZT, d4T and TDF; K65R, which
confers resistance to TDF, DDI, D4T, ABC, and 3TC (and FTC) while increasing
susceptibility to AZT; and L74V, which confers resistance to ABC and DDI while
increasing susceptibility to AZT. These mutations confer increased susceptibility to
AZT whilst conferring increased resistance to the remaining NRTIs. These
mutations interfere with AZT susceptibility by inhibiting excision of incorporate
AZT-triphosphate from the DNA chain, which is mediated by TAMs. The subtype A
and subtype C patients did harbour the M184V mutation and in order to prevent
interference from the strong phenotypic effects of M184V, the valine in the viral RT
was back-mutated to the wild type amino acid methionine. An association between
major NRTI resistance mutations and NNRTI hypersusceptibility has also been
reported, and one of the main NRTI resistance mutations that have been implicated in
this respect is T215Y (Shulman et al., 2004).
The H208Y mutation has been previously implicated in contributing to EFV and
NVP susceptibility. One study using site directed constructed mutants on a wild type
background showed that H208Y contributed to an increased susceptibility to the two
NNRTIs. When the T215Y mutation was added alongside H208Y, this increased
163
susceptibility effect was further augmented (Clark et al., 2006). In this study, H208Y
in the context of wild type subtype B virus showed increased susceptibility to NVP.
However, the effect was not evident with EFV. In fact, the difference in fold change
for EFV in the presence and absence of H208Y was Δ+0.17, which indicates a small 
decrease in susceptibility. This discrepancy maybe explained by the use of a multiple
cycle assay and patient-derived clinical samples, whereas the study by (Clark et al.,
2006) used a single cycle assay with site directed mutants on a wild type background.
There are no previously published susceptibility data regarding the effect of H208Y
on susceptibility to ETV. In this study, we demonstrated that at least in the context of
subtype B virus the presence of H208Y conferred an increased susceptibility to ETV.
The mechanistic basis of NNRTI hypersusceptibility is unknown, structurally, the
NNRTI binding pocket is situated close to the active site, which could provide one
possible explanation (Kohlstaedt et al., 1992). Another possible explanation is that
NRTI mutations could enhance the binding of NNRTIs (Shulman et al., 2004).
In summary, the H208Y mutation showed a decreased susceptibility to TDF in both
the treatment naïve and experienced subtype B patients. However this effect was not
recapitulated with the treatment experienced subtype A and C patients.
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Chapter five
5 Development of a growth competition assay to measure
viral fitness
5.1 Introduction
The results from the drug susceptibility assays indicated that in the context of
subtype B RT with and without major resistance mutations, H208Y conferred
reduced susceptibility to TDF. To complete the analysis of the phenotypic effects of
H208Y, the next step was to address whether the H208Y mutation conferred a fitness
advantage. Fitness is defined as the ability of an organism to adapt to a given
environment. For HIV, fitness can be interpreted as the ability of the virus to
produce progeny (i.e., infect and replicate) in a given environment (Domingo et al.,
1997).
There are several methods that measure viral fitness and these include single cycle
assays and growth competition assays. Single cycle assays measure viral growth
kinetics such as p24 antigen or reporter genes such as luciferase and ß-galactosidase
(Deeks et al., 2001a). Growth competition assays involve incubating two viruses in
differing proportions over a period of time and measuring the growth of each virus
(Quinones-Mateu and Arts, 2002).
(Quinones-Mateu and Arts, 2002) compared the different methods of measuring
fitness for protease and reverse transcriptase mutations. The authors showed that
there was variability in the fitness result with all the methods, possibly reflecting
different methodologies or the use of clinical isolates versus laboratory strains.
One drawback to single cycle assays is that they do not detect significant differences
in fitness between viruses that may differ by only a single nucleotide. However,
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single cycle assays offer the advantage of good reproducibility with minimal
variability, and a relative simple format (Deeks et al., 2001a;Petropoulos et al.,
2000a).
Growth competition assays have the advantage that small changes in fitness can be
detected and provide as close as possible a reproduction of conditions in vivo.
Different methods can be used to distinguish the two competing viral strains. Current
methods include real-time PCR and pyrosequencing (de Ronde A. et al., 2001;Lahser
et al., 2003).
Real-time PCR using TaqMan probes is based on conventional PCR but uses
fluorescent reporter dyes to monitor the progression of the PCR reaction as it is
occurring in real time (de Ronde A. et al., 2001;Heid et al., 1996). It uses sequence
specific probes that are labelled with a fluorescent reporter at the 5’ end and a
quencher at the 3’ end. Once the primers and probe have bound to its target
sequence, the 5’-3’ exonuclease activity of Taq polymerase hydrolyses the bond
between the reporter and quencher. The dissociated reporter is then free to emit its
energy (figure 5.1). The fluorescence emitted by the reporter dye is directly
proportional to the amount of PCR product produced. A fixed threshold is set which
takes into account the background fluorescence in the reaction. The threshold cycle
(CT) is a parameter defined as the cycle number at which the fluorescence exceeds
the fixed threshold. The more concentrated the PCR product, the lower the CT value
is (Nolan et al., 2006;Vanguilder et al., 2008).
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Pyrosequencing is a method of DNA sequencing that is based on the detection of
pyrophosphate as nucleotides are incorporated (figure 5.2). A single stranded
biotinylated DNA strand is bound onto sepharose beads where the sequencing primer
is hybridised. A mix of ATP sulfurylase, luciferase, apyrase, adenosine 5’
phosphosulphate (APS) and luciferin are added to the DNA strand. Each of the four
nucleotides are added in turn to the DNA strand. As DNA polymerase catalyses the
incorporation of the complementary dNTP into the DNA strand, pyrophosphate is
released as a proportion to the amount of incorporated nucleotide. In the presence of
APS, ATP sulfurylase converts the released pyrophosphate to ATP. ATP is then used
to mediate the conversion of luciferin to oxyluciferin which generates light in
proportion to the amount of ATP. The light is detected by a charge coupled device
(CCD) camera, and is displayed as peaks in the resultant pyrogram. The height of
the peak is proportional to the number of nucleotides incorporated into the DNA
strand. Apyrase degrades the unincorporated nucleotides and ATP before the
addition of the next dNTP (Royo et al., 2007;Ahmadian et al., 2006;Diggle and
Clarke, 2004;Ronaghi et al., 1998).
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Figure 5.2 Principle of pyrosequencing. The sequencing primer is annealed to the
single stranded DNA template. A mix of enzymes, APS, luciferin and dNTPs are
added and light is released in proportion to the amount of nucleotide that is
incorporated. The light emitted is represented as peaks in the pyrogram. Figure
taken from (Diggle and Clarke, 2004).
Emission of light
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The technique of allele-specific PCR (ASPCR) was first introduced in the mid
1980’s and was previously known by many synonymous names such as PCR
amplification of specific alleles (PASA), allele-specific amplification (ASA), and
amplification refractory mutation system (ARMS) (Sarkar et al., 1990). This
technique has been used to identify polymorphisms in genetic diseases such as sickle
cell anaemia (Wu et al., 1989) and haemophilia (Bottema et al., 1990).
With regard to HIV research, ASPCR was used to address the issue that some HIV
genotying methods could not detect viral populations that represented less than 20%
of the total population. (Hance et al., 2001) used ASPCR to study the kinetics of
viral populations within patients who harboured drug resistant virus. These patients
underwent structured treatment interruptions and the rate at which the resistant quasi
species was replaced by wild type was monitored using ASPCR.
ASPCR is based on the principle of having a single nucleotide mismatch at the 3’ end
of the primer which destabilises the 3’ end and increases specificity. The
mismatched primer binds more strongly to the wild type sequence than the mutant
sequence and as a result, the Ct value of the mutant sequence is higher than the Ct
value of the wild type sequence. ASPCR is a rapid, sensitive and quantitative assay
and as a result has often been used to characterise minority species in drug resistant
HIV populations (Metzner et al., 2009;Liu et al., 2010;Johnson et al., 2008;Bottema
et al., 1990;Paredes et al., 2007).
In the studies presented in this thesis, viral fitness was determined using the growth
competition assay. This chapter describes the optimisation of the method for
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differentiating H208Y and the H208 SDM in growth competition assays. Three
methods were investigated: allele specific PCR, TaqMan real time PCR and
pyrosequencing.
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5.2 Method
5.2.1 DNA template
Plasmids were produced using the RT gene with H208Y and the H208 SDM derived
from the plasma virus of the treatment naïve and treatment experienced patients
infected with subtype B. Plasmids from the treatment experienced patient infected
with subtype A and the HXB2 wild type were also used. The plasmids were mixed in
combinations containing 100% H208Y/0% H208SDM; 90% H208Y/10% H208
SDM, and 0% H208Y/100% H208 SDM before testing.
5.2.2 Allele-specific PCR
Subtype specific primers targeting H208Y and H208 were designed and tested with
the H208Y and H208 SDM plasmids in three independent experiments. Each
experiment was performed in duplicate and the mean was calculated. Water and no
template were used as negative controls in each experiment. The no template
control contained water instead of a DNA template.
5.2.3 TaqMan real-time PCR
Specific mutant and wild type probes were designed and tested against H208Y and
H208 SDM DNA. In each run, triplicate wells were used for each sample and the
mean ct was calculated. Water and no template controls were run in each assay. The
no template control contained water instead of a DNA template. This was repeated
on three separate occasions.
173
5.2.4 Pyrosequencing
Forward and reverse biotinylated primers were designed for the PCR. Water was run
as a negative control in all runs. Pyrosequencing reactions were analysed using the
SQA and QA analysis programs. The SQA run provides the sequence of the given
sample once the dispensation order has been determined. From these sequences, the
peak heights can be used to determine the proportions of mutant and wild type
codons at position 208. The QA program automatically determines the percentage of
wild type and mutant codons within the samples when a specific dispensation order
is given.
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5.3 Results
5.3.1 Allele-specific PCR
Figure 5.3 shows the sequences of the subtype specific primers used in the ASPCR
assay. Two primers were designed for each subtype, one to amplify H208 SDM
DNA and one to amplify H208Y DNA. In all cases, the mismatched nucleotide was
positioned two nucleotides positions from the SNP site and is shown in red in figure
5.3.
Figure 5.4 shows the amplification plots on both the H208 SDM DNA and H208Y
DNA using mutant and wild type specific primers. Figure 5.4a shows the mutant
primers amplified at a Ct value of 8 and the wild type primers amplified at a Ct of 17
(Δ=9) with the H208Y DNA template.  In contrast figure 5.4b shows the mutant 
primers amplified at a Ct of 18 and the wild type primers amplified at a Ct of 10
(Δ=8) with the H208 SDM DNA template. 
The same experiments were repeated for the plasmids containing the RT from HXB2
wild type and the two treatment experienced patients infected with subtype A and
subtype B. To check reproducibility, the assay was repeated on three separate
occasions. The results are shown in table 5.1, indicating that for the subtype B
plasmids, the delta Ct was between 7.5-9 and between 11-12 for the subtype A
plasmids.
The coefficient of variance was calculated for the Ct values obtained using both the
mutant and wild type primers. All CV values were below 10% for mutant and wild
type primers. For the plasmid from the subtype A infected patient using the wild
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type primers, a CV of 0% was obtained as there was no variation in the Ct value
obtained in the replicate experiments.
In order to quantify proportions of H208Y and H208 DNA present, standard curves
were used. For each patient, two standard curves were constructed, one to quantify
the H208 SDM DNA and one to quantify the H208Y DNA. This is shown in Figure
5.4 (c-d). Standard curves with a slope range of -3.3 to -3.5 and an R2 value of 0.99
were accepted and any curves outside of this range were repeated. In the standard
curve, the range of plasmid copies was from 105 to 10-1 copies per millilitre.
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Reverse Transcriptase Gene Codons 1-560
Codon 194 Codon 215
Subtype A AAATAGGACAGCATAGAGCAAAAATAGAAGAGTTAAGAGGTTATCTATTGAGCTGGGGGTTTTTT
Subtype B AAATAGGGCAGCATAGAGCAAAAATAGAGGAACTGAGACGATATCTGTGGAAGTGGGGATTTTAC
Subtype C AAATAGGGCAACATAGAGCAAAAATAAAAGAGTTAAGAGGATATCTATGGAAGTGGGGGTTTTACigure 5
odons 1
ucleotid
utant a
f the pri176
.3 Schematic of reverse transcriptase gene. Nucleotides encompassing
94-215 are shown. The H208 position is shown in bold and underlined. The
e change from histidine to tyrosine is CAT to TAT. The subtype specific
nd wild type primers are shown in blue and the designed mismatch at the 3’
mer is shown in red.
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Figure 5.4 Amplification curves from the ASPCR. Plasmids containing the RT
gene with H208Y and the H208 SDM derived from the plasma virus of the treatment
naïve patient were used as the DNA template. a) amplification using the mutant and
wild type primers with the H208Y DNA template. b) amplification using the wild
type and mutant primers with the H208 SDM DNA template. c) standard curve
obtained using mutant primers with the H208Y DNA template. The range of the
plasmid copies was from 105 to 10-1. d) standard curve obtained using wild type
primers with the H208 SDM DNA template. The range of plasmid copies was from
105 to 10-1.
A B
C D
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Table. 5.1 Ct values obtained using different plasmid DNA templates with
subtype specific mutant and wild type primers
Template
Mutant Primers Wild Type Primers
Δ Ct 
(range)
ReplicatesCt
Mean
(range)
Ct
Standard
Deviation
Coefficient
of Variance
(CV)
Ct
Mean
(range)
Ct
Standard
Deviation
Coefficient
of Variance
(CV)
Subtype B
Naive
19
(17-20) 1.73 9.1%
10
(10-12) 0.58 6%
9
(7-8) 3
Subtype B
Naïve
+H208Y
8
(7-10) 0.58 6.9%
17
(17-18) 0.58 3.3%
9
(10-8) 3
Subtype B
Experienced
16
(15-17) 1.00 6.3%
8
(8-8) 0 0%
8
(7-9) 3
Subtype B
Experienced
+H208Y
7.5
(7-8) 0.50 6.7%
15
(15-15) 0 0%
7.5
(8-7) 3
Subtype A
Experienced
23
(23-24) 0.58 2.5%
12
(11-13) 1.00 8.3%
11
(12-11) 3
Subtype A
Experienced
+H208Y
12
(11-13) 1.00 8.3%
24
(23-24) 0.58 2.4%
12
(12-11) 3
HXB2 Wild
type
19.5
(19-20) 0.50 2.6%
10.5
(10-11) 0.50 4.8%
9
(9-9) 3
aDelta Ct (Δ) refers to the difference in Ct between the mutant and wild type primers.
The coefficient of variance was calculated by dividing the Ct standard deviation by
the mean Ct and multiplied by 100.
179
5.3.2 Real-time PCR – TaqMan PCR
For the TaqMan real-time PCR, specific probes to amplify H208Y or H208 SDM
DNA were designed as shown in figure 5.5.
Probes were first optimised by titrating primer and probe concentrations. Primer
concentrations varied from 50nM to 300nM and probe concentrations were varied
from 25nM and 300nM. Figure 5.6 shows the primer probe optimisation
amplification plots for the two probes.
Figure 5.6 shows that some DNA is amplified using the H208 SDM probe for all the
primer probe combinations however no amplification was detected with the H208Y
probe.
To improve the sensitivity of the PCR, magnesium sulphate was added to the
reaction but still no amplification occurred. The annealing temperature of the mutant
was also increased but again no amplification occurred.
Reverse Transcriptase Gene Codons 1-560Figure 5.5 Schematic of reverse t
241. PCR primers are in blue a
underlined. Probe sequences are sho
GAAACAGAACAGCACAGAACAAAAATAGAGGAACTGAGACAACATCTGTTGAAGTG
GGGATTTACCACACCAGACAAAAAACACCAGAAAGAACCTCCATTCCTTTGGATGGGCT
ATGAACTCCATCCTGATAAATGGACAGT
Codon 194 Codon 241
1.
2.CTGAGACAACATCTGTT H208 SDM probe180
ranscriptase gene encompassing codons 194-
nd the H208Y codon is shown in green and
wn in green.
CTGAGACAATATCTGTTG H208Y probe
181
Figure 5.6 Real-time PCR amplification plots using TaqMan probes. a)
Amplification plots for the H208 SDM probe (purple) with H208 SDM DNA
template. b) Amplification plots for the H208Y probe (pink) with H208Y DNA
template. c) Amplification plot of the H208Y and H208 SDM templates together.
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5.3.3 Pyrosequencing
Primers were designed so that a 189bp fragment encompassing the H208Y mutation
was amplified. Plasmid mixtures containing the RT gene with H208Y and H208
SDM from the treatment naïve patient were made and consisted of the following
combinations 100% H208Y/0% H208SDM; 90% H208Y/10% H208 SDM, and 0%
H208Y/100% H208 SDM. In order to check that the primers amplified a product, a
PCR was done. Figure 5.7 shows the positioning of the pyrosequencing PCR and
sequencing primers and the gel electrophoresis picture of the PCR using these
primers. The gel electrophoresis picture shows that a clean band is obtained in all the
samples at the 200bp position except for the negative control which contained water
instead of a DNA template.
Different sequencing primers were designed that aligned at different positions in
order to increase the chance of obtaining a clean sequence. The sequencing primers
were designed so that they were between 0 and 4 nucleotides from the SNP. These
sequencing primers were used in the pyrosequencing assay against the 12 mixture
samples at a concentration of 0.3µM and 0.4µM. The pyrosequencer was
programmed for both the SQA and QA analysis.
Table 5.2 shows the analysis from the SQA pyrosequencing runs. Run 1 shows that
in all the samples, there were mixed wild type (C) and mutant (T) nucleotide detected
except for the 100% H208Y sample which failed. In the majority of the samples, the
wild type (C) nucleotide was detected and within these samples, the range of wild
type (C) nucleotide was between 20-89%. The amount of mutant (T) nucleotide
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detected was the highest in the 90% and 80% samples, with 79% and 80%
respectively being detected. In the 0% H208Y sample, 16% detected was mutant
and 84% detected was wild type.
In run 2 4/11 samples detected 100% wild type (C) nucleotide and this included the
0% H208Y sample. Samples 100%, 90%, 80% and 70% H208Y all detected the
mutant nucleotide (T) at higher percentages than the wild type nucleotide (C) and the
100% H208Y sample did have the highest percentage of the mutant nucleotide from
all the samples with 85%. The remaining samples detected higher levels of wild type
nucleotide than the mutant nucleotide.
The 3rd run had no incidences where 100% of either mutant or wild type nucleotides
were detected. In the majority of samples, the wild type nucleotide (C) was detected
at a higher frequency than the mutant nucleotide (T) except for the 100% H208Y
sample where the mutant (T) was detected at 87.5%.
Since the SQA did not give accurate proportions of mutant and wild type amino acids
in the mixture samples, the allele quantification (QA) program was used. Table 5.3
shows the results of the QA from 3 runs. In run 1, the majority of the samples
detected 100% wild type (6/11). Samples 100%, 90% and 80% H208Y all detected
79% of the mutant nucleotide and the samples 20% and 0% detected wild type
nucleotide at 82% and 84% respectively.
In 5/11 samples from run 2, the wild type nucleotide was detected at a range of 97-
100%. The remaining samples detected higher detection levels of the mutant
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nucleotide than wild type amino acid. The highest proportion of mutant (T)
nucleotide was detected in the 100% mutant samples, which detected 96% mutant
and 4% wild type.
Similar to the previous 2 runs, in run 3 the wild type and mutant nucleotides were not
accurately detected in the samples. In the majority of cases the wild type nucleotide
was detected at a higher percentage. In samples, 100%, 90%, 80% and 70%, the
mutant nucleotide was detected at a higher percentage although the wild type
nucleotide was also detected in these samples.
In order to improve the accuracy of this assay, different sequencing primers at
different concentrations were used as well as using fresh PCR samples for each run.
However, the pyrosequencing was not able to differentiate mutant and wild type
nucleotides at an accurate level.
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Reverse Transcriptase Gene Codons 1-560
Codon 151 Codon 215
AATGGAAAGGATCACCAGCAATATTCCAAAGTAGCATGACAAAAATCTTAGAGCCTTTTAGA
AAACAAAATCCAGACATAGTTATCTATCAATACATGGATGATTTGTATGTAGGATCTGACTAG
AATAGGGCAGCATAGAACAAAAATAGAGGAGCTGAGACAACATCTGTTGAGGTGGGGAF
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sed and these are listing 1 to 3 in the figure. b) Gel electrophoresis pictur
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TTACC
1. CAAAAATAGAGGAG
2. GAGGAGCTGAGACAA
3. AAAATAGAGGAGCTGAGACA
1. 10
2. 90
3. 80
4. 70
5. 60
6. 50
7. 40
8. 30
9. 20
10. 10
11. 0%
12. Negative co
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% Mutant
(T)
Run 1 Run 2 Run 3
% C % T % C % T % C % T
100% FAILED FAILED 15% 85% 12.5% 87.5%
90% 21% 79% 24% 76% 87% 13%
80% 20% 80% 21% 79% 80% 20%
70% 89% 11% 24% 76% 89% 11%
60% 85% 15% 100% 0% 94% 6%
50% 86% 14% 100% 0% 95% 5%
40% 84% 16% 89% 11% 91% 9%
30% 83% 17% 89% 11% 88% 12%
20% 88% 12% 87% 13% 90% 10%
10% 88% 12% 100% 0% 92% 8%
0% 84% 16% 100% 0% 93% 7%
Table. 5.2 Pyrosequencing SQA analysis186
% Mutant
(T)
Run 1 Run 2 Run 3
% C % T % C % T % C % T
100% 21% 79% 4% 96% 15% 85%
90% 21% 79% 18% 82% 24% 76%
80% 21% 79% 17.5% 82.5% 21.5% 78.5%
70% 100% 0% 17% 83% 24% 76%
60% 100% 0% 15.5% 84.5% 100% 0%
50% 100% 0% 22% 78% 100% 0%
40% 100% 0% 97% 3% 89% 11%
30% 100% 0% 100% 0% 89.5% 10.5%
20% 83% 17% 100% 0% 87% 13%
10% 100% 0% 100% 0% 100% 0%
0% 84% 16% 100% 0% 100% 0%
Table. 5.3 Pyrosequencing QA analysis
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5.4 Discussion
In order to distinguish between the two competing viral strains in the growth
competition assay, three methods were tested; AS-PCR, pyrosequencing and TaqMan
real-time PCR. In this study the allele-specific PCR assay was the most accurate
technique that was able to differentiate the two viral strains compared to real-time
PCR and pyrosequencing assays.
Growth competition assays involve incubating cells with two viruses and passaging
these viruses over a period of time. The different viruses are monitored and the
outgrowth of one virus is considered to be a measure of fitness (Holland et al., 1991).
One advantage of this assay is that because viruses are monitored over a period of
days, small changes in fitness can be measured. Also, the input ratio of the viruses
can be altered, giving further insights into the relative fitness of these viruses.
There are two major drawbacks to using growth competition assays to measure
fitness. The first drawback is that since the viruses are incubated for a period of
days, and given the plasticity of HIV, the virus may mutate and the output virus may
be altered from the input virus. Another disadvantage is that it is notoriously difficult
to develop a method that is able to distinguish the virus variants, particularly when
they differ at a single nucleotide position. Methods that have been used to
differentiate the different viruses within growth competition assays include
heteroduplex tracking assay (HTA) (Quinones-Mateu et al., 2000b), sequencing
(Harrigan et al., 1998) and real-time PCR (de Ronde A. et al., 2001).
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Not only was the ASPCR the most accurate method of differentiating between the
mutant and wild type templates in this study but it was also highly reproducible. The
coefficient of variance was calculated to look at the variation between replicates for
both the mutant and wild type primers using the different DNA templates. The inter
assay coefficient of variance was below 10% for all samples and a CV of <10% has
been suggested to be satisfactory (Murray W et al., 1993).
The delta Ct was determined for all plasmids and the highest delta was seen with the
subtype A plasmids with a delta Ct of 11-12 for mutant and wild type primers. The
deltas for the subtype B patients were between 7.5 and 9. Having a larger delta Ct
value indicates that the primers are binding with good specificity and would be able
to reliably differentiate between mutant and wild type DNA. Therefore, for this assay
the primers appeared to be differentiating between mutant and wild type DNA with
good specificity. The basis of specificity is the designed mismatched nucleotide
positioned two nucleotides from the SNP. Previous studies have demonstrated that
the mismatched nucleotide in the primer is very disruptive in that it prevents chain
elongation and causes a delay of several Ct cycles (Hance et al., 2001;Bottema and
Sommer, 1993;Bergroth et al., 2005).
There are two possible reasons why the pyrosequencing was unable to accurately
differentiate proportions of mutant and wild type template. These related to the
design of the assay or the practical side of the experiment. In terms of assay design,
the sequencing primer could have misprimed to another region in the PCR product.
There are two potential sites consisting of a stretch of A nucleotides upstream of
H208 that the sequencing primers may have annealed. In doing so, the mutant T
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nucleotide would not have been measured and this may explain why in many cases
there was no accurate presence of the T nucleotide reported by the pyrosequencing.
The other possible reason is that the template itself may self-prime resulting in the
formation of secondary structures within the DNA and therefore hindering the action
of the DNA polymerase and/or the sequencing primer. This pyrosequencing assay
was designed using the Pyrosequencing Assay Design Software Version 1.0 which
does take into account formation of secondary structures and mispriming of primers
however that does not completely rule out the possibility of secondary structures
forming.
Regarding the practical side, the pyrosequencing procedure requires use of a vacuum
prep tool which is awkward to handle. The vacuum prep tool is used to first capture
the sepharose beads containing the biotinylated PCR product and then wash and
neutralise the PCR product. The PCR product is then released into a tray where the
sequencing primer can anneal. One study redesigned the vacuum prep tool as they
found the original tool caused residual liquid to remain causing product dilution and
also unequal aspiration (Gharizadeh et al., 2006).
In the TaqMan real-time PCR assay, the mutant probe did not detect any DNA. The
wild type probe in both cases did produce amplification plots. Possible reasons for
the no amplification in the mutant probe include operational error, template impurity
and secondary structure. Operational error includes factors such as failure to mix the
reaction components or excluding one of the reaction components. However, this
assay was repeated a number of times and since in all cases the wild type probe
hybridised and produced amplification suggests that there was not a problem with
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operational error. The template stock of the template was also changed to rule out
the possibility of using the incorrect template. However, this did not resolve the
problem. Similar to the pyrosequencing, it is possible that secondary structures
formed which prevented the probe from binding. Since these methods were being
developed simultaneously and the ASPCR gave promising results, no further time
was invested in improving the real-time PCR and pyrosequencing assays.
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Chapter six
6 The impact of H208Y on viral fitness
6.1 Introduction
Results from the previous chapters indicated that in the context of a subtype B that
was either wild type or harboured pathway 1 TAMs, H208Y reproducibly conferred a
reduced susceptibility to tenofovir (TDF). To investigate whether the H208Y
mutation conferred a fitness advantage, growth competition experiments were
performed using an optimised allele specific PCR (AS-PCR) assay to differentiate
between mutant and wild type strains. In this chapter the results of the growth
competition assay are presented.
Many studies have shown that the majority of heterosexual infections result from the
transmission of a single virus (Keele, 2010;Keele and Derdeyn, 2009;Kearney et al.,
2009;Haaland et al., 2009). However due to the combined effect of a high viral
replication rate and an error-prone reverse transcriptase that lacks proof-reading
activity, a quasispecies is quickly formed whereby virus variants that are related but
genetically distinct are produced (Domingo et al., 1985). The dominant quasispecies
is constantly subjected to various selective forces such as drug pressure, and as a
result, the dominant quasispecies changes accordingly to adjust to the new
environment. The predominating quasispecies at a given time represents the
population that is best equipped to infect and replicate, i.e., it is most fit under the
given selective pressures (Coffin, 1995). In this scenario variants of higher fitness
out compete variants of lower fitness to become the dominant quasispecies. Hence,
within a HIV infected patient, there are virus variants residing with differing degree
of fitness.
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Major or primary drug resistance mutations are generally associated with a reduced
fitness, often referred to as the “fitness cost” of drug resistance. With ongoing virus
replication under drug pressure, additional mutations emerge that may either increase
the level of resistance or compensate for decreased fitness. These mutations are
known as compensatory, accessory or secondary mutations. These mutations have
been well characterised in the case of the protease gene, but data are more limited in
the case of the RT gene (Nijhuis et al., 1999;Mammano et al., 2000;Borman et al.,
1996;Molla et al., 1996;Condra et al., 1995). To date, there has been only one study
that has investigated the effects of accessory mutations in the RT gene. This study
identified the E40F and K43E mutations and showed that they conferred resistance to
zidovudine (AZT) if present in the background of TAMs however, in isolation, no
resistance was conferred by these mutations. The virus with E40F, K43E and TAMs
was also shown to be more fit than the virus with TAMs (Huigen et al., 2008).
Mathematical models have often been used to compare the fitness of different viral
strains. However there have been a number of different equations used to calculate
relative fitness and this has hindered the ability of comparing results obtained from
different studies. One mathematical model uses the selection coefficient (s) to
measure fitness and takes into account data collected from two time points. The
relative fitness of the variant, defined as 1+s, is the relative contribution of that
variant to the next generation. If mutant and wild type strains are compared and the
mutant strain is more fit than the wild type strain, 1+s will be greater than 1. If the
mutant strain is less fit than the wild type strain, 1+s will be less than 1 (Dykes and
Demeter, 2007;Maree et al., 2000). The first study that used the selection coefficient
in relation to HIV drug resistant variants was Goudsmit et al. 1996. This study
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looked at the dynamics of variants from a patient who was infected with a strain
containing the AZT resistance mutation T215Y. They found that in the absence of
drug, the T215Y variant was replaced by T215S as it was estimated to be 0.4 to 2.3%
more fitter than T215Y (Goudsmit et al., 1996).
The aim of the study described in this chapter was to use growth competition assays
to investigate whether the H208Y mutation contributes to viral fitness in the context
of both wild type virus and highly resistant viruses harbouring TAMs alongside other
major RT resistance mutations.
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6.2 Methods
6.2.1 Growth competition assay
Competitions were set up between H208Y and H208 SDMs derived from subtype B
wild type virus, subtype B virus with pathway 1 TAMs, and subtype A virus with
pathway 2 TAMs. The subtype C virus with TAMs was not tested as the AS-PCR was
unable to differentiate between H208Y and H208 viruses accurately with this subtype
and optimisation could not be completed in time. Competitions were set up at three
H208Y:H208 input ratios: 50:50, 25:75 and 75:25. The two competing viruses were
added to MT4 cells. After 2 hours, cells were washed with PBS and resuspended in
medium. On day 6, aliquots were stored at -80ºC and 50µl of virus supernatant was
used to reinfect fresh MT4 cells to start a new passage. This was continued for 4
passages over 24 days. As controls in all assays, single virus infections as well as
uninfected cells were also set up. Competitions were repeated at least twice on
separate occasions for each combination. The mean proportions from the replicates
experiments are shown. For competitions done in the presence of drug, the IC50
values obtained for these viruses with tenofovir (TDF) were used. TDF was added to
the medium and replenished at each new passage.
6.2.2 RNA extraction
Viral RNA was extracted using the Qiagen QIAamp Viral RNA kit (Qiagen) from
200μl of HIV infected culture supernatant.  RNA was stored at -80ºC until required. 
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6.2.3 Allele-specific PCR
RNA was nanodroped using the NanoDropTM 8000 and 300ng RNA was used in the
AS-PCR assay. Subtype specific H208Y and H208 primers were designed for each
subtype and both primers were tested against mutant and wild type DNA. In each
run, duplicates wells were used for each sample and the mean was calculated. Water
and no template controls were run in each assay.
6.2.4 Sequencing
From each competition, virus recovered from passages 1 and 4 was sequenced using
Sanger sequencing with BioDye Sequencing mix v1.1 (Applied Biosystems, UK).
Four forward and reverse primers were used to obtain overlapping sequences.
Sequences were analysed using a 3100-Avant Genetic Analyzer (Applied
Biosystems, UK).
6.2.5 Fitness Calculations
Fitness calculations were performed as described by (Quinones-Mateu et al., 2000a)
and (Hu and Kuritzkes, 2010). The mean from at least two independent experiments
was used to calculate the fitness difference and selection coefficient. The proportion
of virus recovered relative to the initial inoculum was determined as the amount of
virus produced at day 12 or 18 divided by the proportion present in the initial
inoculum. The relative fitness was determined as the average virus produced from
the three different ratios. The fitness difference was determined as the ratio of
relative fitness values WD = WM/WL, where WM represents the more fit virus and WL
represents the less fit virus in the growth competition assay. The selection coefficient
was determined using the following formula: s = (1/t ln[q(t)p(0)/p(t)(q(0)])*100,
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where t is the time in days, p(t) is the proportion on day 12 or day 18 of the more fit
virus, q(t) is the proportion on day 12 or day 18 of the less fit virus, p(0) corresponds
to the initial proportion in the inoculum of the more fit virus and q(0) corresponds to
the initial proportion in the inoculum of the less fit virus.
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6.3 Results
6.3.1 Growth competitions with wild type subtype B virus from a
treatment naïve patient
Figure 6.1 shows the growth competitions from the subtype B treatment naïve
patient. Plasma virus from this patient harboured no major resistance mutations.
Input ratios for the H208Y vs H208 competitions were 50:50, 25:75 and 75:25 in the
absence of drug and 50:50 in the presence of drug. All competitions were set up on
three separate occasions and the mean proportions of the H208Y and H208 viruses
recovered were calculated.
In the 50:50 H208Y vs H208 competitions, the H208 virus outgrew the H208Y virus.
By day 12, the proportion of H208Y virus dropped from the initial 50% input to less
than 10%. In the 25:75 competitions, the H208 virus out competed the H208Y virus.
In the 75:25 competitions, the H208 virus outgrew the H208Y virus from the outset.
The phenotypic data showed that compared to the H208 SDM, the presence of
H208Y in the absence of major resistance mutations decreased susceptibility to TDF.
The IC50 values were 15.75µM and 7.14µM with and without H208Y, with a fold
change of 0.68 and 0.31 (Δ -0.37) respectively.  In competition experiments in the 
presence of TDF, the IC50 for TDF was used. By day 6 the H208 SDM virus started
to outgrow the H208Y virus and by day 12, the proportion of the H208Y virus fell
from 40% to 18% and remained at low proportions until day 24.
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Figure 6.1 Growth competitions using wild type virus with H208Y and the SDM
virus with H208 from the subtype B treatment naïve patient, in the presence and
absence of TDF. The virus harboured no resistance mutations. The mean from three
independent experiments is shown. The input ratios for H208Y vs H208 were a)
50:50; b) 25:75; c) 75:25 without TDF; and d) 50:50 in the presence of TDF. The
green line indicates proportion of the H208 SDM virus and the blue line indicates the
proportion of the H208Y virus.
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6.3.2 Growth competitions with drug resistant subtype B virus from
a treatment experienced patient
Plasma virus from the subtype B treatment experienced patient harboured the
pathway 1 TAMs M41L, L210W and T215Y together with the TAM-2 D67N and
K219N and V75M. The NNRTI resistance mutations A98G and G190Q were also
present.
Figure 6.2 shows the results of the growth competitions between the virus (referred
to as TAM-1) with and without H208Y. Input ratios for TAM-1 H208Y vs. TAM-1
H208 in the competitions were 50:50, 25:75 and 75:25 in the absence of drug, and
50:50 in the presence of drug. All competitions were set up on three separate
occasions and the mean proportions of the TAM-1 virus with H208Y and the SDM
with H208 were calculated.
From the 50:50 competitions, while the TAM-1 H208Y appeared to prevail at day 6,
by day 12 it had been outcompeted by H208. After day 12 the proportions of the two
viruses remained constant. In the 25:75 and 75:25 competitions, the proportions
remained relatively constant throughout the experiments.
The phenotypic data showed that compared to the TAM-1 H208 SDM, the presence
of H208Y on a background of TAM-1 mutations decreased susceptibility to TDF.
The IC50 was 404µM and 177µM with and without H208Y respectively with a fold
change of 17.3 and 7.6 (Δ –9.7) respectively.  In the 50:50 competitions in the 
presence of TDF, the IC50 obtained for TDF was used. There were no major
changes in the proportions of the two viruses until day 12. After day 12, the TAM-1
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H208 SDM virus started to outgrow the TAM-1 H208Y virus and by day 24, the
proportion of the TAM-1 H208 SDM and TAM-1 H208Y viruses were 65% and 35%
respectively.
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Figure 6.2 Growth competitions using drug resistant virus with TAM-1 H208Y
and the SDM virus with TAM-1 H208 from the subtype B treatment
experienced patient, in the presence and absence of TDF. The virus harboured the
pathway 1 TAMs M41L, L210W and T215Y together with the TAM-2 D67N and
K219N with V75M. The NNRTI resistance mutations A98G and G190Q were also
present. The mean from three independent experiments is shown. The input ratios
for TAM-1 H208Y vs TAM-1 H208 SDM were a) 50:50; b) 25:75; c) 75:25 without
TDF; and d) 50:50 in the presence of TDF. The blue line indicates proportion of the
TAM-1 H208 SDM virus and the purple line indicates the proportion of the TAM-1
H208Y virus.
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6.3.3 Growth competitions with drug resistant subtype A virus from
a treatment experienced patient
Plasma virus from the subtype A treatment experienced patient harboured the
pathway 2 TAMs D67N, K70R, T215F and K219E together with M184V and T69N.
The M184V mutation was back mutated to the wild type amino acid methionine by
side directed mutagenesis in order to eliminate the effect this mutation would have
on viral fitness. The NNRTI resistance mutations A98G and G190Q were also
present.
Figure 6.3 shows the results of the growth competitions between the TAM-2 virus
with and without H208Y. Input ratios for TAM-2 H208Y vs. TAM-2 H208 in the
competitions were 50:50, 25:75 and 75:25 in the absence of drug, and 50:50 in the
presence of drug. All competitions were set up on two separate occasions and the
mean proportions of the TAM-2 virus with H208Y and the SDM with H208 were
calculated.
In all replicate experiments from the 50:50 competitions, the proportions of the
viruses remained relatively constant as the input ratios up to day 12. By day 24, the
proportion of the TAM-2 H208 SDM and TAM-2 H208Y viruses were 68% and 32%
respectively. In both the 25:75 and 25:75 competitions, the proportions remained
relatively unchanged from the input ratios throughout the experiments.
The phenotypic data showed that H208Y did not modify significantly phenotypic
susceptibility to TDF relative to virus without H208Y. The IC50 was 12.17µM and
13.60µM with and without H208Y respectively with a fold change of 0.50 and 0.58
204
(Δ +0.08) respectively. In the 50:50 competitions in the presence of TDF, the IC50 
obtained for TDF was used. By day 6, the TAM-2 H208 SDM outgrew the TAM-2
H208Y virus and by day 24 represented 83% of the virus population.
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Figure 6.3 Growth competitions using drug resistant virus with TAM-2 H208Y
and the SDM virus with TAM-2 H208 from the subtype A treatment
experienced patient, in the presence and absence of TDF. The virus harboured the
pathway 2 TAMs D67N, K70R, T215F and K219E together with M184V and T69N.
The mean from two independent experiments is shown. The input ratios for TAM-2
H208Y vs TAM-2 H208 SDM were a) 50:50; b) 25:75; c) 75:25 without TDF; and d)
50:50 in the presence of TDF. The teal line indicates proportion of the TAM-2 H208
SDM virus and the pink line indicates the proportion of the TAM-2 H208Y virus.
A B
C D
1 2 3 4 5
20
40
60
80
100 TAM 2
TAM 2 + H208Y
Days
R
el
at
iv
e
Pr
op
or
tio
n
at
20
8
(%
)
0 6 12 18 24
20
40
60
80
100 TAM2
TAM2 + H208Y
Days
R
el
at
iv
e
Pr
op
or
tio
n
at
20
8
(%
)
0 6 12 18 24
20
40
60
80
100 TAM2
TAM2+H208Y
Days
R
el
at
iv
e
Pr
op
or
tio
n
at
20
8
(%
)
0 6 12 18 24
20
40
60
80
100
TAM 2
TAM 2 + H208Y
Days
R
el
at
iv
e
Pr
op
or
tio
n
at
20
8
(%
)
0 6 12 18 24
Days
206
Table. 6.1 Relative fitness of viruses with and without H208Y
Virus TDF
Proportion of Virus Relative
to Initial Inoculuma RelativeFitnessb
Fitness
Difference
(fold)c
Selection
Coefficientd
(%)50:50 25:75 75:25
H208Y - 0.14 0.08 0.33 0.18 11.44 21.5
H208 SDM - 1.86 1.31 3 2.06
H208Y + 0.32 ND ND 0.32 5.25 13.8
H208 SDM + 1.68 ND ND 1.68
TAM-1 H208Y - 0.74 0.2 1.13 0.69 1.51 4.4
TAM-1 H208 SDM - 1.26 1.27 0.6 1.04
TAM-1 H208Y + 0.88 ND ND 0.88 1.27 2.0
TAM-1 H208 SDM + 1.12 ND ND 1.12
TAM-2 H208Y - 1 0.8 0.85 0.88 1.32 2.3e
TAM-2 H208 SDM - 1 1.07 1.44 1.17
TAM-2 H208Y + 0.56 ND ND 0.56 2.57 7.9
TAM-2 H208 SDM + 1.44 ND ND 1.44
aThe proportion of virus relative to the initial inoculum was determined as the amount
of virus produced at day 12 divided by the proportion present in the initial inoculum.
Values represent the mean from at least two separate experiments. bThe relative fitness
was determined as the average virus produced from the three different ratios. cThe
fitness difference was determined as the ratio of relative fitness values WD = WM/WL,
where WM represents the more fit virus and WL represents the less fit virus in the
growth competition assay. dThe selection coefficient was determined using the
following formula, s = (1/t ln[q(t)p(0)/p(t)(q(0)])*100, where t is the time in days, p(t) is
the proportion on day 12 of the more fit virus, q(t) is the proportion on day 12 of the
less fit virus, p(0) corresponds to the initial proportion in the inoculum of the more fit
virus and q(0) corresponds to the initial proportion in the inoculum of the less fit virus.
The mean from at least two separate experiments was used to determine the fitness
difference. eThe selection coefficient for this competition used values obtained from
day 18 rather than day 12 because there was no difference in proportion obtained on day
12.
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Figure 6.4 Line graph plotting the selection coefficient (s) against the fitness
difference. There was a direct correlation between the selection coefficient and the
fitness difference, r2 = 0.95, P = 0.001 as determined using Pearson’s product
moment correlation coefficient.
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6.3.4 Relative fitness of viruses containing H208Y
Fitness calculations as described by (Quinones-Mateu et al., 2000a;Hu and
Kuritzkes, 2010) were used to obtain a quantitative estimate of viral fitness on day
12. Day 12 was chosen because in the majority of cases, the fitness effect did not
alter significantly after this time. The one exception was for the competitions with
TAM-2 subtype A virus done in the presence of TDF. On day 12, the proportions
were unchanged; therefore the next time point (day 18) was used in the fitness
calculations.
As shown in table 6.1, the relative fitness of all viruses with H208Y was lower than
that of viruses without H208Y. The relative fitness differences for the TAM-
containing viruses were lower than those observed for wild type subtype B virus.
From the competitions of the subtype B wild type virus, the relative fitness
difference of the H208 SDM virus was 11.44 fold greater than that of the H208Y
virus in the absence of TDF. In the presence of TDF the relative fitness difference if
the H208 SDM virus was 5.25 fold greater than that of the H208Y virus. From the
competitions of the TAM-1 subtype B virus, the relative fitness difference of the
H208 virus was 1.51 fold greater than that of the H208Y virus in the absence of TDF.
In the presence of TDF, the relative fitness of the H208 virus was 1.27 fold greater
than that of the H208Y virus. From the competitions of the TAM-2 subtype A virus,
the relative fitness difference of the H208 virus was 1.32 fold greater than that of the
H208Y virus in the absence of TDF. In the presence of TDF, the relative fitness of
the H208 virus was 2.57 fold greater than that of the H208Y virus.
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The selection coefficient was also calculated for the competitions as shown in table
6.1. For both the subtype B wild type and subtype B TAM-1 containing viruses, the
selection coefficient in the presence of TDF was lower than the selection coefficient
in the absence of TDF. However the selection coefficient for the subtype A TAM-2
containing virus had a higher selection coefficient in the presence of TDF compared
to the absence of TDF.
The competitions with the wild type subtype B virus both in the presence and
absence of TDF had the highest s value of 21.5 and 13.8 respectively. This indicates
that H208Y is less fit compared to H208 in the presence and absence of TDF and that
this fitness cost is most apparent within the competitions of the subtype B wild type
virus. This was also observed with the TAM-1 subtype B virus albeit to a lesser
effect that the wild type subtype B virus. The selection coefficient was 4.4 and 2.0 in
the absence and presence of TDF respectively.
The selection coefficient of the subtype A TAM-2 containing viruses were 2.3 and
7.9 in the absence and presence of TDF respectively. This demonstrates that similar
to the subtype B wild type and TAM-1 containing viruses, H208Y is less fit in a
subtype A TAM-2 virus but also that the effect is more apparent in the presence of
TDF compared to the absence of TDF.
To see if there was a correlation between the two different calculation methods used
to calculate the relative fitness, the selection coefficient was plotted against the
relative fitness (figure 6.4). There was a direct correlation between the selection
coefficient and the relative fitness difference with an r2 = 0.95 and P = 0.001,
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indicating that both calculation methods showed that the viruses with H208Y were
less fit than the viruses without H208Y.
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Table. 6.2 IC50 and IC90 values obtained for tenofovir against patient viruses
with and without H208Ya
Virus IC50 (µM) IC90 (µM)
H208Y 15.75 29
H208 SDM 7.14 48
TAM-1 H208Y 404 2942
TAM-1 H208 SDM 177 4673
TAM-2 H208Y 12.17 63
TAM-2 H208 SDM 13.60 193
aDrug susceptibility assays were performed in quadruplicate and the average of the four
was used to calculate the IC50. Mean values were calculated from three replicate
experiments for each virus/drug combination. HXB2 was used as a wild type control in
all assays.
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6.3.5 Drug susceptibility results for TDF
Table 6.2 shows the IC50 and IC90 values obtained for TDF for the viruses with and
without H208Y from the different patients. To compare the IC90 values of the
viruses obtained against TDF, the IC90 was calculated using the same dose response
curve that the IC50 was obtained. In some cases an IC90 value was not available
from the dose response curve because the percentage reduction for the particular
virus-drug combination did not reach 100%, therefore although the IC50 could be
calculated, the IC90 could not be calculated. In such cases, adding a trendline on the
dose response curve and using the equation from the graph, a projected IC90 was
calculated. The IC90 from at least two replicate experiments was used to obtain an
average IC90 value.
For the viruses from the subtype B treatment naïve patient, the IC50 was 15.75µM
and 7.14µM with and without H208Y, with a fold change of 0.68 and 0.31 (Δ -0.37) 
respectively. The IC90 was 29µM and 48µM with and without H208Y respectively.
For the viruses from the subtype B treatment experienced patient, the IC50 was
404µM and 177µM with and without H208Y respectively with a fold change of 17.3
and 7.6 (Δ –9.7) respectively.   The IC90 was 2952µM and 4673µM with and without 
H208Y respectively. For the viruses from the subtype A treatment experienced
patient, the IC50 was 12.17µM and 13.60µM with and without H208Y respectively
with a fold change of 0.50 and 0.58 (Δ +0.08) respectively.  The IC90 was 63µM and 
193µM with and without H208Y respectively.
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6.4 Discussion
In the previous chapters, it was shown that the H208Y mutation conferred a reduced
susceptibility to TDF in the context of a subtype B wild type and TAM-1 RT
sequence. A growth competition assay was developed to investigate whether the
H208Y also had effects on viral fitness. A subtype specific AS-PCR assay was
designed to differentiate between the H208Y mutant and H208 wild type viruses in
the growth competition assays. In the context of a subtype B wild type RT sequence,
the H208 SDM virus was more fit than the H208Y virus regardless of the input
ratios. This was true for competitions done both in the absence and presence of TDF.
In the context of a TAM-1 subtype B and TAM-2 subtype A RT sequence, there was
no appreciable difference in fitness as at all input ratios, the viruses maintained stable
proportions throughout the competition. This was true for the competitions done in
the both in the absence and presence of TDF. TDF is a nucleotide analogue that
unlike the nucleoside analogues contains a phosphate group and so requires two
rather than three phosphorylation steps (Menendez-Arias, 2008).
The finding that in the context of wild type RT the H208 SDM virus was more fit
than the H208Y virus is consistent with the high degree of conservation and therefore
infrequent detection of H208Y among treatment naïve patients. The prevalence of
H208Y in the treatment naïve population has been reported to be between 0.1 and
0.3% (Cane et al., 2007;Nebbia et al., 2007). In this study, prevalence in the Royal
Free treatment naive population was 0.1%. The low prevalence of H208Y in
treatment naïve patients and its moderate increases among heavily treatment
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experienced patients support the hypothesis that H208Y is an accessory mutation that
arises under drug pressure.
Interestingly, in the context of TAM-1 subtype B virus and TAM-2 subtype A virus
H208Y showed no significant effect on relative fitness. Regardless of the initial input
ratio, the viruses maintained stable proportions throughout the experiments, with the
virus that was initially present in the highest proportion remaining the prevalent virus
by the end of the competition. In the 50:50 competitions, there was a slight growth
advantage TAM-1 and TAM-2 H208 SDM viruses over H208Y viruses. These results
suggest that that whereas in the context of wild type RT H208Y has a detrimental
effect on viral fitness, in the presence of TAM-1 or TAM-2 pathway mutations, there
is no appreciable effect of the H208Y mutation on viral fitness.
The fitness contribution of the H208Y has not been extensively explored with only
one study looking at its effect. This study created site directed mutants and used a
single cycle assay to measure fitness in the absence of drug. Results indicated that in
isolation, the H208Y SDM showed a similar fitness to HIVLAI H208 wild type virus.
In contrast, the H208Y + T215Y double SDM was less fit than both the HIVLAI wild
type H208 and single SDM with either H208Y or T215Y (Clark et al., 2006). The
findings presented in this thesis showed that H208Y did not influence the fitness of
TAM containing viruses. While these results are not consistent with the previous
published literature, an important difference that should be appreciated is in the
experimental design, as different assays were used to measure fitness. It should also
be noted that whereas the study from Clark et al. concluded that the T215Y single
SDM had only a slightly lower fitness than the wild type virus, other studies have
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shown a greater impact of T215Y on viral fitness (Harrigan et al., 1998;Cong et al.,
2007). Although one would not expect significant differences in the fitness effect
between different methodologies used, contradictory results have been obtained
when comparing fitness of drug resistance mutations to wild type strains. These
differences have been attributed to the methodology used, the use of primary HIV-1
isolates or laboratory strains (Quinones-Mateu and Arts, 2002).
Several studies have looked at the fitness of TAMs and have found that the TAM-1
pathway mutations, consisting of M41L, L210W and T215Y, are more fit than the
TAM-2 pathway of mutations, consisting of D67N, K70R and K219Q both in the
presence and absence of zidovudine (AZT) (Hu et al., 2006;Paintsil et al.,
2006;Armstrong et al., 2009a). The TAM-1 mutations also contribute to a greater
cross-resistance than the TAM-2 mutations (Miller, 2004). In growth competition
assays, one study used SDMs to show that the TAMs K70R, T215Y, M41L and
M41L + T215Y were all less fit compared to the HXB2 wild type in the absence of
drug. However, once AZT was added to the competitions, the TAM containing
viruses were more fit than the HXB2 wild type virus (Harrigan et al., 1998). This is
an expected result, as one would anticipate that in the absence of drug pressure,
resistance mutants are less fit than the wild type virus; once drug is added, the
resistant mutants acquire a selective advantage.
The hypothesis of this study was that H208Y was an accessory mutation that arose in
highly mutated viral genomes that have acquired multiple mutations, in particular the
TAMs. As a result, the H208Y could increase NRTI resistance or improve the fitness
of this heavily mutated unfit virus particularly in the presence of drug. The expected
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result would be that since the H208Y mutation conferred a reduced susceptibility to
TDF, once TDF was added to the competitions, the viruses with H208Y would be
fitter than the viruses without H208Y. The competitions done in the presence of TDF
in this study did not show this expected result and instead, there was not much
difference between the competitions in the presence or absence of TDF. These
findings may reflect the complex dynamics that characterise the relationship between
viral fitness and escape from drug pressure in vivo. They may also be explained by
methodological considerations, including the type of cells used in the assay, which
may be rather permissive for HIV replication and therefore prevent the appreciation
of fine changes in viral fitness. In addition, differences in drug concentration may
influence the findings, as well as virus evolution during passaging.
Single cycle assays have the advantage that they can be completed in a shorter time
frame but the viruses are limited to a single cycle of replication. Multiple cycle
assays can detect smaller changes in fitness because there are multiple rounds of
replication and the differences between two variants can be amplified over many
rounds of replication. The use of whole virus rather than recombinant virus also
changes the nature of the fitness assay. Whole virus assays involve culturing virus
isolated directly from the patient and therefore have the major advantage that all viral
components can contribute to the measured outcomes. However, these assays are
notoriously difficult to standardise, at least in part due to the common use of
peripheral blood mononuclear cells that must be activated to support HIV replication.
Recombinant virus assays involve amplifying a gene of interest and cloning the gene
into a laboratory derived recombinant vector. The advantage of this assay is that
isolation of the infectious HIV-1 is not required and a greater degree of
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standardization can be achieved. The vector can be modified to incorporate reporter
genes such as luciferase (Dykes and Demeter, 2007;Quinones-Mateu and Arts,
2002). A study that compared the fitness of whole virus with that of recombinant
virus containing the corresponding envelope gene demonstrated comparable results
(Rangel et al., 2003). It should be noted however that the envelope is a key
determinant of viral fitness thus it is conceivable that its effects in isolation will be
close to those of the whole virus. In this study, the growth competition assay was
used to measure fitness because they have the advantage that small changes in fitness
can be detected and the fact that they provide as close as possible reproduction of
conditions in vivo.
The use of cell lines and primary human cells has also been shown to affect the in
vitro fitness of drug resistant mutants. For instance, the M184V mutation, which
confers resistance to lamivudine, was reported to have a reduced fitness compared to
the wild type in primary human cells but the observation was not repeated in a
lymphoid cell line. Similar findings have been found with K65R and the TAMs
(Back et al., 1996;Perez-Bercoff et al., 2007).
It is also important to note that the use of patient-derived RT containing multiple
mutations rather than a site directed mutant containing few selected mutations on
HXB2 RT. Thus, while this may make it difficult to appreciate the effect of any
individual mutation, it is also more representative of the in vivo scenario where
H208Y is known to emerge in the context of highly mutated virus that has been
subjected to extensive selective pressure.
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One other possible reason for the lack of a fitness effect of H208Y in the presence of
TDF may be related to the long half-life of the drug. (Delaney et al., 2006). The
phenotypic assay involved incubating infected cells in the presence of drug for 4
days. However, the drug in the growth competition assays was replenished every 6
days. Therefore it is plausible that the IC50 level of drug was not maintained
throughout the competition and this may have affected the relative fitness reported.
Maintaining the correct drug levels in the growth competition assays is a critical
parameter, which could alter the outcome of the assay if not maintained accurately.
Having too a high level of drug would mean that replication would be suppressed
whereas having a low concentration of drug would mean that virus replication would
not be suppressed to the correct levels.
The major resistance mutation associated with TDF is K65R. It is possible that the
continuous passage of these viruses in the growth competition assays in the presence
of TDF could have selected K65R and this could have affected the fitness result. It
has been reported that it would take at least 75 weeks to select K65R when passaging
wild type virus in the presence of TDF (Brenner et al., 2006). To rule out the
possibility of mutations arising in the RT during passage that may influence the
fitness result, the RT gene from passages 1 and 4 were sequenced from each
competition (data not shown). No non-synonymous mutations were found in the
sequences. However since only the RT was sequenced, this does not rule out the
possibility that a mutation else where in the virus may have developed and had an
effect on the fitness. However, this possibility seems unlikely given that TDF exerts
pressure on the RT gene.
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The gold standard for growth competition assays involves passaging viruses over a
period of 12-24 days (Cong et al., 2007;Hu et al., 2006;Hu and Kuritzkes,
2010;Huigen et al., 2008;Armstrong et al., 2009b). It is possible that by increasing
the number of passages and decreasing or increasing the amount of supernatant used
to passage the virus could have influenced the fitness result. However, due to time
constraints, these options could not be tested.
The fact that both wild type and drug resistant RT containing H208Y showed a
reduced susceptibility to TDF in the absence of appreciable fitness advantages in the
presence of TDF was an unexpected result. An important consideration is the slope
of the dose response curve achieved in the phenotypic assay. Conventional
phenotypic assays use the IC50 value as a measure of resistance and do not report the
slope of the dose response curve. It has been shown that viruses with the same IC50
values but differing steepness of the dose response curve may achieve different
inhibition at clinically relevant concentrations (Shen et al., 2008). Furthermore, the
IC90 may also be relevant. Mutant viruses that have a higher IC50 than the wild
type virus may have a lower IC90 than the wild type virus due to the slope of the
dose response curve. As a result, if the correct drug levels were not obtained, one
virus may have had an advantage over the other in the growth competition assay.
In all cases, the IC90 was higher for the viruses with H208 compared to the viruses
with H208Y. Therefore it is possible that if a too high drug concentration were used,
viruses with H208Y would be at a growth disadvantage.
Despite these possible explanations to address why a fitness effect was not observed
in the growth competition assays in the presence of drug, it is possible that the
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H208Y mutation does not contribute to viral fitness and is purely a resistance
mutation. There are examples whereby mutations confer resistance but do not have a
significant effect on fitness. The L74V mutation confers high level resistance to
didanosine (DDI) and intermediate level resistance to abacavir (ABC) (McColl et al.,
2008;Trivedi et al., 2008). In a multiple cycle system, p24 antigen measurements
were used to measure fitness of L74V compared to wild type. The L74V mutation
has been shown to have the same fitness as wild type (Deval et al., 2004a). Another
example includes the NNRTI resistance mutation K103N which confers high level
resistance to efavirenz (EFV), nevirapine (NVP) and delaviridine (DLV) (Clavel and
Hance, 2004b;Dykes and Demeter, 2007). Despite having a significant effect on
resistance, K103N does not have a significant effect on fitness. Growth competition
assays have shown that K103N had a lower fitness compared to the wild type virus in
the absence of drug (Collins et al., 2004). In the presence of 3nM EFV or 30nM
NVP the K103N containing virus had a similar fitness to the wild type virus,
however with higher concentrations of EFV and NVP, the K103N virus was more fit
than the wild type virus (Gatanaga et al., 2006).
In summary, the growth competition assays showed that in the context of a subtype B
wild type RT sequence, the H208Y mutation was detrimental to viral fitness, both in
the absence and presence of drug. However in the context of a subtype A TAM-2
and subtype B TAM-1 containing RT sequence, H208Y had a similar fitness to the
viruses without H208Y. In the context of drug resistant RT, an appreciable effect on
fitness was not observed, which may be either due to the fact that the viruses were
too highly mutated and “adapted” to be impacted significantly by just one small
change, or methodological issues that require further work to be elucidated.
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Chapter seven
7 General discussion
7.1 Discussion
The emergence of resistance can be divided into two stages. The first stage involves
the emergence of mutations that directly affect the functioning of the drug and cause
resistance. These mutations are called primary or major resistance mutations and are
generally associated with a decreased fitness, commonly referred to as the “fitness
cost” of drug resistance. The second stage involves the emergence of secondary or
accessory mutations that may contribute to increased resistance or may compensate
for the reduced fitness. The latter are also known as compensatory mutations.
Accessory mutations are initially identified through statistical analyses of large
databases that compare the frequency of mutations in treatment naïve and treatment
experienced patients. Accessory mutations are found more frequently in treatment
experienced patients that treatment naïve patients as they require drug pressure to
arise (Cane et al., 2007;Perno et al., 2006;Svicher et al., 2006). The characterisation
of accessory mutations in reverse transcriptase (RT) has not been extensively studied.
The work presented in this thesis characterises the H208Y mutation as an accessory
mutation in RT.
The HIV Resistance Database held at the Royal Free Hospital contains the pol gene
population sequences of all patients undergoing drug resistance testing locally. The
patient population is highly diverse, with approximately 46% of sequences showing a
HIV-1 subtype other than B, including all prevalent non B subtypes, common
recombinant forms and some complex sequences of unclear subtype assignment. The
database was searched for RT sequences with the H208Y mutation. The prevalence
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of the H208Y mutation was found to be 5/3783 (0.1%) in treatment naïve patients
and 12/1304 (0.9%) in treatment experienced patients. Four patients were chosen for
further analysis; a treatment naïve patient infected with a subtype B virus and three
treatment experienced patients infected with subtype A, subtype B and subtype C
virus respectively. Cloning the gene RT from these patients showed that the H208Y
was most often observed with the thymidine analogue mutations (TAMs), in
particular, the TAM-1 pathway of mutations, which consists of M41L, L210W and
T215Y. H208Y was always associated with TAM mutations at positions D67, T215
and K219. TAMs accumulate in step-wise fashion in patients receiving therapy with
the thymidine analogues zidovudine (AZT) and stavudine (D4T) and take several
months of incompletely suppressive therapy to emerge. In addition to conferring
resistance to AZT and D4T, TAMs reduce susceptibility to all other available
nucleoside and nucleotide RT inhibitors (NRTI), including abacavir (ABC),
didanosine (DDI) and tenofovir (TDF), and to a lesser extent lamivudine (3TC) and
emtricitabine (FTC). The effects on resistance and cross-resistance grow
progressively with increasing numbers of TAMs. Taken together these initially
findings confirmed the high degree of conservation of the RT residue 208 in wild
type HIV-1 across a wide range of subtypes, and the emergence of H208Y under
selective drug pressure in the context of a highly mutated and NRTI resistant RT
(Cane et al., 2007;Nebbia et al., 2007;Svicher et al., 2006). The clones from the
treatment experienced patients showed that H208Y was consistently associated with
accessory mutations at positions V35, K122 and T200 and other mutations with
unknown effects on drug susceptibility and fitness at positions V245, A272, I293,
T377, K390, E404, V435, H483 and L491.
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In order to examine the contribution of H208Y to drug susceptibility and viral
fitness, the RT gene from plasma virus recovered from the four patients with H208Y
was used to create recombinant viruses to be tested in drug susceptibility and growth
competition assays. For this purpose, strains with H208Y were subjected to site
directed mutagenesis to produce sequences with H208. While it may have been
possible to simply compare site directed mutants (SDMs) with and without H208Y,
the advantage of this approach was that it allowed the impact of the mutation to be
studied in the context of the sequence within which it emerged. The drawback of this
approach however was that comparisons among viruses derived from different
patients were difficult to interpret given the significant differences observed in terms
of major and accessory mutations co-existing with H208Y. One attempt at
circumventing this problem was the reversion of strains with M184V to strains with
M184, to remove the strong phenotypic effects of M184V on drug susceptibility
(partial resensitisation to AZT, D4T and TDF) and viral fitness (high fitness cost).
The drug susceptibility assay showed that the H208Y mutation conferred a reduced
susceptibility to TDF in the context of both wild type subtype B RT and subtype B
RT containing TAM-1 mutations. This effect was statistically significant (p<0.001)
as determined by two tailed ANOVA. The IC50 values from replicate experiments
were all within a 2 fold range of one another showing that this effect was
reproducible.
The resistance effects of H208Y were not observed with other NRTIs and the
mutation was shown to confer an increased susceptibility to some NRTIs and
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NNRTIs, although these effects were not statistically significant when comparing
viruses with and without H208Y. Previous data on the phenotypic impact of H208Y
have been contradictory and have indicated both increased and decreased
susceptibility to AZT (Clark et al., 2006;Sturmer et al., 2003). These studies created
site directed mutants on a subtype B RT backbone and used a single cycle and
multiple cycle assay respectively. In this work, a phenotypic effect could not be
demonstrated for AZT, and this is due to the fact that the treatment experienced
patients harboured highly AZT-resistant viruses with multiple TAMs and any
phenotypic effect of H208Y was clearly too small to be appreciated in this context.
However, the virus from the treatment naïve patient showed an increased
susceptibility to AZT and D4T but this effect was not statistically significant.
The resistance effects for TDF seen with H208Y were not recapitulated with the
subtype A or subtype C viruses. Possible explanations include subtype related or
drug induced sequence differences and structural differences in the enzyme. The
TAMs present in the treatment experienced patients are similar although not
identical. The subtype B virus had the TAMs M41L, D67N, L210W, T215Y and
K219N alongside V75M, V118I and the NNRTI resistance mutations A98G and
G190Q. The subtype A virus had the TAMs D67N, K70R, T215F and K219E
alongside T69N and the NNRTI resistance mutations A98G and G190Q, while the
subtype C virus had the TAMs M41L, D67N, L210W, T215Y and K219R alongside
E44D, L74V, and the NNRTI resistance mutations A98G, K101H, V108I, Y181C and
G190A/Q.
226
Alignment of the RT sequences from the four patients identified 12 positions that
were the same in the subtype B sequences but differed in the subtype A and subtype
C sequences. From these 12 positions, 2 positions were associated with NRTI
resistance and these were at positions Q207 and G335. These mutations contribute
to AZT and 3TC resistance when present with TAMs and TAMs with M184V
respectively (Lu et al., 2005;Zelina et al., 2008). No phenotypic effect for AZT was
measured for the subtype A and subtype C viruses. But for 3TC, the subtype A
viruses conferred a reduced susceptibility to 3TC and the subtype C patient conferred
an increased susceptibility to 3TC but these results were not statistically significant.
Therefore, the impact of these mutations when present with H208Y is unclear.
It should also be noted that a subtype B molecular clone backbone was used for all
viruses and perhaps using subtype specific molecular clones may have yielded
different results.
In order to assess the contribution of H208Y to viral fitness, an allele-specific PCR
(AS-PCR) was developed. The assay was used to differentiate between competing
strains with and without H208Y and quantify proportions of mutant and wild type
viruses in growth competition assays. The growth competitions with virus from the
subtype B treatment naïve patient showed that the presence H208Y was detrimental
and made the virus less fit relative to a SDM without the H208Y. This observation
may contribute to explain the high degree of conservation of H208Y among viruses
from treatment naïve patients. The mutation appears to be equally rare among
different HIV-1 subtypes, suggesting the fitness effect observed with subtype B is
likely to be reproduced across different clades. However, no samples were available
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from treatment naïve patients with non B subtypes and H208Y to test this hypothesis.
Further work will require testing non-B RT with H208Y introduced by site directed
mutagenesis.
In the presence of TAM-1 or TAM-2 mutations, viruses with H208Y maintained
stable proportions throughout the competitions, suggesting there was no measurable
impact of H208Y on viral fitness. Viral fitness data on H208Y are limited, with only
one study that has explored its impact. This study created site directed mutants with
T215Y and H208Y and showed that it was less fit than the wild type and single
mutants with T215Y or H208Y alone (Clark et al., 2006). In this work, an effect was
not appreciated. Possible reasons include the fact that patient derived RT containing
multiple TAMs was used rather than using a wild type RT with one or two mutations,
which would be easier to look however, how useful this would be since they are
unlikely to occur just in pairs. Methodological issues such as the ensuring the correct
concentration of drug was maintained and the half life of the drug may also have
influenced the result.
In summary, the findings presented in this thesis show the H208Y is highly
conserved among treatment naïve patients infected with diverse HIV-1 subtypes. The
conservation may be explained by its negative impact on viral fitness seen with wild
type subtype B virus. The findings also showed that H208Y was linked on the same
viral genome with the TAM-1 pathway of mutations, and occurred consistently with
mutations at positions V35, K122, T200, V245, A272, I293, T377, K390, E404,
V435, H483 and L491. In both wild type and TAM-1 containing subtype B virus,
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H208Y reproducibly reduced susceptibility to TDF. In the context of highly mutated,
drug-resistant RT, H208Y showed no appreciable effect on viral fitness.
The finding that in the presence of the TAMs, H208Y did not increase fitness does
not support the hypothesis that the H208Y mutation is a compensatory mutation.
This is because compensatory mutations are defined as occurring alongside major
resistance mutations and augmenting viral fitness. This leads to the question of
whether H208Y is in fact an accessory mutation that acts by augmenting resistance.
Future work will focus on determining the mechanism of TDF resistance conferred
by H208Y. For instance, RT fidelity and processivity as well as NRTI excision could
be examined. Methodological modifications to the growth in the presence of TDF
could also be done. This includes increasing the concentration of TDF used or using
AZT, increasing the number of passages and the volume of supernatant used to
continue the passage. Furthermore, using primary cell lines in the growth
competition assays could also be done.
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